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“So, a graduate student, huh? How come you guys can go to the moon                  
but you can’t make my shoes smell good?”      
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The project began as a cooperation with the National Center for Ultrasound                 
in Gastroenterology (NCUG) and Medical Department, both at Haukeland 
University Hospital in Bergen. This is where I met professor Gilja and my main 
supervisor, Mette Vesterhus, resulting in Paper I. The studies were financed                 
by the University of Bergen from 2017, as part of the Ph.D. program. 
The National Center for Ultrasound in Gastroenterology (NCUG) was founded           
in 2001, established to perform teaching and research on gastroenterological 
ultrasound, focusing on standard B-mode ultrasound and more advanced 
methods such as elastography, contrast-enhanced ultrasound, gastrointestinal 
motility, and endoscopic ultrasound. NCUG is a European Learning Centre, 
acknowledged by the European Federation of Ultrasound Societies in Medicine 
and Biology (EFSUMB).  
We have also been dependent on the collaboration with the Norwegian PSC 
Research Center (NoPSC), established in 2008 at Oslo University Hospital, 
Rikshospitalet. NoPSC is internationally acknowledged for spearheading 
research related to basic and clinical aspects of primary sclerosing cholangitis 
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2D-SWE  – Two-dimensional shear wave elastography 
ALP  – Alkaline phosphatase 
APRI  – Aspartate aminotransferase-to-platelet-ratio index 
ARFI  – Acoustic radiation force impulse  
AST  – Aspartate aminotransferase 
AUC  – Area under the curve 
BMI  – Body mass index 
B-mode – Brightness mode 
CI  – Confidence interval  
CT  – Computerized tomography 
EFSUMB  – European Federation of Societies for Ultrasound in Medicine and   
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ELF   – Enhanced liver fibrosis test 
FIB-4  – Fibrosis-4 
IBD  – Inflammatory bowel disease 
ICC   – Intraclass correlation coefficient 
IQR   – Interquartile range 
IQR/M – Interquartile range divided by the median 
kPa  – Kilopascals 
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LS  – Liver stiffness 
LSM  – Liver stiffness measurement 
MRI  – Magnetic resonance imaging 
M/S  – Meters per second 
PPV  – Positive predictive value 
PSC  – Primary sclerosing cholangitis 
pSWE  – Point shear wave elastography 
ROI  – Region of interest 
SD  – Standard deviation 
SWE  – Shear wave elastography 
SWS   – Shear wave speed 
TE   – Transient elastography 
ULN  – Upper limit of normal 
WFUMB  – World Federation for Ultrasound in Medicine and Biology 
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SUMMARY OF THE THESIS 
Liver elastography applies ultrasound-based measurements of liver stiffness 
(LS), used as a quantification of liver fibrosis. Correlation between liver stiffness 
measurements (LSM) and histological stages of liver fibrosis was already 
established; however, technological and methodological differences between 
ultrasound equipment and biological differences related to age or liver disease 
etiology, may influence the interpretation of LSM. Correct assessment of disease 
relies on a precise definition of normality, but reference values and inter-system 
differences were lacking for several elastography systems. Data were 
particularly scarce for children and patients with primary sclerosing cholangitis 
(PSC). In this rare and complicated liver disease, non-invasive surveillance of 
fibrosis development is recommended as part of follow-up. 
Thus, we aimed to establish reference values for LSM in children and adults 
using several elastography systems and to compare principally different 
methods such as transient elastography (TE), point shear wave elastography 
(pSWE), and two-dimensional shear wave elastography (2D-SWE) in a head-to-
head setup. We furthermore investigated, for the first time, the feasibility of 
pSWE and 2D-SWE in PSC patients.  
In studies II and III, we included 343 healthy individuals aged 4-70 years. 
Applying two or three elastography systems head-to-head in every participant, 
we defined age-specific reference values for each system. 
Reference values were determined for different age groups: 4-7 years, 8-11 
years, 12–14 years, 15–17 years, and 20–70 years. We found a gender difference 
in subjects 12–70 years, with no similar difference in young children.                               
LSM was higher in adolescents and adults compared to younger children. 
Correlation between different observers was good.  
In studies I and IV, a cohort of adult PSC patients was followed, collecting clinical 
data and performing LSM and blood tests. Paper I describes pSWE in PSC for the 
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first time, comparing assessments of both liver lobes and concluding that left 
liver LSM is unreliable; hence, subsequent measurements forming Paper IV were 
applied in the right liver lobe only. All PSC patients were examined by pSWE at 
every visit. For Paper IV, all patients were examined head-to-head by both 
pSWE, 2D-SWE, and TE: all three systems were feasible in PSC patients, and all 
were highly correlated with other indications of liver fibrosis (B-mode findings, 
liver biochemistry, fibrosis scores, and prognostic scores).  
In conclusion, the results demonstrate that elastography systems representing 
three principally different methods are feasible and perform well in healthy 
subjects and PSC patients. We have established reference values for healthy 
children and adults, with head-to-head inter-system comparisons and 
descriptions of interobserver differences. Ultrasound elastography of the liver 
should be adopted broadly in the medical environment; in screening, 
diagnostics, and clinical patient follow-up of both children and adults. 
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Liver elastography is well established as a non-invasive method for liver fibrosis 
assessment, but opportunities and limitations remain to be fully explored, partly 
due to an ever-increasing jungle of different systems and platforms. For every 
system, there is a need for investigations in both healthy individuals and chronic 
liver patients to establish reference and cutoff values where fibrosis or cirrhosis 
can be suspected. Comparably, suppose a producer wants to introduce a new 
way of measuring serum sodium values. In that case, this will need proof of 
performance using reference standard testing before being applied in clinical 
practice – this is not necessarily the case with liver elastography.  
In addition to establishing reference values, studies in healthy individuals are 
warranted to evaluate the effect of various factors and confounders, such as 
gender, age, or body mass index (BMI), as the impact of such factors may be 
obscured by unpredictable diseases with fluctuating or elevated LSM values. 
Published studies have concluded differently regarding the effect of gender and 
age on LSM. 
Liver elastography has been shown to correlate well with liver fibrosis 
evaluation by liver biopsy, with an overweight of investigations performed in 
adults with infectious hepatitis [1-3]. Data are scarce for rare diseases such as 
PSC, and the few published studies prior to the present thesis were all limited to 
TE [4, 5], demonstrating that LSM by TE is associated with clinical outcome and 
indicating elastography as a sorely needed prognostic tool in this severe, but 
hitherto unpredictable disease. 
Serum markers are shown to correlate with the outcome. Specifically, the 
Enhanced liver fibrosis (ELF) test has demonstrated a strong and independent 
correlation with prognosis in PSC patients [6, 7]. While LSM is indeed a robust 
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surrogate marker of liver fibrosis, it may not outperform all serum-based tests 
under all conditions. Some studies have demonstrated that the combination of 
LSM and fibrosis markers performs better than LSM alone [8-10]. In PSC, 
dominant stenosis causing cholestasis is a frequent finding and may influence 
LSM, without being indicative of true liver fibrosis [11]. Thus, comparing each 
elastography platform to the ELF test as the leading serum-based liver fibrosis 
test in PSC is of high interest. 
Non-invasive evaluation of liver fibrosis encompasses serum based tests and 
scores directly or indirectly assessing fibrogenesis, as well as imaging-based 
methods assessing LS, a physical property of the liver. Acknowledging that each 
strategy carries its advantages and disadvantages, both showing utility [12],           
we compared LSM results to serum markers and fibrosis scores. These 
approaches can be used in a step-up manner: several publications advocate 
using simple serum biomarkers in primary care, with non-invasive tests, 
including elastography as part of the subsequent specialist evaluation [13-17].  
 









1.2.1 Basic concept of ultrasound 
Sound is a wave of mechanical energy, caused by vibration of molecules within a 
medium [18]. Humans can hear sound with frequencies between 20 and 20.000 
Hz [19]. Ultrasound does not differ from sound waves, except for the fact that 
the frequency is higher than what is audible for man (>20.000 Hz), thus the 
word ultrasound (ultra: from Latin, meaning ‘beyond’ [20]). Ultrasound used in 
medical applications is commonly in the range of 1–20 MHz (MHz = 106 Hz). 
Diagnostic ultrasound uses ultrasound waves to generate an image, providing a 
valuable source of clinical information. A B-mode (brightness mode) image (Fig. 
1) is constructed from echoes generated by the reflection of ultrasound waves 
from boundaries between different tissues and from scattering from subtle 
irregularities within tissues [21, 22].  
 
 
Fig. 1. B-mode ultrasound image without (left) and with (right) color flow, highlighting 





The brightness of each point in the created image is related to the returning 
echo’s strength. The same principle is applied when echo sounding is used to 
determine the distance to the bottom of the sea: an ultrasound wave is sent from 
the boat towards the seabed, which reflects the wave and transmits it back to the 
boat, where the signal is received and interpreted (Fig. 2). If the speed of sound 
through water is known, the distance to the seabed can easily be calculated once 
the time taken is measured.  
Fig. 2. Echo sounding. Image: Batman 
The human anatomy is obviously more complex than in this example, with 
multiple interfaces and tissues with different characteristics. This leads to a 
tremendous amount of information, with echoes returning from various depths 
and with different amplitudes or strength of the echo, creating a multifaceted 
picture. The return time will define the depth and thus, where the signal is 
placed in the B-mode image, while the echo’s strength will determine the 
intensity of the specific points.  
Ultrasound systems used in medicine typically consist of a transmitter, a 
transducer, and a screen for image display. The transmitter generates electric 
energy and activates the transducer, causing it to vibrate and create an acoustic 
pulse transmitted through tissues [19, 22]. The transducer holds ceramic crystal 
elements, referred to as piezoelectric crystals. This is where the conversion of 
electric energy to pulse waves, and back again to electrical energy, takes place 
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(Fig. 3). Piezoelectric materials generate voltages when an external force 
imposes compression or stretching [21, 22]. The transducer receives the 
reflected echo, and the wave is then converted back to an electric signal.  
 
Fig. 3. Transverse section of an ultrasound transducer. Image: Selma Sundt Mjelle.  
 
1.2.2 Development of ultrasound technology 
The first experiments on ultrasound demonstrating the probable existence of 
ultrasound were performed in bats by Lazzaro Spallanzani (1729-1799), an 
Italian priest and physiologist [23]. He found that when the bat’s mouth was 
covered, it would crash into objects in the dark, concluding that the bat used its 
ears for “seeing” and measuring depths. The concept of piezoelectricity, 
necessary for ultrasound, where electric charge accumulates in solid materials in 
response to mechanical stress, was first demonstrated in 1880 by the Curie 
brothers [24]. Devices using echolocation were patented in 1912, with the first 
sonar (sound navigation and ranging) being built in 1914. With the fear of 
German submarines, World War I pushed technology forward, ending in the first 
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construction of an underwater sound generator, considered to be the prototype 
of modern ultrasound devices [25]. Ultrasound in medical diagnostics started 
with the attempt of locating brain tumors and cerebral ventricles measuring the 
transmission of ultrasound beams through the head, published in 1942 [23]. The 
next decade, in 1958, saw the Lancet publication describing differentiating cystic 
and solid abdominal masses [26], a publication considered a hallmark paper in 
ultrasound development. In the latter part of the 1960s, pulsed Doppler 
technology was developed, allowing investigation of blood flow in the heart [27]. 
In the 1970s, several developments were described, including continuous wave, 
spectral wave Doppler, and color Doppler [28]. In 1986, three-dimensional 
imaging was performed on a fetus [28]. The overall quality of imaging gradually 
improved and is still improving. The last 10–20 years have seen exponential 
improvement in both image quality and new platforms, with handheld devices, 
including tablets and probes designed for use with smartphones, applied in all 
fields of medicine.  
1.2.3 Clinical use of ultrasound 
Ultrasound is widely used in health care globally, in radiology only second to 
conventional x-ray imaging. The 2018–2019 report from the UK National Health 
Service showed that ultrasound was used 10.3 million times during 12 months 
in the UK – more than all computer tomography (CT) and magnetic resonance 
imaging (MRI) scans combined (9.7 million) [29].  
One of the major advantages of diagnostic ultrasound compared to conventional 
x-ray imaging is the dynamic imaging in real-time. It allows the investigation of 
rapidly moving organs, such as the heart or the blood. It is especially relevant for 
application in children, performing well even in those too small to lay still or 
hold their breath while lacking the ionizing radiation, which is particularly 
harmful in growing children. Furthermore, children are often thin and easy to 
examine, with a short distance from the skin to the organs of interest. 
Ultrasound may easily be performed bedside, which is a significant advantage 
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compared to MRI or CT and can thus be performed even when patient 
transportation is difficult or unwanted, e.g., in an intensive care setting.   
1.3 ELASTOGRAPHY 
1.3.1 The concept of elastography 
Elastography is essentially an upgraded version of palpation, the ancient 
diagnostic technique, described more than 3’500 years ago [30]. Palpation gives 
the clinician the opportunity to locate organs and tumors and assess its’ 
properties, e.g., size, form, position, and stiffness. A typical example is lymph 
nodes, which typically will be harder when growing due to malignancy than in 
the event of an infectious etiology. A malignant tumor will feel stiffer than a 
benign tumor, and scar tissue/fibrosis will feel stiffer than healthy organ tissue. 
Standard ultrasound may solve some of this issue, analyzing the size, position, 
and form of the organ or lesion. Still, with little correlation between elasticity 
and echogenicity, there was an obvious need for a new modality. Elastography, 
applied in both ultrasound and MRI technology, allows the clinician to evaluate 
what is beyond palpation, yielding a more objective description of the tissue’s 
mechanical properties. Different forms of ultrasound elastography exist (see 
1.3.3): commonly, a pulse, either ultrasound-induced or mechanically induced, is 
transmitted by the transducer, causing waves through the adjacent tissue, which 
subsequently give rise to slow traveling, perpendicular shear waves (Fig. 4). 
Since waves will travel faster in a stiff medium compared to a soft medium, a 
high shear wave speed (SWS) indicates a stiff tissue. Measurements are either 
given directly as SWS in meters per second (m/s) or converted to Young’s 
modulus (see 3.3 DEFINITIONS) value using the equation kPa = 3𝜌(m/s)2. As 
this equation requires some assumptions, SWS (using m/s) is considered more 
accurate. However, most publications report values in kPa [31].  
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Fig. 4. Shear waves are created perpendicularly to the acoustic push pulse. The shear 
wave speed (SWS) will vary depending on the tissue stiffness, traveling faster in stiffer 
tissues. A high SWS thus suggests the presence of liver fibrosis. Image: Batman 
 
 
1.3.2 The development of elastography 
The field of elastography starts with strain, a term used in physical sciences, 
describing how an object is displaced when subjected to an external force. It is 
intuitive that applying the same amount of force to a soft and a hard object, will 
cause different deformation between objects; but, how to describe this? The 
concept of imaging tissue strain was developed in the 1970s and early 1980s 
[32]. In the early 1990s, different research groups expanded on this, describing 
tissue stiffness imaging, either as a quasistatic pressure (producing an 
elastogram, a depiction of the estimated tissue strain [33]) or vibrator-induced 
excitation, measuring the tissue motion with a color Doppler instrument [34, 
35], eventually resulting in lesion detection [36]. Doppler ultrasound was also 
used to estimate strain applied in Strain Rate Imaging, providing relative strain 
in contracting tissue [37-39] or stiffness in tumors [40-42]. Studies on the 
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propagation of shear waves in phantoms and beef muscle were also performed 
[43, 44]. In 1999, transient elastography was first described, demonstrating 
biases during shear wave propagation, with the formation of different wave 
types [45, 46]. These different wave types could be identified using transient 
excitation, facilitating measurement of shear elasticity and shear viscosity. The 
method was termed transient elastography (TE). The same year featured a 
paper describing a system setup with a piston built on a vibrator, with an 
imaging system producing up to 1’000–2’000 frames of shear wave propagation 
images per second [47]. From these images, both wavelength and SWS were 
estimated. The same research group continued to develop the system further, 
and in 2003 they reported on the use of TE using the Fibroscan system in 
patients with hepatitis C [1]. At the beginning of the current century, acoustic 
radiation force was applied for tissue stiffness evaluation. This allowed 
elastography coupled with standard B-mode ultrasonographic imaging [48, 49], 
based on a technique described a decade earlier [50]. The last decade has seen 
an explosion in technique development, with a wide variety of systems [51].  
 
1.3.3 Different elastography techniques 
Elastography systems can be divided into either strain imaging, shear wave 
speed measurement, or shear wave imaging. 
In strain imaging, the system uses echo signals before and during external 
compression, comparing these signals. This is then used to calculate how the 
tissue is displaced [52]. An elastogram is produced, with different colors 
depicting the degree of strain, indicating tissue stiffness. The method is 
qualitative and does not give a measurement value. Fig. 5 shows an example of 
strain imaging: with B-mode imaging side-by-side, it is easy to appreciate how 
regions with different degrees of stiffness are impossible to single out using B-
mode imaging. Thus, the mechanical properties of the various tissues are 
emphasized, irrespective of their echogenicity. Strain imaging is particularly 
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useful when screening for focal lesions, which often will have elastographic 
properties differing from healthy parenchyma. Correspondingly, it will be less 
useful when searching for subtle progression of (average) organ stiffness during 
clinical follow-up. 
 
                                                 
Fig. 5. Strain elastography of a healthy liver. Image: Batman 
A dynamic variant of strain imaging is acoustic radiation force impulse (ARFI) 
imaging, where the same transducer both monitors tissue displacement and 
generates the original push pulse.  
In point shear wave elastography (pSWE), which is available in many 
ultrasound systems and sometimes referred to as ARFI quantification, an 
acoustic radiation force impulse described above produces perpendicular shear 
waves measured in a region of interest (ROI). The speed given is the average 
speed within the boundaries of the ROI (Fig. 6, Fig. 7). Conventional B-mode 
imaging is used, with no visualization of LS as in strain elastography or 2D-SWE. 
Thus, the operator cannot choose a measurement site based on assumed 
stiffness but uses the B-mode image to select a homogenous area free of vessels 
and visible biliary tracts.  
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Measurements are given in m/s but can be converted to Young’s modulus, 
displaying values in kPa. Guidelines recommend using the median value of 10 
acquisitions, similar to TE. 
 
                                           
Fig. 6. Point shear wave elastography (pSWE) by Samsung RS80A.                                                
Image: Anesa Mulabecirovic 
 
                                              
Fig. 7. Point shear wave elastography (pSWE) by Philips iU22. Image: Mette Vesterhus 
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Two-dimensional shear wave elastography (2D-SWE) is, similar to pSWE, 
incorporated into high-end ultrasound systems. Acoustic radiation force creates 
tissue displacement at all positions along the pulse axis [51]. A high frame rate 
allows following the shear waves in 2D, creating a vast and fine-meshed map of 
information, depicted as a color elastogram (Fig. 8). The operator determines 
the placement of the color elastogram, before placing a circular ROI in the most 
homogenous part of the elastogram. Having chosen the ROI site, an LSM value is 
generated. Guidelines recommend using the median value of at least three 
acquisitions, though this is subject to an ongoing debate.  
 
                                                
Fig. 8. Two-dimensional shear wave elastography (2D-SWE) by GE Logiq E9. The color 
elastogram is seen as a light blue rectangle, with the yellow stapled ROI in its center.                       
Image: Batman 
 
Transient elastography (TE) is the most studied version of ultrasound 
elastography systems, launched as early as 2003. It has a system-specific 
transducer that applies a mechanical push at the skin level, causing an acoustic 
wave into the adjacent tissue. The ultrasound system tracks the arising shear 
waves, and a median value of 10 acquisitions is reported in kPa. The often-used 
criterion of IQR/median ≤30%, is derived from the Fibroscan system, where it 
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was first applied. TE does not produce a B-mode image, making the operator 
unable to evaluate signs of liver disease or select a homogenous measurement 
site free of vessels or lesions. Moreover, TE does not function in the presence of 
ascites, which is easily visualized during a conventional ultrasound examination.  
TE transducers come in three different sizes: S, M, and XL. M is most commonly 
used, while S is developed for small children, and XL for the obese (with a skin-
to-capsule distance of ≥ 25 mm).  
1.3.4 Clinical application of elastography 
Liver elastography represents an estimation of LS, used to assess both the 
current level and the progression of liver fibrosis. There is a progressive 
replacement of healthy liver tissue with scar tissue in most chronic liver 
diseases, making the liver stiffer and less elastic. This is a continuous process, 
and surveillance of fibrosis development is a crucial part of clinical follow-up of 
patients with chronic liver disease. Inflammation plays a vital role in this 
process, sometimes contributing to the increased LSM, thus constituting a 
possible confounder in fibrosis evaluation. Inflammation causes increased LSM 
along two separate paths: an abrupt, often fully reversible LSM increase due to 
the ongoing inflammation process per se, and a chronic, less reversible LSM 
increase due to inflammation-induced scar tissue development. It is thus 
essential to look for ongoing acute inflammation when evaluating LSM values: 
significantly elevated liver transaminases (as an indication of inflammation; >5x 
of upper normal limit (ULN) is commonly used as a cutoff value) may indicate a 
falsely elevated LSM. Similarly, reduced LSM (e.g., when treating hepatitis C 
patients) can signify either reduced ongoing inflammation or actual regression 
of fibrosis. 
The widely accepted criterion standard of liver fibrosis evaluation, the liver 
biopsy, has inherited limitations, such as sampling variability and its non-linear 
fibrosis grading [53, 54], with cirrhosis being missed by as much as 10–30% [55-
57]. It is also an invasive procedure with the potential of clinical complications. 
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Furthermore, it necessitates general anesthesia in children, which should be 
avoided unless absolutely necessary, as it has been shown to affect nerve cells 
and learning and memory abilities [58, 59]. 
In all qualitative, dynamic elastography methods, a predetermined number of 
acquisitions are acquired: EFSUMB recommends different amounts for different 
methods, but always recommends reporting the median value. For TE, “10 
measurements should be obtained”; for pSWE “at least 10 measurements” and 
for 2D-SWE “a minimum of three” [31]. A datasheet is used to show all 
acquisitions, with an automatic calculation of the median value (Fig. 9). The 
same guidelines recommend an interquartile range/median (IQR/M) ≤30% for 
valid measurements (See 3.3 DEFINITIONS) for TE and pSWE. EFSUMB states 
that there is no agreement on the use of quality criteria for 2D-SWE, but 
mentions that the IQR/M criterium is used in several studies on 2D-SWE and 
that the producer has recommended its use for 2D-SWE by GE Logiq E9 [31].  
 
Fig. 9. Datasheet on GE Logiq E9 from scanning of a human liver. Image: Batman 
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1.4 THE LIVER 
1.4.1 Liver physiology 
The liver is an intra-abdominal organ, weighing as much as 1.5 kg in adults, in 
mature newborns between 0.1 and 0.2 kg and in our smallest premature infants 
treated at our institution, unless aberrant fetal growth, 0.03 kg [60, 61]. In 
pregnancies with decreased fetal growth, the liver volume will be reduced [62-
65], while in some conditions, it can be increased, e.g., in pregnancies 
complicated by trisomy 21 [66, 67] or maternal diabetes [68].  
The liver bud appears in the middle of the 3rd week of gestation, and by week 10, 
the liver constitutes 10% of the body weight, primarily due to a vast amount of 
hematopoietic cells, producing red and white blood cells [69]. This activity 
decreases the last eight weeks, and at term, the liver makes up 5% of body 
weight. Bile is produced from week 12. The neonatal liver has similar functions 
as in adults but is initially hampered by immaturity, leaving the neonate 
particularly susceptible to hypoglycemia, hyperbilirubinemia, and impaired drug 
metabolism [70]. The two latter conditions influence one another, as 
hyperbilirubinemia will cause bilirubin occupying albumin binding sites, 
yielding increased available drug concentration, which increases the chances of 
toxic effects. The liver’s enzymatic ability increases quickly, and drug dosage 
increments are often needed after only a few days or weeks of life. For some 
drugs, we see an increased metabolism during childhood, necessitating higher 
dosages per kilogram than adults, and pediatricians have to be skilled in dosing 
medications according to both body weight and age group. 
The liver has a wide variety of physiological tasks vital for survival. It is part of 
the digestive system, synthesizing proteins and detoxifying metabolites, and is 
our largest and most important metabolic organ, sometimes termed the body’s 
major biochemical factory [71, 72]. Amongst other, the liver A) processes 
carbohydrates, proteins, and lipids after absorption of nutrition from the 
intestine; B) synthesizes plasma proteins necessary for blood clotting and 
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transport of hormones and cholesterol; C) stores glycogen, fat, iron, copper and 
vitamins; D) activates vitamin D (together with the kidney), and E) secretes 
bile/bile salts.  
The liver is part of the biliary system, alongside the gallbladder and biliary ducts. 
Bile is an aqueous alkaline fluid containing bilirubin, cholesterol, and bile salts 
(derivates of cholesterol). Bile flows through the biliary system and into the 
duodenum, where it promotes the absorption of fat. This action depends on two 
abilities: bile salts’ detergent action, converting large fat droplets into a lipid 
emulsion, making it available for the pancreatic lipase; and its role in facilitating 
fat absorption through forming micelles, a practical vehicle for transporting 
water-insoluble substances such as free fatty acids and fat-soluble vitamins [71].   
1.4.2 Liver fibrosis 
To put it simply, liver fibrosis is hepatic scar tissue, representing the healing 
process after the damage has occurred. It is the inevitable result of almost all 
chronic liver diseases, depending on the etiology and certain host factors. 
Fibrosis is characterized by an extracellular matrix (ECM) increase, where the 
dynamic balance between formation and degradation is skewed, leading to 
increased ECM and fibrosis load. While the matrix amount is similar across 
different etiologies, different diseases show different distribution characteristics 
throughout the organ [73]. Comparing PSC with viral hepatitis, we find that the 
former is characterized by a concentric onion-skin like scar around the bile duct, 
causing degeneration and bile duct stricture, while the latter by fibrosis 
deposition initially in the portal tracts, in time with periportal and bridging 
fibrosis (fibrous septa between lobules) [74]. Fibrosis commonly occurs due to 
chronic inflammation induced by oxidative stress, autoimmune reactions, 
ischemia, trauma, or as a spontaneous process [75]. The development is a rather 
slow process, requiring months and sometimes years in the context of ongoing 
inflammation or damage (although exceptions exist) and is thus absent after 
acute injury, even in fulminant hepatitis [73]. Cirrhosis is considered a late 
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product of fibrosis development. Still, fibrosis and cirrhosis are both parts of a 
dynamic process with some degree of reversibility, an ability which lessens as 
the disease progresses. Cirrhosis represents a distortion of liver architecture, 
and in cases of advanced cirrhosis, it is considered irreversible, with liver 
transplantation as the only viable treatment option. It is not established 
precisely when the condition becomes irreversible [76, 77]. With this change in 
architecture, portal hypertension follows, contributing to increased LSM, 
complicating interpretation of these measurements. 
Although advanced cirrhosis is not very available to treatment, milder liver 
fibrosis can be substantially reversible in cases of treatable underlying causes, as 
demonstrated in several studies. In a large study on hepatitis B patients with 
liver fibrosis or cirrhosis, 87% showed histological improvement, and, more 
impressively, 74% of cirrhosis patients had no cirrhosis on follow-up biopsy               
(≥1 unit score decrease) [78].  
Antifibrotic treatment is a major area of research in hepatology, aiming to 
develop liver-specific medications promoting resorption of fibrous tissue, 
without affecting the healthy parenchyma [79]. Animal studies have shown that 
degrading hepatic fibrous tissue is possible (156, 158), and in humans, 
medications such as obeticholic acid have been shown to reduce fibrosis in non-
alcoholic steatohepatitis (NASH) [80]. Obeticholic acid is also applied in primary 
biliary cholangitis (PBC), hitherto showing improved serum liver tests, but high-
quality randomized controlled studies are lacking [81]. Recently the same 
medication was shown to reduce alkalic phosphatase in PSC as well [82].   
Several histologic scoring systems exist, and liver fibrosis is often characterized 
using a scale of F0–F4: F0 = no fibrosis; F1 = portal fibrosis without septa; F2 = 
few septa; F3 = numerous septa without cirrhosis; and F4 = cirrhosis. For PSC, 
three different scoring systems are applied: Ishak, Nakamura (developed for 
primary biliary cholangitis, PBC), and Ludwig and Batts, all showing histological 
staging of PSC to be associated with transplant-free survival [83-85].     
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1.5 PRIMARY SCLEROSING CHOLANGITIS 
1.5.1 Epidemiology and demographics  
The prevalence of PSC in northern Europe and the US is approximately 1 in 
10’000, while much lower in southern Europe or Asia, with an estimated 
prevalence of 0.02–0.1 in 10’000 [86, 87]. The incidence lies between 0.4 – 
2.0/100’000/year [88], and it has been speculated that it is rising, although 
some attribute this partly to better diagnostics [89-92]. The rising incidence is 
part of a general uprise in inflammatory disease, for which there are several 
suggested mechanisms [85, 93], but certainty is lacking.  
PSC patients typically present in their 30s or 40s. The disorder is rare in children 
and adolescents, with a calculated incidence of 0.2/100’000 person-years [94, 
95], but may be underestimated since the cholangiographic anatomy of liver 
disease remains to be well described [96]. Furthermore, the diagnosis of PSC 
may be delayed as liver pathology is rare in children, and thus often not 
considered early on, and the diagnosis is often seen in conjunction with 
autoimmune hepatitis, with the initial focus on the latter. 
Studies find that 2/3 have concomitant inflammatory bowel disease (IBD) in 
Europe and North America, compared to only 1/3 in Japan [85, 97]. The 
frequency of IBD is notoriously difficult to determine as the two entities do not 
necessarily present themselves together: IBD can appear after liver 
transplantation for PSC, while PSC can be diagnosed after colectomy for 
ulcerative colitis [98-101]. Thus, the removal of one entity does not offer the 
patient full protection against the other one. One in four may have other 
autoimmune diseases [102]. Male patients are overrepresented, but studies 




In summary, PSC is a mix of inflammation, fibrosis, and cholestasis, with a 
multifactorial and poorly understood pathogenesis, hindering the development 
of an effective therapy [85]. A typical description is a pathologically activated 
immune system with genetic and environmental factors, linked to the following: 
• autoimmunity  
• bile homeostasis 
• leakage of gut bacteria or bacterial products                                                             
into the enterohepatic circulation 
 
The most striking pathogenic features are seemingly autoimmune, even though 
immunosuppressants do not alleviate symptoms or affect disease progression: 
prednisolone, budesonide, colchicine, penicillamine, azathioprine, ciclosporin, 
methotrexate, mycophenolate, and anti-tumour necrosis factors monoclonal 
antibodies have all been investigated without success [105, 106].                                        
Genetic factors are involved, with increased risk in siblings of PSC or IBD 
patients [107], and more than 20 genes have been identified [108-116].  
All these possible explanations are flawed by inseparable elements of 
contradictions: an autoimmune disease affected by no known anti-inflammatory 
medications; a condition with cholestasis and bile toxicity, though no effect of 
ursodeoxycholic acid treatment; a disease with inflammation affected by gut 
bacterial products leaking from the intestine, but with no halt in disease 
progression following removal of the intestine.  
No matter the specific etiology, PSC is characterized by progressive 
inflammation affecting the biliary tree, with biliary strictures and fibrosis. The 
fibrosis is described as concentric layers surrounding the cholangiocytes lining 
the bile ducts, often referred to as “onion skin” scarring or periductal fibrosis. 
This finding is considered a hallmark finding of PSC, but may not be visible in the 
early stages of the disease [117]. Histopathology may support the diagnosis but 
is considered obsolete as part of diagnostic practice, rarely offering relevant 
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contributions if performed [118]. It should, however, be part of the diagnostic 
armamentarium for atypical or difficult cases.  
1.5.3 Symptoms, diagnostics, and follow-up 
The development of PSC is typically insidious, rarely symptomatic in the early 
stages. Symptoms develop over time and include right upper quadrant pain, 
pruritus, jaundice, fever, fatigue, and weight loss (11,15). Suspicion is often 
raised in the following settings: incidental finding of abnormal liver 
biochemistry; during diagnostics of patients with newly diagnosed cholestasis, 
cholangitis or IBD; (in more severe cases) liver failure, including variceal 
bleeding or ascites; malignancy (cholangiocarcinoma) [119]. 
The preferred method for diagnosing PSC, is magnetic resonance 
cholangiopancreatography (MRCP), with endoscopic retrograde 
cholangiopancreatography (ERCP) typically reserved for cases with biliary 
strictures requiring intervention or tissue sampling [119]. Liver biopsy is rarely 
recommended, mainly used when suspecting overlap variants with autoimmune 
hepatitis, when small duct PSC is suspected, or when there is doubt regarding 
the diagnosis. Since as much as 2/3 of PSC patients have IBD, colonoscopy is part 
of the diagnostics, even in asymptomatic patients.  
Although no definitive treatment exists besides liver transplantation in cases of 
malignancy or end-stage liver disease, a life long follow-up, preferably in a 
center participating in clinical trials, is recommended [119]. However, the latter 
part of this advice is not always followed, including in Norway. Follow-up 
includes screening for liver failure, fibrosis development, and hepatobiliary and 
colorectal malignancy, and risk assessment regarding poor nutrition, weight 
loss, vitamin deficiencies, and osteoporosis. Annual ultrasound investigation of 
the gallbladder, to search for polyps or other pathology, is recommended in all 
patients. Colonoscopy is performed regularly in patients with and without an 
IBD diagnosis, annually/biannually or every 5 years, respectively [119].  
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The mean time from diagnosis to death or liver transplantation is highly 
variable, ranging from 10 to 22 years in different studies [89, 92, 120-122]. 
1.5.4 Non-invasive risk stratification 
The first PSC specific prognostic model was published by the Mayo Clinic in 
1989 [123]. The revised Mayo risk score is currently the most widely used 
worldwide: an advanced formula based on age, variceal bleeding, and specific 
blood tests (bilirubin, albumin and aspartate aminotransferase (AST)), although 
not validated at the individual level [124]. The Enhanced Liver Fibrosis (ELF) 
test is a specific liver fibrosis test developed to assess fibrosis in chronic liver 
diseases, recently validated in several independent PSC cohorts, where it has 
been shown to predict transplant-free survival [6, 7]. However, these tests have 
yet to be proven valuable in deciding treatment and further investigations in 
individual patients.  
LSM is in some centers part of routine follow-up. Although not part of the recent 
British recommendations on PSC [119], it is recommended in international 
guidelines to evaluate liver disease severity [125]. LSM using transient 
elastography (TE) has been independently validated in PSC, proven to correlate 
well with the histological degree of fibrosis (in particular when severe) and to be 
associated with clinical outcome both at baseline and over time [4, 5, 126]. 
Diagnostic accuracy by TE for severe fibrosis and cirrhosis in PSC was shown to 
be superior to prognostic scores such as aspartate aminotransferase/platelet 
ratio index (APRI), Fibrosis-4 score (FIB-4) and the revised Mayo risk score, and 
found to increase with time [4]. Due to this, TE has been named one of the 
preferred candidates for surrogate endpoints by the International PSC Study 
Group [127]. In this thesis, we describe - for the first time - the use of pSWE and 




2. AIMS OF THE THESIS 
Liver elastography data for healthy individuals and PSC patients are scarce.                     
The ultimate aim was A) to evaluate elastography in children and B) to establish 
LSM as a safe and effective tool for disease monitoring in PSC.                                            
Our specific aims were: 
1. To explore liver elastography in PSC patients 
a. To describe the use of pSWE in PSC, including feasibility                             
and LSM levels (Paper I) 
b. To compare feasibility of pSWE between liver lobes (Paper I) 
c. To describe the correlation between LSM and other signs of liver 
fibrosis: biochemistry, risk scores, B-mode findings (Papers I & IV) 
d. Assuming that 2D-SWE, with its color elastogram, would offer 
advantages in a PSC setting (due to several PSC specific factors: 
scattered fibrosis, dominant stenosis with cholestasis, and transitory 
cholangitis), to compare 2D-SWE, pSWE, and TE head-to-head in a 
PSC cohort (Paper IV) 
e. Describe the change of LSM over time in a PSC cohort                               
(data remains to be published) 
2. To explore liver elastography in healthy participants 
a. To establish reference values for LSM in healthy children and adults 
(aged 4-70 years) using pSWE, 2D-SWE, and TE (Papers II & III) 
b. To compare the different elastography systems head-to-head:                
LSM levels and feasibility (Papers II & III) 
c. To evaluate any effect on LSM by age, gender, or body 
mass/composition, or by different observers (Papers II & III) 
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3. METHODS 
3.1 STUDY DESIGN AND SELECTION OF PARTICIPANTS 
3.1.1 Papers I and IV 
Invited patients were adult non-transplanted PSC patients in western Norway, 
prospectively included 2013-2014 (Study I) and 2017-2018 (Study IV). All 
examinations were performed at Haukeland University Hospital, Bergen. For 
both studies, we used the same cohort, but the number of individuals grew 
between intervals: for study I, we included 55 PSC patients (38 males, 69.1%; 
mean age 46.4 years), compared to 66 PSC patients in study IV (51 males, 77.3%; 
mean age 49 years). In study I, 24 healthy controls were included. 
The medical history was taken, and a B-mode ultrasound examination was 
performed. Patient records were searched for clinical information, including 
complications of liver disease (ascites, encephalopathy, esophageal bleeding). 
Blood was sampled, and standard biochemical analyses were performed as part 
of every visit. APRI and FIB-4 scores were calculated at both intervals. The ELF 
test was analyzed for the second interval (Study IV). For study I, LSM was 
performed using pSWE (Philips iU22); for study IV, we used three different 
systems: pSWE, 2D-SWE (GE S8), and TE (Fibroscan). Two observers 
investigated all patients (pSWE: MV; 2D-SWE and TE: ABM). 
 
3.1.2 Paper II 
A total of 246 healthy children aged 4–17 years were recruited from September 
2017 through January 2018, see flowchart (Fig. 10). All subjects were healthy 
and were divided into predefined age groups: 4–7; 8–11; 12–14 and 15–17 
years. All examinations were performed at Haukeland University Hospital by a 
single pediatrician (ABM), who recorded the medical history and performed a 
clinical examination including height, weight, and waist circumference. B-mode 
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scanning was performed before LSM, including scanning for signs of liver 
steatosis, comparing attenuation of the liver and right kidney (Fig. 11). Three 
subjects were excluded due to either steatosis and/or splenomegaly (n=2) or 
lack of fasting prior to the examination (n=1), leaving 243 for final analyses  
(108 boys, 44.4%). In all subjects, pSWE (Samsung RS80A with Prestige)                
was performed, followed directly by 2D-SWE (GE Logiq E9).                                                  
In a subset of children aged 8–17 years (n=87), TE (Fibroscan) was performed 
following pSWE and 2D-SWE. In another subset from all age groups (n=50),                
two observers performed pSWE and 2D-SWE measurements for                 
interobserver analysis. Blood tests were not performed.  
 
 
Fig. 10. Flowchart, study II.    
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Fig. 11. B-mode image showing liver and kidney tissue, for comparison of attenuation. 
Image: Batman 
 
3.1.3 Paper III 
One hundred healthy adults were recruited and divided into five age groups  
(20-30; 31–40; 41–50; 51–60 and 61–70 years) with ten men and ten women. 
LSM was performed using three systems: pSWE (Samsung RS80A with Prestige), 
2D-SWE (GE Logiq S8), and TE (Fibroscan). A B-mode ultrasound examination 
and blood tests were performed in all subjects. Height and weight were 
recorded, and participants were divided into normal (18–25 kg/m2) and high 
BMI (25.0–30 kg/m2). A flowchart for study III is shown in Fig. 12. 
For interobserver analysis, pSWE and 2D-SWE were performed by two 
observers in a subset of 24 subjects, 
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3.2 ULTRASOUND EQUIPMENT 
In Study I: Philips iU22 (ElastPQ, Philips Healthcare, Andover, MA, USA), 
software version 6.3.2.2, with a convex C5-1 probe.  
In Study II: Samsung RS80A with Prestige (Samsung Medison Co, Ltd, Seoul, 
Korea), with a CA1-7A probe; GE Logiq E9 (GE Healthcare, Milwaukee, 
Wisconsin, USA), with a C1-6 probe and Fibroscan (Echosens, Paris, France; 
incorporated into a GE Logiq S8), using an M-probe.  
In Study III: Samsung RS80A with Prestige (Samsung Medison Co, Ltd, Seoul, 
Korea), with a CA1-7A probe; GE Logiq S8, with a C1-6 probe and Fibroscan 
(Echosens, Paris, France; incorporated into a GE Logiq S8), using an M-probe. 
In Study IV: Philips iU22 (ElastPQ, Philips Healthcare, Andover, MA, USA), 
software version 6.3.2.2, with a convex C5-1 probe; GE Logiq S8, with a C1-6 
probe and Fibroscan (Echosens, Paris, France; incorporated into a GE Logiq S8), 
using an M or XL probe. 
3.3 DEFINITIONS 
The body mass index (BMI) is a unit defining the proportion between height          
and weight, used as a predictor of obesity. It is defined as the body weight in 
kilograms divided by the height in meters squared: kg/m2. Although a validated 
predictor, it is must be converted into z-scores in children, as a BMI of 18 is 
considered overweight in a five-year-old child, while underweight in an adult. 
Furthermore, an increased BMI will not tell you if it is due to fat or muscle tissue. 
The median is used to combat extreme values, easily affecting the mean value, 
pulling it away from the true value. When using the median value, 50% of all 
values are below the median and 50% above. The median is thus sometimes 
referred to as the 50th percentile. 
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The IQR/M is the interquartile range divided by the median, given in percent. 
Just as the median is the 50th percentile, we commonly use the 25th percentile 
and the 75th percentile, which are the values with 25% and 75% of values 
directly below, respectively. Since 25% is a quartile, the 25th percentile is the 
lower quartile, and the 75th percentile is the upper quartile. The values between 
the 25th and 75th percentile are the middle 50% of the data points. This is the 
interquartile range (IQR) and is a measure of the dispersion of the central data 
points (Fig. 13). This must be seen in relationship with the median value, and it 
is thus divided by the median. When creating a boxplot, the lower limit of the 
box is the lower quartile, while the upper limit is the upper quartile (and the end 
of the lines represents the lowest and highest observation in the dataset).  
 
 




Young’s modulus is a term used in physics and is often mentioned in papers on 
elastography. It is merely a description of the relationship between stress and 
strain.  
Imagine the liver (black triangle, Fig. 14) with a given length, L0. When a force is 
applied as shown, the length will increase to Ln. Stress is the force applied 
(relative to the size of the object: in this case, the liver), while strain is the 
relative deformation (Ln minus L0). In this figure, the horses exert a particular 
force, which is the stress, and the difference in length between the red line (Ln) 
and the black line (L0), is the strain. Young’s modulus thus describes the object’s 
properties subjected to this force, how it withstands stress, fighting against 
deformation. In the figure, we see a relatively big difference, with the Ln 
approximately 2x L0. The higher this difference becomes with a given stress,              
the lower Young’s modulus will be.  
 
 
Fig. 14. Young’s modulus is defined as stress/strain. Stress is the force (the pull of the 
horses) relative to liver’s size (black triangle), while strain is the change in length. The 
liver deforms substantially (red triangle), doubling its length (Ln-L0), indicating a low 
Young’s modulus (i.e., a soft liver). Image: Batman. 
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3.4 PERFORMING THE STUDIES 
For all systems, the LSM was defined as the median of 10 acquisitions. LSM was 
performed following B-mode ultrasound scanning, selecting a homogenous area 
of liver tissue free of visible vessels or biliary ducts. In study II, smooth logistics 
was emphasized to ensure optimal cooperation from the participating children: 
children were placed on the examination table and moved between ultrasound 
machines. As always, when examining children, there was an emphasis on 
keeping a pleasant atmosphere, communicating with both the children and their 
legal guardians, explaining everything thoroughly. Children rarely welcome 
surprises in a hospital setting. 
Reliable elastographic measurements were defined according to the specific 
manufacturer’s recommendations: a success ratio ≥60% (i.e., a minimum of 6 
valid acquisitions for every 10 attempts) for all systems and an IQR/M ≤30% for 
all systems except Philips iU22.  
3.5 STATISTICAL METHODS 
Statistical analyses for all studies were performed using SPSS (SPSS Inc, Armonk, 
NY), versions 22, 24 or 25, and MedCalc version 12.7.0.0 (MedCalc Software, 
Mariakerke, Belgium). The candidate performed all analyses in study I, II, and IV.  
All variables were tested for normality using the Shapiro Wilk test and the Q-Q-
plot. Data were presented as either mean (standard deviation, SD) or median 
(range). Student’s t-test or the Mann-Whitney U-test were applied as 
appropriate. We used the Pearson or Spearman’s rank correlation coefficient as 
appropriate. P-values less than 0.05 were considered statistically significant. 
The limits of agreement method with Bland-Altman plots was used to test for 
inter- and intraobserver agreement. The intraclass correlation coefficient (ICC) 
was used to assess interobserver reliability (studies II and III) or inter-system 
correlation (study IV).  
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3.6 ETHICAL CONSIDERATIONS 
Oral and written information was given to all participants. Participation was 
always voluntary, irrespective of age. Written consent was obtained from all 
participants and legal guardians when the participants were too young to give 
legal consent (<16 years). Protocols were in accordance with the Declaration of 
Helsinki and approved by the Regional Committee on Medical and Health 
Research of Western Norway. 
For PSC patients, studies were part of a routine clinical follow-up of chronic liver 
patients, with little risk of adverse events caused by the study, but would cause 
an extra visit for some patients. 
There was a risk of incidental findings for the healthy participants, which could 
raise concern in the participants and their parents and guardians and possibly 
lead to unnecessary investigations and treatment. This was discussed prior to 
the study start and was part of the information to the individual participants and 
their parents.  
The risk of such incidental findings is much smaller in children compared to 
adults. This was part of the evaluation when we deemed the study to have more 
possible benefits than disadvantages. There were no serious incidental findings 
– but liver steatosis, splenomegaly, gall stones, and gall bladder polyps were 
found in a few select subjects and followed up according to clinical guidelines. 
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4. SUMMARY OF RESULTS 
4.1 PAPER I  
Paper I is the first report of liver pSWE in adult PSC patients. We recruited 55 
non-transplant PSC patients (38 males, 17 females; mean age 46 years) and 24 
matched controls. B-mode ultrasonography and blood sampling for biochemical 
analysis were performed on the same day. SWV was measured using Philips 
iU22 in both the right and left liver lobe and the spleen. In 16 healthy controls, 
intra- and interobserver variation were investigated, with right liver lobe LSM 
performed twice by one operator or once by two independent operators, 
respectively.  
Overall, we demonstrated that pSWE was feasible in PSC patients. Intra- and 
interobserver variability were low. Valid LSM in the right liver lobe was 
achieved in all patients and controls. Left liver lobe SWV showed a low success 
rate (valid LSM in 66% of patients) and did not differentiate patients and 
controls. PSC patients were found to have a higher median SWV in the right liver, 
compared to healthy controls (1.26 vs. 1.09 m/s), with the optimal cutoff as 
decided by Youden’s index of 1.24 m/s (~4.6 kPa), yielding a sensitivity and 
specificity of 56.4 and 95.8%, respectively. Right liver LSM correlated with 
indirect fibrosis scores (APRI and FIB-4), but not significantly with the Mayo risk 
score (rho 0.296, p=0.06). Right liver lobe SWV was significantly higher in 
patients with B-mode signs of liver fibrosis (n=21, 38%), coarse liver 
parenchyma, irregular liver capsule, and periductal fibrosis (p-values 0.002, 
0.001 and 0.049, respectively).  
PSC patients without visible B-mode signs of liver fibrosis had an average LSM 
similar to healthy controls, but 12 patients without B-mode signs of fibrosis, 
expressed an LSM above our proposed cutoff value for increased liver stiffness, 
>1.24 m/s. The presence of splenomegaly (n=19, 35%) or bile duct dilatation did 
not impose a significant effect on LSM (p=0.11 and 0.61, respectively). 
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4.2 PAPER II 
Paper II was the first report comparing three principally different elastography 
systems investigated head-to-head in children and established reference values 
for LSM in children for 2D-SWE, pSWE, and TE. A total of 243 children aged 4–17 
years were included. All children were examined clinically, including height, 
weight, and waist circumference. Following a B-mode scan, pSWE and 2D-SWE 
were performed in all subjects, while TE was performed in a subset (n=87) aged 
8–17. In 50 children, pSWE and 2D-SWE were performed by two independent 
operators.  
Feasibility was shown to be high across all systems: 242/243 (99.6%) for 2D-
SWE, 238/243 (97.9%) for pSWE, and 83/87 (95.4%) for TE. TE feasibility was 
significantly lower than 2D-SWE, but not different from pSWE. For the entire 
cohort, the average LSM value was 3.3, 4.1, and 4.1 kPa for 2D-SWE, pSWE, and 
TE, respectively.  
LSM by 2D-SWE was lower than pSWE and TE, with no difference between the 
two latter systems. The inter-system difference between pSWE and 2D-SWE was 
not linear: in individuals with a low average LSM, pSWE was higher than 2D-
SWE, while the opposite was true when average LSM was high, reflecting a 
steeper LSM value slope for 2D-SWE (Fig. 15). 
Interobserver reliability analysis did not show any significant difference 
between observers for any system, with ICC of 0.83–0.84. Individual                           
LSM differences between observers were rarely clinically relevant,                                 
with only 1 in 50 exceeding 1.6 kPa for 2D-SWE and none for pSWE.  
Liver stiffness increased with age, reaching adult values in adolescence.                
We found a gender difference in adolescence, with boys having stiffer livers       




Fig. 15. Scatter plot showing the difference between pSWE and 2D-SWE against 
average LSM. Dots above the horizontal line (0-line), indicate a higher pSWE than                 
2D-SWE; while dots below the line mean that 2D-SWE is higher than pSWE.                          
Dividing average LSM into <3.5 kPa, 3.5–5.5 kPa and >5.5 kPa (vertical lines),                          
the number (%) of subjects with a pSWE LSM above the 2D-SWE LSM,                                               













4.3 PAPER III 
The aim of study III was to establish reference values for LSM in healthy adults, 
using two new pSWE and 2D-SWE systems: Samsung RS80A and GE Logiq S8.  
TE was used as reference. One hundred healthy adults aged 20–70 were 
included, ten subjects for each ten year age period. B-mode ultrasound was 
performed before LSM, and blood was drawn for biochemical analyses in            
all subjects. Interobserver agreement was evaluated in 24 participants.  
All methods showed perfect feasibility (100%). Average LSM was 4.5, 4.1,                 
and 4.2 kPa for 2D-SWE, pSWE, and TE, respectively. LSM by 2D-SWE was 
significantly higher than pSWE and TE, while there was no difference between 
the two latter systems. There was no difference between average LSM between 
operators for pSWE, but a significant difference was found for 2D-SWE (4.5 vs. 
5.1 kPa). However, the interoperator reliability was deemed good for both 
systems, with rho values 0.74 and 0.65 (p-values <0.001) for 2D-SWE and PSWE, 
respectively. Males had significantly higher LSM compared to females for TE and 
2D-SWE. A similar difference failed to reach significance for pSWE (p=0.06).  
There was no significant difference when comparing median LSM values                  







4.4 PAPER IV 
In Paper IV, we aimed to explore feasibility and LSM levels of three different 
elastography systems in PSC patients. Sixty-six patients were evaluated with               
B-mode ultrasonography, blood tests, and LSM by pSWE, 2D-SWE, and TE. 
Feasibility was 93.9%, 71.2, and 89.4% for pSWE, 2D-SWE, and TE, respectively, 
with corresponding median LSM values of 4.9, 7.1, and 6.4 kPa, respectively.  
LSM values correlated well across systems, with rho values 0.65–0.72, p-values 
<0.001. ICC was excellent for pSWE vs. TE (rho 0.91), while moderate for pSWE 
vs. 2D-SWE, and TE vs. 2D-SWE (rho values 0.49 and 0.43, respectively). 
Including normal weight patients only, the latter ICC values increased to 0.92 
and 0.81, respectively.   
Inter-system differences were not linear. 2D-SWE displayed higher LSM than TE 
when average LSM was low, while lower than TE when average LSM was high.  
LSM values correlated significantly with liver enzymes and serum-based fibrosis 
scores, including the ELF test. The suggested ELF cutoff value of 11.2 
discriminated well between high and low LSM. Similarly, LSM rose steeply             
when the Mayo risk score exceeded a value of 0.5, and LSM was higher in 
patients with B-mode signs of fibrosis.  
There was no difference in LSM between those with splenomegaly and normal 
spleen length. However, applying a cutoff of 13 cm, we found a significant 
relationship between splenomegaly and LSM, and we argue that a universal 
cutoff value of 12 cm, regardless of gender or body size, should be reevaluated.  
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5. DISCUSSION 
5.1 METHODOLOGICAL CONSIDERATIONS 
This thesis delves into liver elastography, with liver stiffness measurements of 
both healthy individuals and chronic liver disease patients. Both European 
(EFSUMB) and global (WFUMB) guidelines have explained basic principles and 
technology, and given recommendations on the use of the different elastography 
technologies in practice [31, 51, 52, 129]. Its use has been advocated by the 
international liver disease community [125]. These guidelines are the basis of 
our practice both clinically and in this thesis.  
Chronic liver disease leads to fibrosis, replacing soft liver tissue with stiff fibrous 
tissue. The degree of stiffness corresponds with the fibrosis stage, which 
corresponds with disease severity. An easy, non-invasive way of measuring 
stiffness represents a great leap forward in follow-up of chronic liver diseases.  
New ultrasound models and systems are continuously being developed, 
necessitating new investigations and inter-system comparisons. LSM differs                
due to many differences: elastography methods; underlying algorithms and 
assumptions for calculation; probes/transducers; system users (interoperator 
variability); intraoperator variability; choice of measurement site/scattered 
fibrosis; other underlying biases, e.g., suboptimal measuring technique, non-
fasting state, recent physical exertion, inflammation, cholestasis or right-sided 
heart failure. Some factors represent inherent sources of bias existing 
irrespective of system chosen and should be searched prior to LSM.  
Every system, including different models and probes, needs to be evaluated 
before application in a clinical setting to establish reference values and values 
corresponding to stages of fibrosis. This thesis set out to establish reference 
values for healthy individuals, particularly children, with inter-system 
comparison, and to explore different elastography systems in PSC. 
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Reference values are typically determined by selecting healthy individuals using 
stringent methodology, collecting samples based on a predefined protocol, 
evaluating data distribution and defining the middle 95% as normal, while 
continually searching for errors and/or outliers [130]. These reference values do 
not necessarily correspond to medical decision limits, which may vary based on 
the need for test sensitivity or specificity in a given clinical setting. 
 
When establishing a quantitative method, we have to consider both accuracy 
and precision [131]. A liver subject for evaluation will always have a true LS.    
The true value can never be established with absolute certainty; thus, we aim to 
establish an approximation of the true value. The true LS will have a mean value 
for the entire liver, while different regions may have different LS. Measuring LS 
through multiple acquisitions, results will concentrate around a mean value, 
with a variation that can be either low or high, thus indicating the quality of the 
analysis. In LSM, the variation is described using IQR/M – a high IQR/M indicates 
a less reliable measurement (See 3.3 DEFINITIONS). 
In our case, accuracy would be how close the LSM (median value) is to the true 
LS, while precision describes the degree of variation. Fig. 16 illustrates the 
concept of accuracy and precision. 
 
Fig. 16a-d. a) High precision, high accuracy; b) High precision, low accuracy;                         
c) Low precision, high accuracy; d) Low precision, low accuracy. Image: Batman 
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A good test does not need both high precision and high accuracy, as long as the 
bias is known: in Fig. 16b, the measured value is not close to the true value,             
but this constitutes no problem if the difference is known.  
Imagine that we have a patient with a true LS of 1.0 m/s and two different 
elastography systems. System A always shows measured LSM twice the true 
value, meaning a value of 2.0 m/s. System B yields different values: sometimes 
0.8 m/s, sometimes 1.3 m/s, but always within 50% of the true value. Thus,               
the latter system yields a more accurate LSM, always closer to the true value,  
but it is impossible to know if the LSM at hand is below or above the true value. 
Knowing the systematic difference for system A, this system would, without 
doubt, be preferred. If this difference is unknown, one will choose system B, 
which gives a value closer to the true value.  
It is a problem that clinicians often do not consider these biases in quantitative 
measurements, whether it measures serum lab values or LSM. The measured 
value will always be an approximation, and there will always be some 
variability. The value approximation, or the accuracy, will typically be handled 
by the producer based on internal control and research such as in this thesis, 
while the clinician should focus on the precision level: does a higher value 
during follow-up represent an actual rise, or is it just an expression of random 
variation? These factors are often subject to more control in laboratory medicine 
than in elastography, and there is obviously a need for more investigations.                  
In laboratory medicine, the internal control is strict, with calibration on a regular 
basis: at regular intervals, a test with a known value is analyzed to check for 
accuracy and precision. A similar system for elastography would mean checking 
accuracy and precision regularly using liver fibrosis phantoms with known 
stiffness values. 
Investigating the accuracy of LSM is notoriously difficult since the true LS is 
unknown. The criterion standard is the liver biopsy, but this method is flawed by 
sampling errors and interobserver discrepancy [132, 133], meaning it does not 
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tell the full tale. Furthermore, it is an invasive procedure with serious 
complications seen in approximately 1% [134, 135], and necessitates general 
anesthesia in specific patient groups.  
When investigating normal LSM in healthy individuals (Papers II & III), we are 
quite confident that all or close to all subjects were free of significant liver 
fibrosis, although this is impossible to prove. Performing liver biopsies would 
strengthen our belief’s foundation but would also be unethical in this setting. 
Liver biopsies in our PSC patients (Papers I & IV) would be have been of interest 
as these patients often have liver fibrosis but would be unethical since there was 
no clinical benefit for the patients. In Papers II-IV, we did what is often done 
when lacking the possibility of liver histology: we used TE as a proxy criterion 
standard. TE has been proven to correlate with histological fibrosis score and is 
the most widely studied method. However, it is not evident that TE correlates 
better with histological fibrosis than pSWE or 2D-SWE, as pSWE, 2D-SWE, and 
TE show similar results when compared to biopsy-proven liver fibrosis levels 
[136-138].  
 
5.2 LIVER ELASTOGRAHY IN HEALTHY INDIVIDUALS 
A total of 343 healthy individuals were included: 243 children aged 4–17 years 
and 100 adults aged 20–70 years. One operator examined all children, another 
operator examined all adults, and the two operators were each others’ 
interobservers. All subjects were examined with B-mode ultrasound scanning of 
the liver, kidneys, and spleen prior to LSM. Blood tests were performed in all 
adult participants to rule out liver disease but were deemed unethical in the 
children. This was compensated by a thorough anamnesis and clinical 
examination. All subjects underwent liver elastography using pSWE and 2D-
SWE. TE was performed in all adults and a subset of children aged 8–17 years 
(n=87). A total of 81 subjects had valid measurements for all three systems.  
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              Mean LSM (normal range, mean±1.96 SD)  
                          (lowest observation), kPa 
 
























































        


















(1.7 – 6.1) 
 
* lowest observation; given when higher than the lower end of calculated normal range 
Table 1.                                                                                                                                                                 
Liver stiffness measurement (LSM) values for all age groups and elastography systems.  
For pSWE, mean values across age groups were 3.9–4.9 kPa, increasing 
significantly from 4–7 years to 12–14 years. LSM for age group 15–17 years was 
significantly lower than for 12–14 years (p=0.002). We have no reason to believe 
that LS decreases between these two age groups, supported by the fact that this 
finding only applied to pSWE, and not 2D-SWE and TE. However, LSM 15-17 
years was similar to LSM in adults, and the finding of higher LSM 12-14 years 
compared to LSM 15-17 years and in adults, was made by two independent 
observers. 
The upper limit of normal (ULN) ranged from 5.0 kPa in the youngest children to 
5.7 kPa in female adults, with the highest ULN in boys aged 12–14 years (6.6 
kPa). The feasibility was excellent: 97.9% in children and 100% in adults. 
Interobservation analysis revealed no difference between observers (medians 
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4.10 vs. 4.15 kPa) and an ICC of 0.83 (95% confidence interval (CI) 0.7–0.91), 
with no systematic differences. We found that 4/48 (8.3%) showed a 
discrepancy >1.0 kPa, with the highest value 1.6 kPa. Correspondingly, 7/48 
(15%) showed a discrepancy >20% of the mean LSM between observers, with 
the highest value 42.1%. All values were still within the normal range – meaning 
that the discrepancy did not move healthy patients into a category where 
fibrosis ought to be suspected. A high discrepancy in percentage poses no 
clinical implications if the absolute LSM value is low, but is problematic in 
patients with a high LSM.  
Bland-Altman plots visualize discrepancies, searching for any systematic bias. 
We can assume that in a stiff liver, there is an increased risk of a big difference in 
absolute values (since LSM values are higher) between two observations. 
However, in our normal material, there are only soft livers, albeit with variations 
in softness. The relative differences are not necessarily different in soft and stiff 
livers. However, due to system differences, e.g., software technology and 
underlying algorithms, measurements may increase more in some systems 
compared to others. E.g., when a tissue’s true stiffness increases with a factor of 
2x, one system may display an increase of 1.7x, another system 2.4x. A further 
increase may be linear or non-linear, e.g., another increase of 2x can result in 
LSMs of 3.4x and 4.8x or 3.4x (linear) and 6.7x (non-linear), respectively.   
In Paper II, we used Bland-Altman plots with the difference portrayed in 
percent, but it is equally attractive with absolute LSM values for clinicians.          
Fig. 17a-b shows identical measurements displayed either with differences in % 














Fig. 17a-b. Bland-Altman plots with the average value between the two observers on 
the x-axis, and the difference between observer values, either in percent (a) or in 
absolute values (b), on the y-axis. The figures are created to look for systematic bias:         
is there any tendency of deviation or difference between observers depending on the 
average LSM? Fig. 17a reprinted from Paper II with permission [139].  
In adults, the ICC for pSWE was 0.85, similar to the findings in children. 
Pearson’s correlation coefficient was 0.74 for adults and 0.71 for children.                      
We found 3/24 (12.5%) cases with an interobserver difference >1.0 kPa when 
using 10 acquisitions, compared to 1/24 (4.2%) when using 15 acquisitions. 
There was no observer bias for pSWE in children or adults. In adults, we found 
no significant difference in LSM when applying 5 or 10 acquisitions when 
measuring: 4.1 vs. 4.1 kPa (p=0.08). 
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For 2D-SWE, mean values across age groups ranged from 2.9 to 4.7 kPa. LSM 
rose steadily with age until age 12–17 years. The correlation between age and 
LSM was stronger for 2D-SWE compared to pSWE, with Pearson’s correlation 
coefficient of 0.42 compared to 0.15 (p-values <0.001). ULN ranged from 4.0 kPa 
in the youngest children to 5.7 kPa in female adults, with the highest in boys 
aged 12–14 years (6.9 kPa). The feasibility was excellent: 99.6% in children and 
100% in adults. Interobservation analysis found identical mean values between 
observers, with an ICC of 0.84 (95% CI 0.71–0.91), and no systematic bias. We 
found that 5/50 (10%) showed a discrepancy >1.0 kPa, with the highest value 
2.2 kPa. Correspondingly, 12/50 (24%) showed a discrepancy >20% of the mean 
LSM between observers, with the highest interobserver difference of 51.3%; 
however, none of these discrepancies in LSM resulted in discrepant classification 
regarding the stage of fibrosis. In the subject with the highest percentage value, 
the LSM by observer A was 4.4 kPa, compared to 2.6 kPa by observer B. 
Performing a similar study in children with known liver fibrosis, with identical 
ultrasound systems and observers, would be of interest.  
In the 24 adults, there was a significant difference between observers (4.5 vs. 5.1 
kPa, p=0.009). The ICC, however, was good, with a value of 0.78. Our suggested 
explanation of this interobserver discrepancy is that 2D-SWE is particularly 
user-dependent and that there is a longer learning curve for this method 
compared to pSWE. However, this discrepancy was not present in the 
interobserver analysis of children, which took place only two to three months 
later. Furthermore, in a liver phantom study conducted one year earlier, the 
same two operators had no LSM discrepancy for 2D-SWE [140]. Thus, we cannot 
conclude on the reason for this discrepancy with any certainty.  
An absolute interobserver difference >1.0 kPa was present in 2/24 (8.3%) when 
performing 10 acquisitions and 1/24 (4.2%) when performing 15 acquisitions. 
There was no significant difference in LSM applying 5 or 10 acquisitions when 
measuring in adults: 4.4 vs. 4.5 kPa (p=0.05). 
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For TE, mean values across all age groups were between 3.8 and 4.8 kPa, with 
values increasing significantly from 8–11 years to 12–14 years, and no 
significant difference between 12–14 and 15–17 years. The ULN ranged from 5.6 
kPa in children aged 8–11 years to 6.5 kPa in male adults, with the highest ULN 
in boys aged 15–17 years (6.7 kPa). The feasibility was excellent, with 95.4% in 
children and 100% in adults. Interobservation analyses were not performed. 
The interobserver differences seen across systems are essential to notice, 
with 8-12% deviating more than 1.0 kPa in healthy children and adults, for 
observations made only 5 minutes apart, with different observers. A recent 
study using TE in healthy children found 25% with an interobserver difference 
>1 kPa [141] for examinations >24 hours apart. Studies have shown that 
intraobserver ICC falls from 0.9 to 0.65 when comparing observations 
performed the same day or a few days apart [142, 143]. Interestingly, we find a 
reduced amount of clinically relevant interobserver differences when using 15 
compared to the standard 10 acquisitions, though the number of participants 
(n=24) precludes firm conclusions. At the same time, we find no significant LSM 
difference using 5 acquisitions, compared to the standard of 10, for the 
individual observer. 
Typically, studies report correlations and p-values, but this does not necessarily 
indicate the frequency of large individual discrepancies or whether these 
differences have clinical implications. Studies may report a very high overall ICC, 
while simultaneously reporting individual variability leading to patients moving 
between fibrosis groups F0-1 and F2-4, in one study 17% [144]. Studies report 
the ICC, but do not mention individual differences, whether for TE [145-147], 
pSWE [148-156] or 2D-SWE [142, 143, 157]. Some report agreements for 
fibrosis stages, ranging from 75-92% [145, 146, 155, 156]. In some cases, it is 
possible to find individual differences in tables or figures; however, even in 
studies with individual differences >10 kPa in healthy participants, this may not 
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be specifically mentioned in the manuscript [154]. An expected difference 
between expert investigators of 0.5 kPa has been suggested [142]. 
A near-perfect correlation using consistency instead of absolute agreement 
could still mean significant differences, no matter how low the p-value. In clinical 
practice, we need to know if there is a risk of values fluctuating >1-2 kPa, not 
whether the rho value of correlation is 0.92 or 0.97. Current guidelines highlight 
reproducibility, but only report the degree of correlation, and not the percentage 
of clinically significant differences in individuals [31, 129].  
For all methods, the feasibility was high, ranging from 95.4–100%. High 
feasibility is described in most studies, with values commonly above 90–95%. A 
lower feasibility is described in very young children: one study reporting 66.7% 
in those <2 years, compared to an overall feasibility of 90% [158]. Feasibility is 
affected by several factors: mainly obesity, but also inexperienced operators, 
narrow intercostal spaces, ascites, high age, and female gender [159, 160]. In a 
clinical setting with the same subjects, the feasibility would probably be higher: 
in cases with an IQR/M above 30%, the operator can choose to erase all 
acquisitions and repeat a second time or carry on with acquisitions, choosing            
a total of 15 or 20 acquisitions, increasing the probability of a valid result.                               
In a research setting demanding stringency, we strictly followed our protocol, 
but it would be interesting to perform studies with a protocol describing such 
actions in cases with invalid LSM.  
There was a significant gender difference in adolescents aged 12–17 years 
across all three systems, in adults for 2D-SWE and TE, with males showing a 
higher LSM. Fig. 18 depicts this difference for 2D-SWE. A similar difference was 
noted for pSWE in adults without reaching significance (p=0.06). Adult studies 
have reported a gender difference, for both 2D-SWE [128, 161, 162], pSWE [151] 
and TE [128, 163, 164], but results are conflicting. European guidelines [31] 
mention gender only when describing pSWE, reporting no difference, while 
global guidelines describe higher LSM in males for TE [129]. All studies 
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describing a gender difference find that men have increased LS, never the 




Fig. 18. Liver stiffness measurements by 2D-SWE for all age groups,                                             
with males in blue and females in red. 
 
There is no definite explanation of why liver stiffness should be increased in 
men. However, we know that ovarian hormones, including estrogen, affect 
collagen synthesis, which is the basis for liver fibrosis development [165]. It has 
been shown in animal studies that the response to antifibrotic treatment is 
lower in females [166]. Likewise, estradiol treatment has been shown to reduce 
liver transaminase levels and suppress hepatic collagen content, with a negative 
relationship between the percentage of affected liver tissue and serum estradiol 
levels [167]. Female gender is regarded as protective against fibrosis, and 
menopause and late menarche have been shown to correlate with increased 
severity of liver fibrosis in untreated chronic hepatitis B infections [168]. Muscle 
stiffness, as measured by elastography, is higher during menstruation than 
during ovulation, indicating that fluctuating sex hormones affect tissue stiffness 
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[169]. The same has not been found for breast tissue [170]. As the described 
gender difference in LSM is observational and somewhat inconsistent,                                
a study on LSM in women could help answer this question.  
The finding of increasing LS through childhood was consistent across all systems 
in our study, with no difference between younger and older adults in the range 
20 to 70 years. Previous studies have produced conflicting results in children, 
with several studies describing the influence of age [171-179], while some 
report no correlation [158, 180-183]. The largest pediatric study to date was 
recently published, describing a significant increase with age and a higher LSM 
in males [179]. One study concludes on no influence by age, while reporting 
increasing LSM in subjects above 10 years [184]. All these studies have been 
performed with different approaches, with different age groups and only one 
elastography system. Some studies describe higher LSM in the youngest 
children: one study in children less than one month [174], another in children    
<6 years [175]. Several studies find that children above 12 years have higher 
LSM than those under [171, 172, 176, 177], one describing a U-shaped curve 
with higher LSM in ages 0–2 and 12–18 compared to those 2–11 years [176]. 
There are only three large studies with no significant correlation between age 
and LSM [158, 181, 182], and all report a tendency of higher LSM in older 
children and adolescents. One study found a mean LSM of 4.6 kPa in children >6 
years, compared to 4.1–4.2 kPa in younger children [158], another with mean 
LSM 1.14 m/s (equals 3.9 kPa) (95% CI 1.1–1.7 m/s) in children 10–17 years, 
compared to 1.08 m/s (equals 3.5 kPa) (95% CI 1.05–1.13 m/s) in those <10 
years [182]. It is particularly difficult to compare studies since they define age 
groups differently. It would interesting if all studies used similar definitions or at 
least published scatter plots with individual values across all ages, as in Fig. 19.  
Fig. 19 demonstrates several aspects regarding age influence on LSM values. In 
our studies, age seems to exert a more substantial influence on LSM by 2D-SWE 
than pSWE. We see a rising LSM from early childhood to adolescence, influenced 
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mainly by a raise of the top values more than a raising of the lower bar (the 
lower limit of normality is not much changed with age, while the upper limit is). 
For both systems, there are seemingly more outliers for adolescents than for 
adults. When comparing 12–14 and 15–17 years for pSWE, we see that the 
highest outliers are in the oldest age group. However, it is still evident that LSM 
12–14 is higher than LSM 15–17 years, where values seem to stabilize below 5 
kPa, similar to adult LSM. The same tendency is not seen for 2D-SWE.  
The tendency of outliers in children and adolescents may be the result of several 
underlying factors. With more participants (243 vs. 100), there will be more 
outliers. It is also possible that sex hormone levels during puberty and 
adolescence contribute. We were prepared for more outliers in young children 
since cooperation can be difficult, but there was no such tendency. However, it 
was noted in the preparations to the adult study, that some, in particular lean 
and fit adults, had surprisingly high values. These values lowered significantly 
when participants were instructed carefully regarding mid-expiratory breath-
hold. Participating children were instructed in mid-expiratory breath-hold, but 
no pre-study LSM was performed, and there was no new investigation in cases 






Fig. 19. Liver stiffness measurements according to age for (a) pSWE and (b) 2D-SWE. 
Of note, 2D-SWE was performed by two systems from the same producer: GE Logiq E9 
in children and GE S8 in adults. pSWE is performed using the same machine across all 
ages. Two different observers performed LSM in children and adults, respectively.  
 
We describe increasing LSM with age for all systems, from group 1 (4-7 years) to 
group 2 (8-11 years) to group 3 (12-14 years), where LS seemingly reaches a 
plateau after age 12. LSM in group 4 (15-17 years) was similar to LSM in group 3 
for 2D-SWE and TE but to our surprise, significantly lower than group 3 for 
pSWE, for which we have no good explanation. 
When comparing LSM by pSWE for 15–17 and 12–14 years, we used median 
values since data were not normally distributed: 3.9 kPa and 4.6 kPa, 
respectively, yielding a difference of 0.7 kPa. Some high outliers were noted in 
the older age group, which hindered normal distribution. Using mean values, the 
difference was reduced to 0.4 kPa. However, no matter how this is approached, 
LSM for the older adolescents remains lower. Thus, there is no question whether 
pSWE LSM is reduced in the oldest adolescents, but a question if this represents 
a true LS difference. Why we find this LSM difference, remains to be answered.   
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To explore this inconsistent finding of reduced LSM for pSWE, we performed 
post hoc analyses of LSM by observer B. The same phenomenon appeared                
(Fig. 20), but the statistical strength was substantially lower due to fewer 
participants. Mean LSM was 4.0, 4.5, 4.5 and 3.8 for age groups 4–7, 8–11, 12–14 
and 15–17 years, respectively: LSM group 4 was significantly lower than group 2 
and 3. It is possible to assume that the boxplots (For observer B: Fig. 20a, for 
observer A: Fig. 20b) reveal more information that the inter-group t-tests: we 
see a rising LSM with age from 4–7 to 15–17 years for 2D-SWE, while only a rise 
between 4–7 and 12–14 years for pSWE, with a subsequent fall in LSM for those 
15–17 years. It is easy to assume that such a discrepancy is operator dependent, 
but this is less likely given similar findings in both observers. Furthermore, 
pSWE LSM for adolescents aged 15-17 years, and adults 20-70 are identical. 
There seems to be some factor during early adolescence for which pSWE is 
particularly sensitive to, be it a biological factor or user-subject factors, e.g., a 
different ability to perform breath-hold. We have no indications that 12-year-
olds behaved differently or took instructions differently than 17-year-olds,                  
but this cannot be ruled out.  
It is crucial to keep in mind that the actual LS when measuring was close to 
constant in our studies, as the inter-system investigation was performed in the 
same subjects with only minutes apart. The differences are thus system and/or 
user-dependent. Hypothesizing that LSM increases during childhood, it is 
impossible that both pSWE and 2D-SWE yield perfect measurements of the true 
liver stiffness: the former with a 0% increase in LSM from 4–7 years to 
adulthood in females, compared to nearly 50% in the latter. It is the 
measurement values that increase. It is possible that LSM reaches a peak value 
during puberty before slightly decreasing before entering adulthood and that 
some systems may be more sensitive to such changes during this period, but we 




Fig. 20a-b. Liver stiffness measurements by age groups and elastography systems for 
a) observer A and b) observer B. Fig. 20b reprinted from Paper II with permission [139].  
 
Figures 22–24 depict boxplots across all age groups for the different systems. 
For 2D-SWE, we see LSM from 4–7 years steadily rising into adulthood (Fig. 21), 
while for pSWE, we see a decline in LSM for age 15–17, stabilizing in adulthood 
(Fig. 22). For TE, we see a rise from 8–11 to 12–14 years, with no difference 
between the three older groups, including adults (Fig. 23). It should be 
mentioned that for 2D-SWE, we used one system for adults and another system 
for children and adolescents, while systems were identical for pSWE and TE 




                                                                           
Fig. 21. Liver stiffness measurements by two-dimensional shear wave elastography 
(2D-SWE) for all age groups. 
 
                                                         
Fig. 22. Liver stiffness measurements by point shear wave elastography (pSWE)                      
for all age groups. 
 
Fig. 23. Liver stiffness measurements by transient elastography (TE) for all age groups. 
 67 
The influence of age on liver stiffness, although commonly observed, cannot 
presently be explained, and we have not been able to find any specific 
hypotheses on this subject. Similar findings are described in other organs, 
including the pancreas [185] and spleen [186]. A possible explanation can be 
similar to the cause of a gender difference, as discussed above. The body of the 
developing child and adolescent goes through massive changes well beyond a 
mere gain in weight and height, and influences of different hormones are 
present during the entire childhood, not only a part of adolescence and puberty.  
5.3 LIVER ELASTOGRAPHY IN PSC 
In Paper I, we describe how pSWE is feasible in PSC patients, with successful 
measurements in 100% using a right intercostal approach, compared to 93.9% 
in Paper IV (see Discussion section of Paper IV regarding feasibility and quality 
criteria). Left liver lobe LSM showed only moderate feasibility (66%) and (more 
importantly) poor diagnostic value. The 55 PSC patients were compared to 24 
healthy controls, demonstrating a significant difference in LSM, with an optimal 
cutoff of 1.24 m/s (~4.6 kPa) as decided by Youden’s index. In Paper IV, we 
describe a similar cutoff of 4.9 kPa, but this is calculated using TE values as gold 
standard. Our cutoff value of 1.24 m/s is identical with an earlier published 
cutoff for the same system, yielding a sensitivity of 75% and a specificity of 90% 
[187]. We report a lower sensitivity of 56%, but with a higher specificity of 96%: 
only 1 in 24 healthy controls had an LSM above cutoff. Using our cutoff value, we 
can be quite confident of disease if above this value (high positive predictive 
value, PPV), but the corresponding negative predictive value was low.  
The LSM difference between patients and controls is readily appreciated using a 
boxplot (See Fig. 3, Paper I [188]). 
The area under the curve (AUC) value was 0.775, which is considered good. 
However, the curve displays a problem (Fig. 24): We will catch 50% of PSC 
patients without false positive results, but the test shows poor qualities when 
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trying to find more patients, rapidly including healthy controls.                                           
If we want to find 90% of patients, 75% of healthy controls will follow,                               
which is clearly unwanted.  
                       
Fig. 24. Area under the curve (AUC), displaying sensitivity and specificity of LSM, 
where sensitivity is the percentage of PSC patients found by the test; and 100-
specificity is the percentage of healthy controls with a “positive” test, falsely indicating 
that they have PSC. Reprinted from Paper I with permission [188]. 
 
Thus, if LSM was above 1.24 m/s, PSC was deemed very probable in our mixed 
cohort consisting of both patients and controls. Two clarifications are needed 
having said this:  
1) LSM is not a diagnostic test, but as chronic liver disease leads to a higher liver 
stiffness, increased LSM will heighten the probability of liver disease;  
2) when applying a cutoff value to separate patients and the healthy, the test’s 
predictive values will depend on the disease prevalence. With a sensitivity of 
56.4% and a specificity of 95.8%, our cutoff value will cause us to label 56.4%             
of patients and 4.2% of healthy controls as ‘positive.’ With 55 patients and 24 
controls, we will have 31 patients and one healthy, yielding a PPV of 31/32 = 
0.97. Thus, in our cohort, chances of disease will be 97%, given a value >1.24 
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m/s. Screening the general public, where the prevalence is very low, the same 
cutoff value would cause a much lower PPV: our 55 PSC patients would be 
matched by 550’000 non-PSC individuals. Using the same test criteria, we would 
still label 31 PSC patients as ‘positive,’ but now compared to 23’100 non-PSC 
individuals with a positive test, lowering PPV from 0.97 to 0.0013. If 
implementing a screening program, the cutoff value would have to be set much 
higher, lowering sensitivity and increasing specificity. Prevalence and pretest 
probability is important to consider before implementing such testing [189].                     
Our example ignores the fact that there any many other liver diseases and other 
confounding factors which may increase LSM, and that there may be PSC 
patients without a diagnosis in the general public. 
In those with a lower LSM, other tests are warranted to separate PSC patients 
from the healthy. Analyzing PSC patients from Paper IV, 41% had an LSM <1.24 
m/s, and 49% an LSM <1.28 m/s. No PSC patients with an LSM below these 
values had an elevated ELF test ≥11.2 or an increased Mayo risk score (≥0.5).  
Analyzing PSC patients with an elevated pSWE LSM, we find that 21/31 (67.7%), 
displayed normal liver parenchyma at baseline (Paper I), with nearly identical 
figures during follow-up (Paper IV). All participants displaying coarse 
parenchyma had an LSM indicating fibrosis, both for pSWE and TE. B-mode 
findings will appear well into the disease course and are thus not a sensitive 
marker for subtle progression of fibrosis. The literature reports sensitivity                
and interobserver agreement as low as 41 and 35%, respectively [190-192].                            
It has been shown that this can be improved using artificial intelligence [193], 
but this is not currently available in clinical practice.  
Splenomegaly is not part of the mentioned B-mode signs of liver fibrosis, but 
may indicate portal hypertension secondary to the liver disease and is easily 
quantified by B-mode ultrasound. A spleen length ≥12 cm has been reported to 
be negatively associated with prognosis in PSC patients [5, 194]. We could not 
replicate this finding, but setting the cutoff at 13 cm, we found a difference with 
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significantly higher LSM in those with splenomegaly. Spleen size depends on 
body size and weight, and we propose that cutoff values should consider body 
size and that a change in spleen size may be an even better prognostic marker. 
There was a highly significant relationship between LSM and serum markers at 
baseline and in follow-up, with APRI scores showing the highest correlation to 
LSM in both investigations, in Paper IV equal with Mayo risk score correlation 
(Table 2). All correlations increased between the two time points. A possible 
contributing factor to this rise is increased fibrosis over time in the cohort,            
as tests are more precise in cases of more advanced fibrosis.  
Another factor may be missing data: for APRI and Mayo risk score there                     
was missing data in 25% at baseline, compared to only 1.5% in follow-up.                            
It is also possible that an increasing number of participants contributed,                            
and that the operator technique improved over the years, yielding more               
precise measurements. 
 Baseline (Paper I) Follow-up (Paper IV) 
 pSWE LSM P-value pSWE LSM P-value 
ELF – – 0.57 <0.001 
APRI 0.49 0.001 0.67 <0.001 
Mayo RS 0.30 0.06 0.67 <0.001 
FIB-4 0.37 0.017 0.59 <0.001 
AST 0.21 0.187 0.60 <0.001 
Albumin –0.36 0.011 –0.46 <0.001 
Thrombocytes –0.32 0.022 –0.40 0.001 
ALP 0.25 0.085 0.58  <0.001 
Table 2. Correlation between liver stiffness measurements and laboratory values and 
fibrosis/prognostic scores.  
 
The ELF test was only investigated in follow-up; thus, we cannot provide any 
data on change over time. A strong and independent correlation with prognosis 
in PSC patients has previously been reported for ELF [6, 7]. 
While LSM is indeed a robust surrogate marker of liver fibrosis, it may not 
outperform all serum-based tests under all conditions. Some studies have 
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demonstrated that the combination of LSM and fibrosis markers performs better 
than LSM alone [8-10]. In PSC, a dominant stenosis causing cholestasis is a 
frequent finding and may influence LSM, without being indicative of true liver 
fibrosis [11]. Thus, comparing each elastography platform to the ELF test                            
as the leading serum-based liver fibrosis test in PSC is of high interest. 
PSC is a complex disease with many factors other than fibrosis affecting disease 
progression and risk of death or transplantation. Even a simple blood test such 
as alkaline phosphatase (ALP) is strongly linked with outcome [195]. Several 
factors other than traits of the disease, may negatively influence the ability to 
perform successful LSM, necessitating the use of serum markers [12]. A recent 
study demonstrated the excellent properties of liver elastography while arguing 
that serum markers still have a role due to both availability and cases of failure 
to obtain a valid LSM [196]. Furthermore, serum-based tests are not operator 
dependent [7]. Several publications advocate using simple serum biomarkers              
in primary care, with non-invasive tests including elastography as part of the 
subsequent specialist evaluation [13-17].  
When trying to separate PSC patients with or without advanced fibrosis, it is 
paramount to evaluate the puzzle pieces at our disposal. The perfect test does 
not exist, and LSM remains only a part of the puzzle. Together with clinical 
information, biochemistry, serum fibrosis markers and prognostic markers,                   
the LSM value, and perhaps especially a tendency of changing LSM over time,    
has its place in the diagnostic armamentarium in chronic liver patients. 
The interquartile range divided by the median, given in percent (IQR/M, see 
3.3 DEFINITIONS), is a measurement of dispersion: when measuring, are values 
close to each other, or is there a substantial variability? A high IQR/M means 
that measurements vary, representing uncertainty. When TE (Fibroscan) was 
introduced in 2003, the producer recommended two reliability criteria: the 
IQR/M, which should be 30% or less, and success rate (the ratio between valid 
and the total number of acquisitions), which should be 60% or above [31]. The 
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latter has since been removed [197]. The same authors introduced the concept 
of dividing IQR/M into “very reliable,” “reliable” and “poorly reliable,” for IQR/M 
values of ≤10%, 10–30%, and >30%, respectively. This finding has not been 
externally validated but is still adopted by the producer. The concept of IQR/M 
≤30% has been adopted in pSWE and 2D-SWE systems, even though it is 
specified that evidence is lacking [31]. Guidelines recommend using this 
reliability criterion but do not specify whether this is independent of the 
measuring unit. In Paper II, we describe how IQR/M is different for identical 
measurements given in either kPa or m/s, with IQR/M twice as high in kPa as             
in m/s (Fig. 25). Thus, when using m/s, an IQR/M of 30% equals 60% with 
measurements in kPa; still, publications have been made where IQR/M ≤30%             
is applied even in the setting of measurements in m/s [198].      
Fig. 25. Scatter plot of interquartile range / median (IQR/M) in % for kPa (x-axis) and 
m/s (y-axis). We see a near-perfect linear correlation, with IQR/M in kPa twice the 
IQR/M in m/s. Reprinted from Paper II with permission [139].  
 
In Paper IV, we used three systems for measuring LSM in adult PSC patients:            
2D-SWE and TE, both recommending IQR/M ≤30% as a reliability criterion, and 
pSWE from a producer not recommending this criterion. In our paper, we noted 
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that the feasibility was 93.9% for pSWE, compared to 89.4 and 71.2% for TE and 
2D-SWE, respectively. We speculated that the difference in reliability criteria 
was part of this difference, even if inter-system differences have been 
demonstrated, with higher feasibility for TE compared to 2D-SWE in                       
difficult-to-scan patients [199].  
Post hoc calculation of the IQR/M for pSWE reveals that applying this criterion 
for all systems, would have dramatically changed the outcome: only 45/66 
(68.2%) patients had an IQR/M ≤30%. Since measurements with pSWE were 
performed using m/s and not kPa, the real feasibility would be even lower: only 
11/66 (16.7%) had an IQR/M ≤15% (Table 2). Thus, most of the accepted and 
valid measurements by pSWE would be deemed invalid if all systems applied the 
same criteria. This finding should raise suspicion regarding how we use IQR/M 
as a reliability criterion, as we found that pSWE seemingly performed as good or 
better than the other systems, even when accepting measurements with a very 
high IQR/M. 
 
 Requirements for valid liver stiffness measurement 
 Producer 
recommendations 
SR >60   
only 
IQR/M ≤30             
+ SR>60 
IQR/MkPa ≤30 + 
SR>60 
pSWE 93.9%                                
(4 SR) 
93.9%            
(4 SR) 
65.2%                   
(4 SR, 19 IQR/M) 
13.6 %                         
(4 SR, 53 IQR/M) 
2D-SWE 71.2%  
(4 SR, 15 IQR/M) 
93.9%                 
(4 SR) 
71.2%  
(4 SR, 15 IQR/M) 
71.2%  
(4 SR, 15 IQR/M) 
TE 87.9%                                
(6 SR, 2 IQR/M) 
90.9% 
(6 SR) 
87.9%                   
(6 SR, 2 IQR/M) 
87.9%                    
(6 SR, 2 IQR/M) 
* Ignoring the success rate requirement, 2D-SWE would still have four patients with invalid results                 
(not able to obtain LSM), pSWE would still have four patients (2 patients: unable to obtain invalid results, 
the final two had an IQRM >30 as well), for TE 5 had no valid acquisitions, but the last one would have 
yielded a valid result. 
 
Table 2. Feasibility based on different recommendations for point shear wave 
elastography (pSWE), two-dimensional shear wave elastography (2D-SWE), and 
transient elastography (TE). The different recommendations are combinations of either 
interquartile range divided by the median in percent (IQR/M) or success rate (SR).  
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For TE, IQR/M is a key factor for discrepancy in fibrosis staging by TE and 
histology [200, 201]. Although this link is not found in all investigations [202], it 
is recognized by EFSUMB guidelines [31]. These studies, comparing histological 
fibrosis and TE, found that an IQR/M <21% was the best cutoff for a reliable 
LSM, but with acceptable reliability for IQR/M 21–50% in patients where LSM 
was below 9.5 kPa. This is consistent with what we see in clinical practice, that        
a low LSM probably reflects a truly soft liver, even in the presence of a high 
IQR/M, while a high LSM «needs» a lower IQR/M to be trusted. Thus, both the 
real LS and the different systems play a role, affecting the IQR/M. In Paper IV, 
where we discussed the vast difference in feasibility, we also describe that the 
different systems revealed differences in LS measurements. Applying the 
mentioned cutoff of 9.5 kPa, we find that 57 patients were below this limit       
when using pSWE, compared to 48 and 41 by 2D-SWE and TE, respectively.                              
Our findings are consistent with the mentioned study, with acceptable 
measurements, even with IQR/M up to 50%, or even above.                                              
Median (IQR) for the entire cohort was 4.8 (2.8), 6.8 (4.5), and 6.9 (5.6)                           
for pSWE, 2D-SWE, and TE, respectively. 
The inter-system differences are challenging to characterize in a few words. 
Differences were not linear, but subject to a more complex relationship, as 
described in healthy individuals and liver elasticity phantoms. In Paper IV, we 
were able to show that various inter-system differences were affected by 
different factors, such as increasing differences between pSWE and TE levels 
with increasing BMI. pSWE LSM was the single factor affecting the difference 
between pSWE and 2D-SWE, which only reflects the non-linear relationship: 
when pSWE levels increased, the 2D-SWE level did not follow accordingly, which 




Fig. 26. Scatter plot showing liver stiffness measurement (LSM) by pSWE vs. 2D-SWE: 
with very high pSWE values, the 2D-SWE did not follow accordingly. 
 
The correlation between LSM values across systems was assessed using ICC.  
The ICC was excellent between pSWE and TE, but only moderate, nearly poor, 
for 2D-SWE versus the two other systems. This was primarily caused by a high 
BMI, and excluding obese and moderately overweight individuals (cutoff 27-28 
kg/m2), caused the ICC to increase from 0.43-0.49 to 0.81-0.92. We also suggest 
that the real inter-system ICC involving 2D-SWE may have been falsely elevated, 
as 2D-SWE often yielded invalid measurements in cases with a massive LSM 
difference between pSWE and TE. If one system provides no value in difficult-to-
scan patients with a high degree of variability, the results will necessarily seem 
better than what is reality. It is thus not only essential to provide readers with 
feasibility in numbers, but also try to explain factors causing invalid 
measurements. This can be compared to a study on LSM variability where one 
system is applied in a cohort of morbidly obese patients with cirrhosis, while 
another system investigates lean, healthy young adults. Highly significant 
differences would be expected without providing any useful information on real 
inter-system differences. 
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5.4 STRENGTHS AND LIMITATIONS 
The main strength to be mentioned is a substantial amount of data acquisition, 
gathered using stringent methodology: 343 healthy persons were subject to 
ultrasound investigation and liver elastography using two different elastography 
systems – with 187 investigated by three different systems and 74 investigated 
by two observers. Every measurement consisted of a minimum of 10 
acquisitions. Our pediatric material represents the first description of multiple 
elastography systems in a head-to-head comparison in healthy children. Care 
was taken to conduct everything according to protocol and to ensure that all 
participants were healthy.  
For the PSC cohort, we investigated a substantial amount of patients (55 in study 
I and 66 in study IV), considering that PSC is a rare disease and with 
investigations performed in a sparsely populated country. In both papers, 
investigations were performed in a clinical setting with blood tests, clinical 
examination, and B-mode ultrasonography being performed, allowing a broad 
approach to the included patients. We explored three different systems (two of 
which for the first time) and evaluated interobserver differences and feasibility 
of LSM in both the right and left liver lobe. 
The main limitation is the lack of a criterion standard. In liver elastography, 
where an estimation of liver fibrosis is the goal, the criterion standard, although 
flawed, is the liver biopsy. It would be especially welcome in the studies on PSC, 
where liver fibrosis was probable but the degree unknown. However, liver 
biopsy was considered an unethical procedure as it was not clinically indicated. 
Liver histology in the healthy subjects would be highly unethical. Furthermore,       
it would have necessitated general anesthesia in the children, and the risk of 
complications would be present in all age groups.  
The use of TE as a gold standard is complicated. TE has been shown to correlate 
with liver histopathology but represents a surrogate assessment with imperfect 
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correlation with a flawed criterion standard. Still, it is the elastography method 
most validated thus far. Investigations comparing both pSWE and TE with liver 
histopathology, do not find any convincing evidence of these systems performing 
differently [155, 203, 204], and 2D-SWE has demonstrated diagnostic 
performance similar to TE, with a high degree of correlation with fibrosis staging 
by liver biopsy [204-207].   
Thus, we are left with an imperfect gold standard at best performing at the same 
level as the very systems we are trying to evaluate.  
Another way to increase the probability of a healthy liver is blood tests, which 
we performed in adults, but not in the children. Liver disease in children is rare 
in Norway, and children are less able than adults to give proper consent. It was 
thus judged unethical to impose blood tests on healthy children. Furthermore, 
negative blood tests would not rule out liver disease with absolute certainty. 
Ideally, we should have included children from infancy, to create reference 
values for all ages, and TE should have been performed in smaller children. The 
latter would require a different TE probe, which we did not possess. It would 
also be better to have the B-mode ultrasound investigation performed by an 
experienced pediatric radiologist, but was practically not feasible.  
Paper I has no gold standard, with no liver biopsy and no TE. Ideally, there 
should have been a TE examination to strengthen findings and, preferably, a 
liver biopsy. The study’s scope was not to calibrate LSM against a gold standard 
but to explore pSWE in PSC and compare LSM against other signs of fibrosis. 
Furthermore, the ELF test was not available at the time.  
Another limitation is where LSM was gathered. In all studies, all 10 valid 
acquisitions were made in the same part of the liver. It is unknown whether 
having a protocol attempting to establish LSM in the entire liver, would have 
yielded different results. This would have been especially interesting in the PSC 
cohort, with its inherent scattered fibrosis.  
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6. CONCLUSION 
Liver elastography is feasible across multiple ultrasound systems, both in the 
healthy and in patients with chronic cholestatic liver disease, and there is a high 
degree of interobserver correlation. We have established LSM reference values 
for both children and adults, and find that LSM seems to increase with age until 
adolescence, stabilizing on adult levels. In children, 2D-SWE yields lower values 
than pSWE and TE, while 2D-SWE yields the highest values in adults. There is a 
gender difference, with males exhibiting higher LSM than females in adolescence 
and adulthood, but not in early childhood. 
LSM is increased in PSC, and it is correlated with other signs indicating liver 
pathology: serum biomarkers; fibrosis and prognostic scores; and B-mode 
ultrasonographic findings, including spleen length ≥13 cm. The latter finding 
indicates that splenomegaly should be defined according to gender and body 
size.  
We find that the correlation between LSM by 2D-SWE and the other systems is 
affected by BMI, and care should be made when investigating obese patients.              
It is interesting to note that while 2D-SWE showed near-perfect feasibility in the 
healthy, its feasibility dropped dramatically in a cholestatic liver disease cohort. 
This could be due, at least partly, to the fact that 2D-SWE demands more training 
than pSWE and TE. 
The IQR/M varies greatly depending on the measurement unit and should be 
used actively when interpreting LSM values.  
Through demonstration of feasibility and correlation with liver fibrosis, this 
thesis strengthens the belief that elastography in combination with conventional 
ultrasound allows us as clinicians to perform a thorough and in-depth evaluation 
of the patient’s liver in a single session, without spending much time or causing 
the patient any discomfort.  
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7. FUTURE PERSPECTIVES 
Elastography is already established as a valuable tool for non-invasive liver 
stiffness measurement, and reference values for both adults and children have 
been published. Similar studies with a head-to-head comparison of different 
systems are missing in younger children (0-3 years). Gender difference is not 
fully explored, and future studies should include a thorough examination of this, 
including more healthy subjects of both genders, assessing puberty and 
menarche as part of the study. It could also be of interest to perform LSM in 
adult women in different parts of the menstrual cycle, to establish whether 
hormones affect measurements. Similarly, it would be of value to explore how 
LSM fluctuates in both healthy subjects and chronic liver patients, as it is 
unknown how much LSM can increase without representing a true worsening: 
such a study calls for interobserver analyses and the use of different 
elastography systems. It is paramount that not only correlation is reported,           
but also discrepancies in absolute values. Research questions should reflect 
clinical needs whenever possible. 
The use of quality criteria such as IQR/M and SR is still under debate, 
necessitating more investigations. More studies with multiple systems and 
simultaneous liver biopsy, emphasizing quality criteria, should be performed. 
That pSWE seemingly outperformed 2D-SWE even in cases where the 
measurement should have been deemed invalid if the criteria of IQR/M≤30 had 
been applied, warrants future studies. Maybe a lack of such criteria could be met 
by an increased number of acquisitions? A protocol could include 20 
acquisitions, noting the IQR/M level at the first 10, 15, and 20 acquisitions, 
respectively. Rather than accepting old criteria established by TE, care should be 
taken to find if IQR/M should be used and if so: at what level. 
Although having cemented the obvious strengths of liver evaluation through 
elastography, there is still much to do. 
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Abstract—Point shear wave elastography (pSWE) is an ultrasound-based method for non-invasive quantification
of liver fibrosis. The objective of this study was to explore liver pSWE in patients with primary sclerosing cholan-
gitis (PSC) for assessment of fibrosis. Fifty-five non-transplant patients with PSC (38 males, 17 females; mean age:
46.4 y) were included and compared with 24 matched controls. Median (range) PSC duration was 8.1 (0–33) y. Ul-
trasonographic scanning followed by liver stiffness measurement by pSWE was performed using a conventional
ultrasound system (Philips iU22). Signs of liver fibrosis on B-mode were identified in 21 patients (38%). Spleno-
megaly was found in 19 patients (35%) and ascites in two patients (4%). Successful pSWE measurements were
achieved in the right liver lobe of all individuals and in the left liver lobe of 36 patients (65.5%). PSC patients
had significantly higher median shear wave velocity (SWV) than controls in the right liver (median [range]
SWV 1.26 [0.73–2.57] m/s vs. 1.09 [0.88–1.25] m/s, p , 0.001). SWV measured in the left liver lobe and spleen
did not differ between PSC patients and controls. Our findings indicate that PSC patients have increased median
SWV, indicatingmore fibrosis comparedwith controls; however, a wide range of SWVvalues were obtained among
PSC patients, possibly reflecting the various stages in disease development. (E-mail: mette.vesterhus@
helse-bergen.no)  2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Key Words: Primary sclerosing cholangitis, Point shear wave elastography, Non-invasive, Liver fibrosis, Elastog-
raphy, Ultrasound.
INTRODUCTION
Primary sclerosing cholangitis (PSC), a chronic inflam-
matory disease affecting the biliary tree, leads to liver
fibrosis and cirrhosis over time, with a reported median
transplant-free survival time of 12–21 y (Boonstra et al.
2013; Broome et al. 1996). Medical therapy with
proven benefit is lacking, and PSC is a frequent
indication for transplantation.
A major challenge in PSC is the lack of valid prog-
nostic markers and biomarkers of disease activity
(Hirschfield et al. 2013; Karlsen et al. 2014).
Fibrogenesis is an important pathogenetic pathway in
PSC and a target of treatment in several clinical trials.
A serum marker panel of fibrosis, the enhanced liver
fibrosis (ELF) test, was reported to distinguish mild
from advanced disease in PSC by an area under the
curve of 0.81 and to predict prognosis independently of
other biomarkers, underscoring the importance of
accurate liver fibrosis estimation in PSC (Vesterhus
et al. 2015). However, for other etiologies of liver fibrosis,
some studies indicate an improved performance of ultra-
sound elastography compared with ELF or an incremen-
tal value of the combination of the ELF test and liver
stiffness evaluation by ultrasound elastography
(Cobbold et al. 2010; Wahl et al. 2012). Hence, better
methods for the diagnosis, grading and monitoring of
liver fibrosis are warranted.
Ultrasound elastography is a technique measuring
liver stiffness as an expression of fibrosis and has
emerged as an important tool in the diagnosis and
follow-up of liver fibrosis and cirrhosis, largely replacing
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liver biopsy in hepatitis B and C (Cosgrove et al. 2013;
Ferraioli et al. 2015). The status of liver biopsy as the
gold standard for liver fibrosis assessment has long
been challenged because of its invasiveness and risk of
serious complications, as well as the substantial
sampling error and inter-observer variation between pa-
thologists (Castera and Pinzani 2010; Cholongitas et al.
2006; Thampanitchawong and Piratvisuth 1999). Liver
biopsy is generally not indicated in PSC for either
diagnosis or follow-up because of the patchy disease dis-
tribution and consequent sampling bias, except in cases of
suspected small-duct disease or autoimmune hepatitis
overlap (Chapman et al. 2010; European Association
for the Study of the Liver 2009). Ultrasound
elastography has the advantages of being non-invasive
and repeatable and offers the possibility of investigating
several regions of the liver, thus reducing sampling
bias. Guidelines for the use of elastography in clinical
practice have been published (Bamber et al. 2013;
Cosgrove et al. 2013); however, reports on elastography
in PSC are scarce (Corpechot et al. 2006; Hagstrom
et al. 2012; Righi et al. 2012).
Interestingly, a recent publication reported that base-
line values of transient elastography (TE), as well as the
change in liver stiffness measured by TE, are associated
with clinical outcome in PSC (Corpechot et al. 2014).
Point shear wave elastography (pSWE) is a more recent
technology than TE, with the advantage of being incorpo-
rated into high-end ultrasound equipment, allowing B-
mode ultrasound guidance of elastography measurements
and an integration of liver stiffness measurement with a
full evaluation of the liver. Some studies of pSWE in pa-
tient populations with chronic liver disease of heteroge-
neous etiologies have included PSC patients in small
numbers insufficient for sub-analysis (Righi et al.
2012). To our knowledge, there are no studies exploring
pSWE in PSC alone. In this study, we aimed to evaluate
liver stiffness in PSC patients and compare them with
healthy controls using ultrasound pSWE.
METHODS
Patient population and data collection
The protocol was in accordancewith the Declaration
of Helsinki and approved by the Regional Committee for
Health and Research Ethics in Western Norway. Patients
invited to participate in the study belonged to a known
cohort of non-transplanted PSC patients in western Nor-
way. Informed written consent was obtained from each
patient enrolled. PSC patients with a histologically
confirmed diagnosis of autoimmune hepatitis (AIH)
were classified as PSC–AIH overlap. Patients were exam-
ined, and patient records were searched for information
on clinical data, including ascites, encephalopathy,
esophageal varices, variceal bleeding and inflammatory
bowel disease status at the time of serum extraction. On
the day of ultrasound and elastography, blood was
sampled and biochemical analyses were performed using
the standard routine laboratory protocols, including C-
reactive protein, hemoglobin, leukocytes, platelets,
creatinine, total bilirubin, albumin, International Normal-
ization Ratio, aspartate aminotransferase, alanine amino-
transferase, alkaline phosphatase and g-glutamyl
transferase. The Aspartate Aminotransferase-to-Platelet
Ratio Index (APRI) and Fibrosis-4 (FIB-4) scores of
fibrosis were calculated using published algorithms
(Sterling et al. 2006; Wai et al. 2003). Mayo risk scores
were calculated using the algorithm for the revised
Mayo risk score (Kim et al. 2000). Blood samples were
not taken from healthy controls.
B-Mode ultrasound examination
Immediately before pSWE examination, all patients
underwent B-mode ultrasound scanning of the liver and
spleen. All examinations were performed by a single
operator (M.V.) using a standardized scanning protocol
on a Philips iU22 (Philips Healthcare, Andover, MA,
USA) scanner. Scores were registered for liver capsule
regularity, parenchyma heterogeneity, liver angle appear-
ance, presence of ascites, gallbladder stones or polyps
and the presence of bile duct variability or sludge. Mea-
sures were taken for liver size in a sagittal section in
the medioclavicular line; gallbladder length, width and
area; spleen length and width; and portal vein diameter.
Splenomegaly was defined as spleen length .12 cm.
Point shear wave elastography
Liver and spleen stiffness was measured in the fast-
ing condition by pSWE using a conventional ultrasound
system (ElastPQ, iU22, Philips Healthcare) equipped
with a convex probe (C5-1). For liver measurements, pa-
tients and controls were examined in the supine position
with their right arm maximally abducted. A 0.5 3 1.5-
mm region of interest was placed 2–6 cm deeper than
the liver capsule in hepatic tissue, avoiding large vessels
or bile ducts (Fig. 1). Right lobe measurements were
made in an intercostal position, whereas left liver lobe
measurements were performed in a subcostal epigastric
position, with sampling from the central portion of the
left liver lobe. Spleen stiffness was measured by pSWE
from a left-side intercostal position. All pSWE measure-
ments were acquired in relaxed mid-breath hold with
minimal scanhead pressure being applied. A valid mea-
surement was defined as the median value of 10 acquisi-
tions, provided the requirement for a success rate $60%
was also fulfilled. The acquisitions were performed dur-
ing separate breath holds in the same general area within
one segment, avoiding visible bile ducts and blood
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vessels. Results were given as median shear wave veloc-
ity (SWV) in meters per second. All measurements were
performed by a single investigator (M.V.). To evaluate the
intra- and inter-observer variation, pSWE of the right
liver lobe was performed twice in 16 healthy controls
by the same investigator (M.V.) or two independent inves-
tigators (M.V. and A.M.), respectively, according to the
protocol described previously.
Statistical analyses
Version 12.7.0.0 of SPSS 22 (IBM, Armonk, NY,
USA) and MedCalc were used to perform all statistical
analyses, and p values, 0.05 were considered to indicate
significance. Variables were tested for normal distribu-
tion, and Student’s t-test or the Mann–Whitney U-test
were applied as appropriate. Data are presented as
mean (SD), or as median (range) when the data were
not normally distributed. Correlations between SWV
and clinical parameters, biochemical scores of fibrosis
or Mayo risk scores were tested by Spearman’s rank order
correlation coefficient (r). Intra-observer agreement was
tested using the limits of agreement method (Bland and
Altman 1999).
RESULTS
Sixty-four non-transplant PSC patients in a region of
western Norway were identified and invited to partici-
pate; 55 (86%, 38 males, 17 females; mean age: 46.4 y;
95% confidence interval [CI]: 42.0–50.8) were included
and compared with 24 healthy controls matched for age
and gender. Median (range) PSC duration was 8.1 (0–
33) y. Baseline demographic characteristics and clinical
and laboratory data are summarized in Table 1. One pa-
tient with small-duct PSC and 5 patients with PSC–AIH
overlap syndrome were included. In total, 3 patients
had biochemical signs of clinically significant cholestasis
or hepatitis as determined by a bilirubin level.30 (2 pa-
tients) or an alanine aminotransferase or aspartate amino-
transferase level .53 the upper limit of normal (1
patient). There were no significant differences in distribu-
tion of age, gender or body mass index (BMI) between
patients and controls. On the basis of B-mode ultrasound
evaluation, signs compatible with advanced liver fibrosis,
including liver capsule irregularity, periductal fibrosis
and coarse liver parenchyma, were identified in 16
(29%), 5 (9%) and 12 (22%) patients, respectively,
whereas 34 (62%) patients displayed no signs of fibrosis
on B-mode ultrasound. Splenomegaly was found in 19
patients (35%) and ascites in 2 (4%) patients. Bile duct
Fig. 1. Screen image of Philips iU22 in Elasto mode. B-Mode
ultrasound image of a section of the right liver lobe in a patient
with percutaneous sclerosing cholangitis. The rectangular box
represents the region of interest where the elastography mea-
surements are being performed. The region of interest has a
fixed size but can be moved freely within the image down to a
maximum depth of 8 cm. Measurements within 1 cm of the liver
capsule or close to large vessels or bile ducts should be avoided.
The measured SWV is given in the lower left corner; in this case
it is 1.55 m/s, which indicates some degree of fibrosis.
SWV 5 shear wave velocity.
Table 1. Baseline characteristics of 55 patients with PSC
and 20 healthy controls undergoing ultrasound
elastography
Baseline characteristics PSC patients Controls p
N 55 24
Males 37 (67%)* 11 (46%) 0.07
Age, mean (95% CI) 46 (42, 51) 43 (37, 49) 0.35
Age at diagnosis 34 (12–73) NA
Body mass index,
mean (95% CI)
25.8 (24.8–26.8) 24.3 (22.9–25.8)y 0.09




Ulcerative colitis 32 (58.2%) 0




Cholecystectomy 4 (7.3%) 0
Mayo risk score 20.4 (22.1 to 1.9) NA
Laboratory data
ALP, U/L 138 (25–838) NI
AST, U/L 45 (20–129) NI








Albumin, g/L 46 (36–53) NI
INR 1.0 (0.9–1.2) NI
Platelets, 109/L 227 (60–765) NI
ALP 5 alkaline phosphatase; ALT 5 alanine aminotransferase;
AST 5 aspartate aminotransferase; CI, confidence interval; INR 5 In-
ternational Normalization Ratio; NA5 not applicable; NI 5 not inves-
tigated; PSC 5 primary sclerosing cholangitis.
* Values are expressed as n (%) or median (range) unless otherwise
noted.
y N 5 17.
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dilation was identified in 25 (46 %) patients. B-Mode ul-
trasound findings are summarized in Table 2.
pSWE of the right liver lobe
The intra- and inter-observer agreement for pSWE
of the right liver lobe in the healthy controls was good,
as evaluated by the limits of agreement method (Fig. 2).
In PSC patients, valid pSWE measurements were
achieved in all patients for the right liver lobe. The me-
dian success rate for the individual patients was 100%
(range: 71.4%–100%). PSC patients had higher median
SWV compared with the healthy controls (1.26 [0.73–
2.57] and 1.09 [0.88–1.25] m/s, respectively,
p , 0.001) (Fig. 3a). Area under the receiver operating
characteristic curve (AUROC) analysis revealed fairly
good discrimination for median SWV of the right liver
lobe between PSC patients and controls, with an AUROC
of 0.775 (95%CI: 0.67–0.86) (Fig. 4). For the discrimina-
tion of PSC patients from controls, the statistically
optimal cutoff for SWV as decided by Youden’s index
was 1.24 m/s, with a sensitivity and specificity of 56.4
and 95.8, respectively.
Figure 5 illustrates right liver SWVs correlated with
APRI and FIB-4 scores (r 5 0.494, p 5 0.001, and
r 5 0.368, p 5 0.017, respectively) (Fig. 5a and b),
whereas there was no significant correlation with the
Mayo risk score (r5 0.296, p5 0.06) (Fig. 5c). No corre-
lation was found between right liver SWVs and BMI, age
or PSC duration (Table 3).
SWV in the right liver lobe was significantly higher
in PSC patients with coarse liver parenchyma (median
[range]: 1.88 [0.99–2.57] m/s vs. 1.22 [0.73–2.34] m/s,
p 5 0.002), irregular liver capsule (1.81 [1.11–2.57] m/
s vs. 1.17 [0.73–2.43] m/s, p 5 0.001) and periductal
fibrosis (1.76 [1.27–2.09] m/s vs. 1.24 [0.73–2.57] m/s,
p5 0.049), compared with patients with normal findings
(Fig. 6a–c). Patients with none of these three visual signs
of liver fibrosis had a median right liver SWV of 1.17
(0.73–2.34) m/s, compared with 1.76 (0.99–2.57) m/s
among patients with minimum one B-mode sign of
fibrosis (p 5 0.001) (Fig. 6c). Right liver stiffness
Table 2. B-Mode ultrasound findings in PSC patients
Liver
Liver size in MCL, cm 14.2 (8.0–28.5)*
Hepatomegaly (.16 cm) 10 (18.2%)
Liver capsule irregularity 16 (29.1%)
Coarse liver parenchyma 12 (21.8%)
Blunted liver angle 16 (29.1%)
Ascites 2 (3.6%)
Gallbladder and bile ducts
Gallbladder length, cm 6.6 (2.1–10.0)
Gallbladder width, cm 3.0 (1.5–5.4)
Gallbladder wall thickness, mm 2.3 (0.3–10.4)
Gallbladder stone(s) 6 (10.9%)
Gallbladder polyp 1 (1.8%)
Cholecystectomy 4 (7.3%)
Bile duct variability 25 (45.5%)
Periductal fibrosis 5 (9.1%)
Spleen
Spleen length, cm 12.6 (8.2–22.7)
Spleen area, cm2 58.3 (25.4–165.7)
Splenomegaly (.13 cm) 19 (34.5%)
MCL 5 medioclavicular line; PSC 5 percutaneous sclerosing
cholangitis.
* Values are expressed as n (%) or median (range).
Fig. 2. Intra- and inter-observer agreement of point shear wave
elastography of the right liver lobe in healthy controls. The
Bland–Altman plots illustrate the (a) intra-observer and (b)
inter-observer differences in liver stiffness evaluation measured
by point shear wave elastography using ElastPQ (iU22, Philips)
and expressed as shear wave velocity in meters per second. The
horizontal solid lines represent the intra- or inter-observer
mean 6 2 SD (limits of agreement, dashed horizontal lines),
respectively. A valid measurement was defined as the median
of 10 valid acquisitions with a success rate.60%. Themeasure-
ments were performed twice by one (a) or two (b) observer(s) on
the same day in the right liver lobe of healthy controls for the
intra-observer agreement assessment.
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assessed by median SWV did not differ significantly be-
tween patients with splenomegaly and patients without
splenomegaly (1.42 [0.73–2.57] m/s vs. 1.24 [0.93–
2.34] m/s, p 5 0.11). Bile duct dilation was identified
in 26 (47.3%) patients, but median right liver SWV did
not differ between these patients and patients without
bile duct dilation (1.32 [0.93-2.57] m/s vs. 1.24 [0.73-
2.43] m/s, p 5 0.61).
pSWE of the left liver lobe
In the left liver lobe, valid SWVmeasurements were
acquired in 36 patients (66%), whereas in 19 patients
(35%) themeasurements were considered invalid because
of too many failed acquisitions (success rate: ,60%).
The median success rate was 83% (46%–100%). Left
liver lobe SWV did not significantly differ between
PSC patients and controls (median [range] SWV: 1.46
[0.59–3.68] m/s vs. 1.13 [0.91–1.24] m/s, p 5 0.11)
(Fig. 3 b). There was no significant difference between
median SWVof the right and left liver lobes in PSC pa-
tients (p 5 0.41). Paired SWV values of the right and
left liver lobes in the individual patient did not signifi-
cantly correlate (r 5 0.233, p5 0.17). Similarly, no sig-
nificant correlation was found between left liver SWVs
and BMI, age or PSC duration (Table 3).
pSWE of the spleen
Valid measurements were obtained in 37 PSC pa-
tients (67.3%), whereas in the remainder of the patients,
measurements either were not performed (n 5 16) or
Fig. 3. Liver stiffness in PSC patients compared with controls.
Liver stiffness evaluation by point shear wave elastography us-
ing iU22 (Philips) in 55 PSC patients and 24 healthy controls
matched for age and gender in (a) the right liver lobe, and (b)
the left liver lobe revealed increased liver stiffness in the right
liver lobe of PSC patients compared with controls
(p , 0.001). No significant difference could be found in the
left liver lobe (p 5 0.11). Liver stiffness is expressed as shear
wave velocity in meters per second. PSC 5 primary sclerosing
cholangitis.
Fig. 4. Point shear wave elastography discriminates between
primary sclerosing cholangitis patients and controls. Area under
the receiver operating characteristic curve analysis revealed
fairly good discrimination for median SWV measured by point
shear wave elastography between 55 primary sclerosing cholan-
gitis patients and 24 age- and gender-matched controls with an
area under the curve of 0.775 (95% confidence interval: 0.67–
0.86). The optimal cutoff for SWVas decided by Youden’s index
was 1.24 m/s, with a sensitivity and specificity of 56.4 and 95.8,
respectively. SWV 5 shear wave velocity.
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failed to fulfill the quality criteria (n5 2). Themedian suc-
cess rate for the patients with valid measurements was
100% (76.9%–100%). There was no significant difference
between PSC patients and controls (median SWV: 1.47
[0.79–3.13] m/s and 1.48 [1.17–1.80] m/s, respectively,
p 5 0.83). A tendency toward higher spleen SWV in pa-
tients with splenomegaly compared with patients without
splenomegaly did not reach statistical significance
(1.71 m/s [0.89–2.71] vs 1.39 m/s [0.79–3.13], respec-
tively, p5 0.05).There was no correlation between spleen
SWV and right or left liver SWV (1.47 m/s vs. 1.24 m/s,
N 5 37, r 5 0.104, p 5 0.54, and 1.39 m/s vs. 1.50 m/
s, N5 22, r5 0.331, p5 0.13, respectively). One patient
had variceal bleeding but did not have a high spleen SWV
(median SWV: 1.55 m/s). No correlation was found be-
tween spleen SWVand BMI, age or PSC duration.
DISCUSSION
Our study indicates how liver fibrosis can be evalu-
ated by both SWE and traditional B-mode findings during
the same procedure. We found excellent intra- and inter-
observer variation for pSWE using the iU22 system for
the right liver lobe, in line with previous reports (Ling
et al. 2013). The non-invasive evaluation of the degree
of and change in liver fibrosis in PSC may be of major
importance in evaluating the stage and prognosis of the
disease, as indicated by recent reports (Corpechot et al.
2014, Vesterhus et al. 2015).
Liver biopsy is generally not indicated in PSC, based
on the inherent sampling error resulting from the patchy
distribution of fibrosis (European Association for the
Study of the Liver 2009). The flaws of biopsies were illus-
trated in a study of whole-section scanning of 50 liver ex-
plants from patients with primary biliary cirrhosis,
another disease of the biliary tree, in which only 20%
of the primary biliary cirrhosis livers had a consistent his-
tologic stage of fibrosis throughout the liver at clinically
defined end-stage disease (Garrido and Hubscher 1996).
Likewise, the distribution of liver fibrosis in PSC is un-
even and follows the bile ducts to a large extent. In our
opinion, it may therefore be preferable to use non-
invasive methods assessing liver fibrosis covering larger
areas of the liver in PSC. Ultrasound shear wave elastog-
raphy is non-invasive and repeatable, can be integrated
into a full liver examination and has been documen-
ted in viral hepatitis as a means of measuring liver
fibrosis, but has not been previously explored in PSC
Fig. 5. Associations of liver stiffness with fibrosis scores and
prognosis in percutaneous sclerosing cholangitis patients. The
scatterplots with regression lines illustrate that SWV (m/s) of
the right liver lobe as measured by point shear wave elastogra-
phy using the iU22 (Philips) was correlated with the (a) APRI
and (b) Fibrosis-4 (Fib4) scores of fibrosis, but not with (c)
the Mayo risk score, a commonly used prognostic score in
primary sclerosing cholangitis. SWV 5 shear wave velocity;
APRI 5 Aspartate Aminotransferase-to-Platelet Ratio Index.
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(Bota et al. 2013a, 2013b; Friedrich-Rust et al. 2012;
Sporea et al. 2012a, 2012b).
Our findings suggest that PSC patients have
increased median liver stiffness as expressed by SWV
compared with healthy controls. The literature reveals
scarce information about pSWE in PSC, but our data
are in line with pSWE findings in a pilot study of patients
with autoimmune liver diseases causing fibrosis,
including PSC (Righi et al. 2012), and support previous
findings describing TE in PSC (Corpechot et al. 2006,
2014; Hagstrom et al. 2012). In the present PSC cohort,
21 (38%) of the patients expressed B-mode signs of
liver fibrosis. SWV was significantly higher in patients
with B-mode signs of liver fibrosis; however, 12
patients without visual signs of liver fibrosis also had
increased SWV (.1.24 m/s). Previous studies have
reported good to excellent AUROCs between pSWE
and histologic evaluation of fibrosis, even in
autoimmune liver diseases (Friedrich-Rust et al. 2012;
Righi et al. 2012). Thus, our findings could suggest an
increased sensitivity in identifying fibrosis in PSC
patients by adding elastography to an ultrasound liver
evaluation. Furthermore, pSWE was associated with
currently acknowledged signs of fibrosis, including TE
in cystic fibrosis liver disease, which displays a patchy
disease distribution similar to that of PSC (Behrens
et al. 2013; Karlas et al. 2012; Manco et al. 2012;
Monti et al. 2012). Because liver biopsy is generally
not indicated in PSC, histologic correlates are lacking
in the present study, but SWV correlated with serum-
based scores of fibrosis, including APRI and FIB-4
scores.
Previous studies have reported that the performance
of SWE and the cutoff values for significant fibrosis and
cirrhosis may vary with the etiology of liver disease
(Friedrich-Rust et al. 2012; Guzman-Aroca et al. 2012;
Karlas et al. 2012; Sporea et al. 2012b). In the present
study, the cutoff SWV value with the best statistical
power to discriminate between PSC patients and
healthy controls was 1.24 m/s with an area under the
curve of 0.775, in line with previous findings
suggesting 1.23 m/s as the statistically best cutoff
between patients with chronic liver disease and controls
(Sporea et al. 2014). It is an interesting characteristic of
patients with PSC that this cutoff is similar to that of other
liver disease populations, although it should be kept in
mind that the clinically ideal cutoff value may differ de-
pending on the aim of stratification (e.g., early diagnosis
of liver fibrosis or identification of a high-risk group).
Longitudinal studies are needed to resolve whether
pSWE can be used to follow disease progression in the in-
dividual patient for prognostic purposes.
The wider variability and lower success rate of ultra-
sound elastography of the left liver lobe has been debated
(Karlas et al. 2011; Ling et al. 2013; Toshima et al. 2011).
We were able to obtain valid liver stiffness measurements
of the left liver lobe in 66% of the patients. SWVs of the
left liver lobe correlated with the APRI score of fibrosis.
There was a wider range of SWV measurements in the
left compared with the right liver, probably caused by
respiratory and cardiac movements affecting
elastography measurements and suggesting reduced
reliability of measurements in the left liver lobe. The
lack of correlation between the two liver lobes may be
due to the higher variability in SWV of the left liver
lobe, and the definition of stricter quality criteria for
pSWE measurements of the left liver lobe might yield
better correlation for the valid measurements.
Previously published studies have indicated that
cholestasis influences the accuracy of pSWE for the
non-invasive evaluation of liver fibrosis (Pfeifer et al.
2014). PSC is a cholestatic disease, and this might be ex-
pected to complicate the evaluation of liver stiffness by
pSWE in this patient group. However, only two patients
had significantly elevated bilirubin .30 mmol/L; and
although some degree of cholestasis was indicated in 26
(47%) patients by bile duct dilation on B-mode ultra-
sound, there was no difference in liver stiffness by
pSWE in these patients compared with patients without
bile duct dilation.
Several articles have reported that increased spleen
stiffness alone or the spleen/liver stiffness ratio may pre-
dict high-risk esophageal varices and, thus, aid the
Table 3. Correlations of median SWV with other
continuous variables in PSC patients
Clinical and
laboratory variables






Age 55 20.004 0.974 36 20.064 0.709
Age at
diagnosis
54 20.06 0.669 36 0.115 0.504
PSC duration 54 0.01 0.945 36 20.179 0.295
Bilirubin 49 0.175 0.23 32 0.207 0.255
Albumin 50 20.358 0.011* 33 20.222 0.215
ALP 50 0.246 0.085 33 0.335 0.057
AST 42 0.208 0.187 26 0.191 0.35
ALT 51 20.072 0.616 34 0.222 0.207
Platelet count 51 20.319 0.022 34 20.301 0.084
Body mass
index
55 20.101 0.463 36 0.281 0.097
INR 47 0.325 0.026 31 20.115 0.539
Mayo score 41 0.296 0.06 25 0.495 0.012
APRI score
(AST/TRC)y
42 0.494 0.001 26 0.468 0.016
ALP 5 alkaline phosphatase; ALT 5 alanine aminotransferase;
AST 5 aspartate aminotransferase; APRI 5 AST-to-Platelet Ratio In-
dex; INR 5 International Normalization Ratio; NA 5 not applicable;
PSC 5 primary sclerosing cholangitis; SWV 5 shear wave velocity.
* p-Values in italic denote significance.
y See Figure 5a.
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identification of patients who should be selected to un-
dergo gastroscopy (Berzigotti et al. 2013, 2014; Takuma
et al. 2013; Sirli et al. 2015). In view of this, the spleen
stiffness of PSC patients is of interest. In the present
study, spleen stiffness did not significantly differ
between PSC patients and controls. However, the
number of patients was small, and only one variceal
bleeding was observed in this cohort, precluding
definitive conclusions. The association of liver and
spleen stiffness with portal hypertension and esophageal
varices in PSC should be further investigated in a larger
cohort and, preferably, in a prospective setting.
Limitations of the study
The lack of liver biopsies in our cohort represents a
limitation to the study. However, liver biopsies are not
indicated in PSC, and biopsy was considered unethical
for study purposes. Previous studies of chronic liver dis-
ease with a range of etiologies have repeatedly indicated
excellent correlation between pSWE and histology find-
ings. The question of prognostic value cannot be
answered by the cross-sectional design of the present
study, and further studies, including prospective follow-
up, are warranted.
Although no standards of quality control have been
agreed on for pSWE, we applied a standardized protocol
and strict quality criteria as previously proposed,
demanding 10 valid acquisitions with a success rate
.60% to have reliable results (Bota et al. 2013a,
2013b). Measurements were made in two selected sites
in the right and left liver lobes, respectively.
Considering the patchy disease distribution in PSC, it is
conceivable that SWV measurements throughout the
entire liver would have revealed variable results within
each lobe of the individual patient, and further studies
should attempt to explore this.
CONCLUSIONS
We found that PSC patients have increased SWV in
their liver parenchymacomparedwithhealthycontrols, indi-
cating increased liver fibrosis. However, a wide range of
SWV values were obtained for PSC patients, possibly re-
flecting various stages in PSC disease development. This
novel method exhibited low intra- and inter-observer varia-
tion,making it suitable for further studies analyzingprospec-
tive follow-up data evaluating pSWE as a prognostic tool.
Fig. 6. Point shear wave elastography and B-mode signs of liver
fibrosis. Boxplots illustrate SWV (m/s) reflecting liver stiffness
as evaluated by point shear wave elastography using the iU22
(Philips) in patients with and without B-mode ultrasound signs
of fibrosis, including (a) coarse liver parenchyma, (b) irregular
liver capsule and (c) any of three signs of liver fibrosis (liver
capsule irregularity, parenchyma coarseness, periductal
fibrosis), compared with none of these.
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Normal Liver Stiffness Values in Children: A Comparison
of Three Different Elastography Methods
yzAnders B. Mjelle, yzAnesa Mulabecirovic, zRoald F. Havre, y§Karen Rosendahl,
jjPetur B. Juliusson, Edda Olafsdottir, yzOdd H. Gilja, and zjj#Mette Vesterhus
ABSTRACT
Objectives: Noninvasive tests for the evaluation of liver fibrosis are
particularly helpful in children to avoid general anesthesia and potential
complications of invasive tests. We aimed to establish reference values for 2
different elastography methods in a head-to-head comparison for children
and adolescents 4 to 17 years, using transient elastography as common
reference in a subset.
Methods: A total of 243 healthy participants aged 4 to 17 years were
examined by a single observer with a full liver B-mode scan before
elastography, following a minimum of 3 hours fasting. Liver stiffness
measurements (LSMs) using 2-dimensional shear wave elastography
(2D-SWE, GE Logiq E9) and point shear wave elastography (pSWE,
Samsung RS80A with Prestige) were performed in all participants, and
compared to transient elastography (TE, FibroScan) in a subset (n¼ 87).
Interobserver agreement was evaluated in 50 children aged 4 to 17 years.
Results: Valid measurements were obtained in 242 of 243 (99.6%) subjects
for 2D-SWE, 238 of 243 (97.9%) for pSWE, and in 83 of 87 (95.4%) for TE.
Median liver stiffness overall was 3.3 (interquartile range [IQR] 2.7–4.3),
4.1 (IQR 3.6–4.7), and 4.1 kPa (IQR 3.5–4.6) for 2D-SWE, pSWE, and
TE, respectively. Intraclass correlation coefficients between observers
were 0.84 and 0.83 for 2D-SWE and pSWE, respectively. LSM values
were significantly lower for 2D-SWE compared to pSWE and TE, and
increased with advancing age. Higher LSM values in males were observed in
adolescents.
Conclusions: All methods showed excellent feasibility. 2D-SWE showed
significantly lower LSM values than pSWE and TE, and lower failure rate
compared to TE. Our results further indicate an age and sex effect on LSM
values.
Key Words: liver fibrosis, pediatric, shear wave elastography, transient
elastography, ultrasound
(JPGN 2019;68: 706–712)
U ltrasound elastography is increasingly used to estimate liverfibrosis in children and adolescents, and has been reported in
pediatric populations with mixed liver diseases (1–3) and in more
homogenous populations (eg, biliary atresia) (4–8). The technique
is continuously improving, and a sensitivity and specificity of 81%
and 91%, respectively, was recently reported for liver fibrosis in
children (2). The criterion standard for liver fibrosis evaluation is
the liver biopsy, challenged due to its invasive nature, the need for
general anesthesia and the potential of sampling errors and clinical
complications (9). Ultrasound elastography is noninvasive and
allows evaluation of the entire organ, with minimal discomfort
for the patient, albeit lacking the liver biopsy’s ability to assess the
What Is Known
 Liver fibrosis is difficult to assess without a liver biopsy,
which in children often require general anesthesia.
 Liver elastography is increasingly used as a noninva-
sive surrogate marker of liver fibrosis.
 Different ultrasound platforms yield different values.
What Is New
 This is the first publication of reference values for both
point shear wave elastography and 2-dimensional
shear wave elastography in healthy children, with
comparison to transient elastography.
 Two-dimensional shear wave elastography yielded
significantly lower liver stiffness measurements than
point shear wave elastography and transient elasto-
graphy.
 Liver stiffness measurements increased with age and
were higher in male than female adolescents.
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etiology. Awareness of factors other than fibrosis which can influ-
ence liver stiffness is necessary (10). Transient elastography (TE)
was introduced first and is established in several clinical settings.
However, recent years have seen the introduction of alternative
platforms allowing simultaneous B-mode imaging, including point
shear wave (pSWE) and 2-dimensional shear wave elastography
(2D-SWE), based on similar principles, with similar recommenda-
tions regarding use and application (10). Liver stiffness measure-
ments (LSMs) have been demonstrated to vary between different
elastography methods in both children (2) and adults (11,12); thus,
normal values should be defined for each platform. There are
currently no publications comparing LSM across platforms in
healthy children. We aimed to establish and compare reference
values for pSWE and 2D-SWE, with head-to-head comparison to
TE in a subset.
METHODS
Subjects
The study was performed at Haukeland University Hospital
in Bergen, Norway from September 2017 through January 2018.
Participants were recruited through hospital employees, local
schools, and social media. Exclusion criteria were a history of liver
disease or chronic disease which could affect the liver. Informed
written consent was obtained. A total of 246 children aged 4 to
17 years were recruited and grouped into 4 predefined age catego-
ries: 4 to 7; 8 to 11; 12 to 14; and 15 to 17 years. Two hundred thirty
(94.7%) had Caucasian parents. The medical history was recorded,
including the use of alcohol or nicotine. All were evaluated clini-
cally by a pediatrician (A.B.M.) with >10 years’ experience.
Height, weight, waist circumference, and body mass index
(BMI) were recorded and converted into z scores by the means
of the Norwegian growth references (13,14). Weight classes were
defined using International Obesity Task Force (IOTF) definitions
(15). Blood tests were not performed. Participants classified as
obese (n¼ 5) were included. Subjects with B-mode signs of stea-
tosis or splenomegaly (n¼ 2), or fasting <3 hours (n¼ 1), were
excluded, leaving 243 (108 boys, 44.4%) for further analyses.
B-mode Ultrasound Evaluation
B-mode ultrasound was performed after a standardized
protocol with evaluation of the liver, gall bladder, spleen, and
kidneys before elastography measurements, using Samsung
RS80A with Prestige, with a convex 1 to 7MHz probe. Skin to
liver capsule distance was recorded. Examinations were conducted
by a single operator (A.B.M.) with >2 years’ experience in
abdominal ultrasound.
Liver Stiffness Measurements
Ultrasound elastography measurements were performed in a
supine position with the right arm maximally abducted, after
3 hours of fasting. Participants were examined with both GE
Logiq E9 2D-SWE, using a C1–6 probe (GE Healthcare, Milwau-
kee, WI) and Samsung RS80Awith Prestige pSWE, using a CA1–
7A probe (Samsung Medison Co, Ltd, Seoul, Korea). SWE mea-
surements were obtained in the right liver lobe applying minimal
pressure through an intercostal space, perpendicular to the capsule,
avoiding large liver vessels, bile ducts, and rib shadowing. Acquisi-
tions were made during mid-expiratory breath hold if possible,
otherwise during calm expiration. LSM values are expressed in
meters per second (m/s) or kilopascals (kPa), the latter being
calculated using the equation kPa¼ 3(ms1)2. We performed 10
valid acquisitions, and reported median values expressed in kPa for
all systems. Every acquisition and mean, median, and interquartile
range/median (IQR/M%; measure of dispersion) was recorded. A
valid LSM value was defined as the median of 10 valid acquisitions
with an IQR/M% 30%. For Samsung, values in m/s, average
measurement depth and reliability measurement index, were auto-
matically recorded, with a fixed region of interest (ROI) of
1 1.5 cm. For GE (2D-SWE), the ROI was a fixed circle with a
diameter of 1 cm. ROIs were placed 2 to 5 cm from the liver capsule.
In a subset of 50 subjects, 2 observers (A.B.M. and A.M.) both
obtained data using GE and Samsung for interobserver reliability
analysis. Both investigators had >2 years of experience in liver
elastography. In a subset of patients 8 years (n¼ 87), TE using
FibroScan (M-probe) incorporated in a GE S8 (GE Healthcare) was
performed, reporting LSM results in kPa. For TE, the additional
criterion of success rate60% was adopted. The M-probe has been
used extensively in children and adults with thorax perimeter under
the recommended 75 cm, having been shown to affect feasibility
only slightly (16); furthermore, we did not have access to the
smaller S probe. The XL probe is known to yield lower values,
and none of the subjects had skin to capsule distance 2.5 cm, for
which an XL probe is warranted.
Controlled Attenuation Parameter
Fat deposits in hepatocytes affect ultrasound propagation,
increasing the attenuation. Controlled attenuation parameter (CAP)
evaluates the ultrasonic attenuation in the liver at 3.5MHz at depth
25 to 65mm using FibroScan, and represents a noninvasive assess-
ment of liver steatosis (17). CAP values in dB/m were reported as
the median of 10 acquisitions for all subjects evaluated by TE.
Statistical Analysis
For all analyses, SPSS version 25 (SPSS Inc, 2016, Armonk,
NY) was used. Variables were tested for normality, and data were
presented as mean (standard deviation [SD]) or median (range), as
appropriate. When establishing age-specific reference values,
mean 1.96 SD was used. For comparison of groups, standard
paired T test, Wilcoxon signed rank test, or Pearson Chi-Square test
were used as appropriate. Correlations were tested by Pearson
correlation coefficient. Intraclass correlation coefficients (ICCs)
were calculated to present interobserver reliability. Limits of agree-
ment were assessed to reveal differences between platforms and
observers. P values <0.05 were considered significant.
Ethical Aspects
Theprotocolwas in accordancewith theDeclaration ofHelsinki
and approved by the Regional Committee on Medical and Health
Research Ethics of Western Norway (2017/290/REK Vest).
RESULTS
The characteristics of the 243 subjects included are displayed
in Table 1. Valid measurements were obtained in 242 of 243
(99.6%) for 2D-SWE, 238 of 243 (97.9%) for pSWE, and 83 of
87 (95.4%) for TE. TE feasibility was significantly lower than 2D-
SWE feasibility (P¼ 0.03), but not different from pSWE
(P¼ 0.47); nonfeasibility was most often due to wide dispersion
(IQR/M% >30%) reflecting insufficient reliability. Median (range)
IQR/M values were 10.1 (1.4–40), 13.9 (1.3–44), and 12.0 (3–44)
for 2D-SWE, pSWE and TE, respectively. Among the excluded was
an extreme outlier of 395% for pSWE, with corresponding reliabil-
ity measurement index of 0.1 (the producer recommends 0.4).
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Two hundred thirty-seven subjects (97.5%) showed valid results for
both 2D-SWE and pSWE; 81 (93.1%) for all 3 platforms.
Median Liver Stiffness and Measurement
Variability for 2-Dimensional Shear Wave
Elastography, Point Shear Wave Elastography,
and Transient Elastography
LSM values for 2D-SWE were significantly lower compared
with pSWE or TE (median LSM 3.3, 4.1, and 4.1 kPa, respectively;
P< 0.001), with no difference between pSWE and TE (P¼ 0.65)
(Table 2). Moreover, the slope of LSM values was steeper for 2D-
SWE compared to pSWE, with lower values for 2D-SWE compared
to corresponding pSWE values for LSM <4 kPa by 2D-SWE, but
higher values for 2D-SWE compared to corresponding pSWE
values for LSM >5 kPa by 2D-SWE (Supplementary Fig. 1,
Supplemental Digital Content, http://links.lww.com/MPG/B612).
In the total panel, 2D-SWE and pSWE showed moderate correlation
(rho¼ 0.51, P< 0.001).
The coefficient of variation (CV) between the 10 serial
acquisitions forming a single LSM value, was low for all systems,
ranging from 0.03 to 1.54, across all age groups (0.03–0.21 for
pSWE, 0.03–0.24 for 2D-SWE, and 0.03–1.54 for TE). The highest
CV for TE was due to a single high acquisition in 1 subject, which if
excluded would have yielded a range of 0.03 to 0.29. The CV was
slightly lower for 2D-SWE compared to pSWE (P¼ 0.009) and TE
(P¼ 0.006), with similar values for pSWE and TE (P¼ 0.12).
Interobserver Evaluation
Interobserver reliability was evaluated in participants from
all age groups with valid LSM for pSWE (n¼ 48) and 2D-SWE
(n¼ 50). There were no significant differences between observers
for pSWE (medians 4.10 kPa [IQR 3.6–4.9] vs 4.15 kPa [3.4–4.6])
or 2D-SWE (medians 3.55 kPa [IQR 2.8–4.3] vs 3.55 kPa [2.8–
4.3]). ICCs between observers were 0.83 (95% confidence interval
0.7–0.91) and 0.84 (95% confidence interval 0.71–0.91) for pSWE
and 2D-SWE, respectively, with no systematic differences between
observers (Suppl. Figs. 2A and 2B, Supplemental Digital Content,
http://links.lww.com/MPG/B612). The average difference (95%
limits of agreement) was þ2.1% (26.2%–30.4%) and 0.1%
(35.9%–35.7%) for pSWE and 2D-SWE, respectively. A small
number of subjects showed a discrepancy >1 kPa between obser-
vers, 4 of 48 (8.3%) and 5 of 50 (10%) for pSWE and 2D-SWE,
respectively. Only 1 of 50 (2%) of subjects showed a difference
>1.6 kPa using 2D-SWE, and none using pSWE.
TABLE 1. Baseline characteristics for all children and adolescents included for liver elastography in a study using ultrasound 2-dimensional shear
wave elastography, point shear wave elastography, and transient elastography
Total panel 4–7 y 8–11 y 12–14 y 15–17 y
Number 243 59 64 59 61
Males, number (%) 108 (44.4%) 31 (52.5%) 26 (40.6%) 30 (50.8%) 21 (34.4%)
Age, y, median (range) 11.7 (4.1–17.9) 6.3 (4.1–7.9) 10.0 (8.1–11.8) 13.4 (12–15.0) 17.1 (15–17.9)
Waist circumference, cm, median (range) 60.0 (45–98) 52 (45–59) 58 (50–75) 64 (51–85) 70 (60.5–98)
Weight, kg, median (range) 40.8 (13.7–105) 22.0 (13.7–32.7) 33.5 (22.2–61.7) 47.5 (28.7–80.7) 63.2 (41.6–105)
Body mass index (BMI) 17.6 (12–30.6) 15.5 (12–18.9) 17.2 (14–25.7) 17.9 (13.4–28.9) 21.5 (17.5–30.6)
Overweight or obese according to IOTF, n (%) 27 (11.1) 3 (5.1) 6 (9.4) 5 (8.5) 13 (21.3)
Mid-expiratory breath hold during measurement 195 (80.2% 11/59 (18.6%) 64/64 (100%) 59/59 (100%) 61/61 (100%)
Skin-to-capsule

, cm 1.11 (0.70–2.64) 0.9 (0.7–1.24) 1.03 (0.72–1.77) 1.17 (0.85–2.14) 1.41 (1.05–2.64)
Alcohol consumption last 72 h, n (%) 7 (2.9%) 0 (0%) 0 (0%) 0 (0%) 7 (11.5%)
IOTF ¼ International Obesity Task Force.
Distance from skin to liver capsule in centimeters.
TABLE 2. Liver stiffness measurements values by 2-dimensional shear wave elastography and point shear wave elastography for children aged 4 to
17 years

















4–7 y 2.87 0.56 (3.96) 2.0–4.7 0.98 m/s (1.15) 3.93 0.56 (5.03) 2.8–5.2 1.14 0.08
(1.30)
8–11 y 3.45 1.03 (5.47) 2.1–6.5 1.07 m/s (1.35) 4.17 0.74 (5.61) 3.1–6.4 1.17 0.10
(1.37)
12–14 y 3.83 1.27 (6.32) 2.0–7.7 1.13 m/s (1.45) 4.65 0.83 (6.27) 3.1–6.5 1.24 0.11
(1.46)
15–17 y 3.96 1.06 (6.03) 2.0–7.0 1.15 m/s (1.42) 4.23 0.91 (6.02) 2.9–7.1 1.18 0.12
(1.42)
Liver stiffness measurement (LSM) values represent the mean of LSM results from children in each age group. Individual LSM results are based on median
values from 10 valid acquisitions.
2D-SWE ¼ 2-dimensional shear wave elastography; pSWE ¼ point shear wave elastography; SD ¼ standard deviation.
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Difference in Liver Elasticity by Age and Sex
For 2D-SWE, LSM was associated with age (rho¼ 0.421,
P< 0.001) and increased steadily until 12 to 17 years, with no
significant difference between the 2 older age groups (Table 2,
Fig. 1).
For pSWE, LSM showed a weak association with age
(rho¼ 0.146, P¼ 0.02) for the 3 youngest age groups (Table 2,
Fig. 1). LSM age 8 to 11 was significantly lower than LSM age 12 to
14 years (P¼ 0.001), and significantly higher than LSM age 4 to 7
(P¼ 0.04), whereas LSM 15 to 17 years was significantly lower
than 12 to 14 years (P¼ 0.002).
Overall, boys showed higher values compared to girls for
pSWE. In subgroup analyses, sex difference was found in adoles-
cence only: isolating ages 12 to 17 years, we found significantly
higher LSM values in boys across all platforms, with mean values
4.27 versus 3.62 kPa (P¼ 0.002), 4.68 versus 4.27 kPa (P¼ 0.01),
and 4.68 versus 4.13 kPa (P¼ 0.02) for 2D-SWE, pSWE, and TE,
respectively (Fig. 2).
Obesity-related Characteristics, Liver Stiffness
Measurement and Controlled Attenuation
Parameter
BMI z scores or IOTF weight classes were not distributed
evenly across age groups, and analyses and comparisons were
performed within age groups. Overweight or obese groups yielded
no significant differences for pSWE, when compared with the
nonoverweight, but for 2D-SWE there was significantly higher
LSM values for the overweight aged 8 to 11 (3.35 vs 4.45 kPa,
P¼ 0.01) and 15 to 17 years (3.78 vs 4.64 kPa, P¼ 0.008), but not
for ages 4 to 7 or 12 to 14 years. TE showed lower LSM values in the
overweight aged 15 to 17 years (4.52 vs 3.4 kPa, P¼ 0.03), but not
for 12 to 14 years.
The skin to capsule distance correlated with LSM for 2D-
SWE (rho¼ 0.355, P< 0.001), but not with LSM for pSWE or TE
(P> 0.2). In multiple linear regression (correcting for anthropo-
metric measurements and age) skin to capsule distance was not
independently associated with LSM. Skin to capsule distance was
moderately correlated to anthropometric measures (rho¼ 0.516,
0.471 and 0.456 for BMI, waist, and weight z scores, respectively;
all P values <0.001).
CAP values (estimating liver steatosis) were normally dis-
tributed, with an overall mean value 191.9 dB/m (SD 38.1), range
100 to 296. Six subjects displayed values above the proposed cut-off
of 249 dB (18); 5 of these had normal weight. Using linear regres-
sion, CAP was associated with BMI z score (P¼ 0.005), but not
with LSM by pSWE or 2D-SWE, age, or sex. CAP was shown to
rise steadily already from BMI z score 0 and was significantly
higher when comparing children with BMI z score 0 and BMI z
score <0 (205 vs 180 dB, P¼ 0.002).
Quality Indicators and Associations With Body
Mass Index and Skin-to-capsule Distance
IQR/M% is a frequently used quality indicator in LSM, with
IQR/M% <30% commonly used as cutoff for a valid result in kPa,
FIGURE 1. Liver stiffness measurements by age groups and elastography systems: point shear wave elastography (pSWE, all age groups, n¼238),
2-dimensional shear wave elastography (2D-SWE, all age groups, n¼243), and transient elastography (TE, age groups 2–4, n¼83). For pSWE:
group 1 significantly lower liver stiffness measurements (LSM) values than groups 2 to 4 and group 3 significantly higher than group 2 and 4. For
2D-SWE: LSM values rising significantly from group 1 to group 2 and from group 2 to group 4. For TE: LSM values in group 3 and 4 were
significantly higher than that in group 2.
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reflecting limited spread in the values of acquisitions that collec-
tively make up 1 LSM value. We found no correlation between
IQR/M% and a high or low LSM value for pSWE and TE, and not
for 2D-SWE after adjusting for age. As expected, IQR/M% values
were approximately twice as high for measurements in kPa com-
pared to m/s in the same individuals.
DISCUSSION
We report on the normal liver stiffness in healthy children
aged 4 to 17 years. To our knowledge, this is the first head-to-head
comparison between 2D-SWE and pSWE, with TE as common
reference in a subset. Feasibility was excellent for all systems with
failure rates of 0.4%, 2.1%, and 4.6% for 2D-SWE, pSWE, and TE,
respectively, showing slightly but significantly superior feasibility
for 2D-SWE compared to TE, in line with previous studies in adults.
Failure was due to a high IQR/M >30% (n¼ 9) or success rate
<60% (n¼ 1; TE). Feasibility was good using the M-probe for TE
in children with a thorax perimeter <75 cm. We have demonstrated
a low variation (CV) for the different platforms, and a good ICC
between observers, but the average interobserver difference shown
as 95% limits of agreement (26.2%–30.4% and 35.9%–35.7%
for pSWE and 2D-SWE, respectively) should be noted.
In the total panel, median liver stiffness was 3.3 kPa (1.05 m/
s; range 2.0–7.7 kPa), 4.1 kPa (1.17 m/s; range 2.8–7.1 kPa), and
4.1 kPa (1.17 m/s; range 2.4–11.2 kPa) for 2D-SWE, pSWE, and
TE, respectively. This is in line with previously published values for
healthy children, reporting mean LSM of 4.6 kPa (19–24) and
1.12 m/s (25–31) by TE and acoustic radiation force impulse
(ARFI), respectively (medians of reported values) (19–31).
Overall, we found significantly lower values using 2D-SWE
compared to pSWE and TE (P< 0.001), whereas pSWE and TE
showed similar LSM values (P¼ 0.65). This contrasts with reports
in healthy adults, showing higher LSM values for 2D-SWE com-
pared to pSWE and TE (11,12). Our results, however, indicate that
the slope of the curve for LSM is steeper for 2D-SWE compared to
pSWE; thus, in subjects with LSM >4 kPa the mean LSM by 2D-
SWE was higher compared to LSM by pSWE (Suppl. Fig. 1,
Supplemental Digital Content, http://links.lww.com/MPG/B612).
Several publications comparing different platforms in adults
(32–34) and phantoms (35,36) have shown similar relationships,
but with these differences only evident outside the normal range. As
higher LSMs are reported in healthy adults compared to children,
the finding of higher values when using 2D-SWE compared to
pSWE in adults (11), fits with our results. We can only speculate
that 2D-SWE may yield higher LSM values than pSWE in children
with significant liver fibrosis. We have not found other studies
comparing the methods used herein. In a small study, children with
heterogeneous chronic liver diseases were investigated with 2D-
SWE, ARFI, and TE, but LSM values were not compared across
platforms in the individual subjects (37) as in our head-to-
head comparison.
Our findings strongly indicate that liver stiffness increases
during childhood and adolescence. Previous studies on children
investigating single elastography platforms (TE, 2D-SWE, and
FIGURE 2. Liver stiffness measurements in boys (blue) and girls (red) aged 12 to 17 years as assessed by point shear wave elastography (pSWE), 2-
dimensional shear wave elastography (2D-SWE), and transient elastography (TE). The figure shows liver stiffness as assessed by pSWE (Samsung
RS80A with Prestige; n¼117), 2D-SWE (GE Logiq E9, n¼120), and TE (FibroScan, n¼60), respectively. Boxes represent the central 50% of the
values, with the median value given as a horizontal line, and whiskers representing minimum and maximum, excluding outliers (small circles).
Overall liver stiffness measurements (LSM) values are significantly lower in girls for all platforms: pSWE (P¼0.01), 2D-SWE (P¼0.002), and TE
(P¼0.02).
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ARFI, respectively) are discordant regarding the association of
age with LSM; some report increasing values with age
(19,21,23,25,31,38), some do not (20,22,26–28,39,40). We found
higher values in boys compared to girls, during adolescence. This is
in line with several adult studies, reporting higher values in males
for 2D-SWE (12,41), pSWE (42), and TE (43,44); however, some
describe no significant sex difference for ARFI (45) and pSWE
(12). Three pediatric studies have similarly demonstrated higher
LSM values in boys compared with girls (19,26,38), one of which
only in older children, whereas 6 others did not find such a
difference (21,22,25,27,31,39).
We aimed to describe liver stiffness in a healthy pediatric
population, and therefore excluded subjects with B-mode signs of
steatosis. Nevertheless, a minority of the subjects were overweight
(n¼ 24) or obese (n¼ 3) as defined by IOTF. Although we found
significant differences in LSM between the overweight and the
normal weight in 2 age groups for 2D-SWE and 1 age group for TE,
our results should be interpreted with caution due to a low number
of overweight and obese in each age group. A recent publication
(46) using a different pSWE method, studied the effect of BMI on
LSM values, and found higher LSM values in the obese. The same
study found no correlation between LSM value and BMI within the
nonobese cohort, which included overweight children.
EFSUMB guidelines (10) describe the use of IQR/M%
30% as a quality indicator for pSWE and 2D-SWE, mimicking
the FibroScan criterion, but do not mention that this parameter will
change significantly based on the measurement unit. Comparing
IQR/M% for m/s and kPa in our material, we illustrated a linear
relationship, with the latter twice as high, demonstrating that the
IQR/M% cut-off applies for kPa only (Suppl. Fig. 3, Supplemental
Digital Content, http://links.lww.com/MPG/B612).
The present article does not allow conclusions regarding the
superiority of any platform. In our experience, however, the avail-
ability of simultaneous B-mode imaging adds important value,
allowing a full investigation in 1 session and sometimes a better
assessment of factors influencing results. The learning curve for
pSWE seems steeper and may thus be better for training users
without extensive experience in B-mode imaging, whereas 2D-
SWE may seem less prone to failed measurements in experienced
users.
The study only includes healthy children and adolescents,
and the findings are not automatically applicable in pediatric liver
patients. Our findings and differences found have to some extent
been described in adult liver patients, and this should be further
investigated in children and adolescents with chronic liver diseases.
Although there is little suspicion of liver diseases in our cohort, a
biochemical evaluation of the participants would have strengthened
our results.
CONCLUSIONS
For the first time we have described normal values for liver
stiffness in healthy children using ultrasound elastography by
pSWE and 2D-SWE in a head-to-head comparison, and compared
to TE as reference in a subset. We demonstrated high feasibility in
children for all methods with best results for the combination of
ultrasound and elastography, but interobserver variability demon-
strates the need of standardization of methods. Our results indicate
different reference values depending on age and sex with increasing
liver stiffness with age and particularly higher LSM values in boys
during adolescence. This must be considered when using the
methods in clinical practice. Further studies exploring elastography
methods head-to-head in pediatric liver patients may further
enhance our understanding of the differences between methods
and the clinical utility of this tool.
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Establishing normal liver stiffness (LS) values in healthy livers is a prerequisite to differenti-
ate normal from pathological LS values. Our aim was to define normal LS using two novel
elastography methods head-to-head and to assess the number of measurements, variability
and reproducibility.
Materials and methods
We evaluated shear wave elastography (SWE) methods integrated in Samsung RS80A and
GE S8 by obtaining LS measurements (LSM) in 100 healthy subjects (20–70 years). Transient
Elastography (TE) was used as reference method. Data were analyzed according to age, sex,
BMI and 5 vs. 10 measurements. All subjects underwent B-mode ultrasound examination and
lab tests to exclude liver pathology. Interobserver variation was evaluated in a subset (n = 24).
Results
Both methods showed excellent feasibility, measuring LS in all subjects. LSM-mean for GE S8
2D-SWE was higher compared to TE (4.5±0.8 kPa vs. 4.2±1.1, p<0.001) and Samsung RS80A
(4.1±0.8 kPa, p<0.001). Both methods showed low intra- and interobserver variation. LSM-mean
was significantly higher in males than females using 2D-SWE, while a similar trend for Samsung
SWE did not reach significance. No method demonstrated statistical significant difference in
LSM across age and BMI groups nor between LSM-mean based on 5 vs. 10 measurements.
Conclusion
LSM was performed with high reproducibility in healthy adult livers. LSM-mean was signifi-
cantly higher for GE S8 2D-SWE compared to Samsung RS80A and TE in healthy livers.
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Males had higher LSM than females. No method demonstrated statistical significant differ-
ence in LSM-mean across age- and non-obese BMI groups. Our results indicate that five
LSM may be sufficient for reliable results.
Introduction
Chronic liver disease is one of the leading causes of morbidity and mortality worldwide [1, 2].
Assessment of liver fibrosis is important for chronic liver disease of various aetiologies for out-
come prediction, risk stratification and selection for screening programs (e.g. endoscopy for
oesophageal varices) as well as therapeutic decisions [2]. Non-invasive methods including
ultrasound elastography have emerged within the past decade and are increasingly replacing
liver biopsy for liver fibrosis assessment, avoiding the risks and discomforts of this invasive
method. Nonetheless, ultrasound elastography encompasses several methods with important
technological differences, ranging from vibration-controlled transient elastography (TE,
Fibroscan) to methods based on deposition of an acoustic pulse such as point shear wave elas-
tography (pSWE) and more recently 2D-SWE. TE has been extensively validated and is recom-
mended for clinical use by several international guidelines, and an increasing number of
studies evaluating the accuracy of various elastography methods have provided evidence for
the utility of elastography imaging. However, with the expanding spectrum of ultrasound
based elastography systems, it has become increasingly clear that the various technologies and
platforms may yield different estimates of liver stiffness (LS) within the same liver. Hence, cur-
rent guidelines acknowledge a need to establish reference values for normal liver stiffness in
healthy livers for each specific equipment model in order to allow accurate diagnosis of patho-
logical liver stiffness[3, 4].
To our knowledge, this is the first study to evaluate liver stiffness measurements (LSM) in
healthy liver subjects using 2D-SWE from GE Logiq S8 (GE Healthcare, Milwaukee, Wi, USA)
as well as SWE from Samsung RS80A (Samsung Medical, Seoul, Korea). Our study primarily
aimed to define normal values of liver stiffness (LS) for males and females across adult age
groups using these two novel platforms. We applied TE using Fibroscan integrated in the GE
Logiq S8 ultrasound scanner (Echosens, Paris, France) as a reference method. Furthermore,
we aimed to analyse influencing factors, such as BMI, and to assess the inter- and intraobserver
variability and reproducibility, as well as to investigate the difference between obtaining five
and ten consecutive liver stiffness measurements in order to calculate a representative median
liver stiffness measurement (LSM).
Material and methods
Study design and subject population
The study was designed as a single-centre cross-sectional prospective study in selected healthy
individuals. The protocol was in accordance with the Declaration of Helsinki for research in
medicine and biology, and was approved by the Regional Committee for Medical and Health
Research Ethics in Western Norway. All subjects were given oral and written information
about the study and were invited to participate. Informed written consent was obtained from
each subject enrolled. The study was performed in August and September 2017, at the Depart-
ment of Gastroenterology, Haukeland University Hospital in Bergen, Norway.
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The characteristics of healthy subjects are shown in Table 1. The subjects consisted of vol-
unteers with various occupational backgrounds recruited amongst staff, their families and
social network. Volunteers were recruited into five groups by age, with 10 males and 10
females per group: 20–30, 31–40, 41–50, 51–60 and 61–70 years (Table 1). Liver disease was
ruled out as far as possible by patients’ history, laboratory tests and negative viral markers. In
total ten subjects were excluded, weekly alcohol use extending 10 units for males and 6 units
for females (n = 2), abnormal laboratory tests (n = 3) or evidence of malignancy on ultrasound
examination (n = 1). Individuals with BMI >30 kg/m2 were excluded (n = 4). Four subjects
withdrew their participation consent (Fig 1). We included 100 healthy subjects in the final
analysis. A random subset of subjects (n = 24) were included for assessment of interobserver
variability. For analyses regarding the effect of BMI, the subjects were divided into two groups
with BMI between 18.0 and 25 kg/m2 (n = 73) and BMI between 25 and 30 kg/m2 (n = 27),
respectively.
Laboratory analyses
On the day of ultrasound and elastography, blood was sampled and biochemical analyses were
performed using standard routine laboratory protocols. The tests included C-reactive protein
(CRP), haemoglobin, leukocytes, platelets, creatinine, total bilirubin, albumin, international
Table 1. The characteristics of healthy subjects, by age group.
20–30 (n = 20) 31–40 (n = 20) 41–50 (n = 20) 51–60 (n = 20) 61–70 (n = 20)
Characteristics
Age, years? (range) 27.8 ± 2 (25–30) 34.1 ± 2.7 (31–40) 44.3 ± 3 (41–50) 55.7 ± 3 (51–60) 64.15 ± 2.5 (61–69)
Gender; Female/Male, n 10/10 10/10 10/10 10/10 10/10
BMI, kg/m2? (range) 22.5 ± 2.4 (19.4–27.2) 23.8 ± 2.3 (20.7–28.4) 24.4 ± 3 (18.1–28.7) 24.5 ± 2.3 (20–29.9) 24.7 ± 2.9 (20–29.6)
Weight group?, n (%)
18.0–25 kg/m2 17 (17%) 15 (15%) 15 (15%) 13 (13%) 13 (13%)
25.0–30 kg/m2 3 (3%) 5 (5%) 5 (5%) 7 (7%) 7 (7%)
Alcohol units per week?(range) 4.4 ± 2.5 (0–8) 3.8 ± 2 (0–6) 3.7 ± 2.6 (1–10) 4.4 ± 2.6 (0–10) 4.2 ± 3 (0–10)
Biochemical profile
Total bilirubin μmol/L
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Data are presented as median?Data are presented as mean ± SD. SD, Standard deviation; IQR, Interquartile range (representing upper and lower bound); Range
(from minimum value to maximum value). BMI, Body Mass Index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; APRI, AST to Platelet Ratio Index;
FIB4, Fibrosis-4. Reference values for our laboratory tests are given in the brackets, normal values cover both genders.
https://doi.org/10.1371/journal.pone.0203486.t001
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normalization rate (INR), aspartate aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT). The laboratory analyses
were performed in our hospital’s laboratory, and reference values were gender specific. Three
subjects had a bilirubin value outside the gender specific reference range, but none of these
were excluded as the values normalized and diagnostic work-up showed no evidence of liver
disease. Viral markers for hepatitis C virus (HCV) and hepatitis B virus (HBV) were also
included. APRI and FIB-4 scores of fibrosis were calculated using published algorithms [5, 6].
B-mode ultrasound examination
All subjects underwent B-mode ultrasound examination of the liver, gallbladder, spleen and
kidneys using a Samsung RS80A before SWE examination. All examinations were conducted
after a minimum of four hours of fasting, using a standardized scanning protocol and by a
Fig 1. Method of selection of healthy subjects. Flow chart of data collection.
https://doi.org/10.1371/journal.pone.0203486.g001
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single operator (AM) with>3 years’ experience in abdominal ultrasound. Small hepatic capil-
lary haemangiomas were found in 9 subjects; none of these subjects were excluded as the
lesions were confirmed by contrast enhanced ultrasound and were considered small and
unlikely to influence the liver stiffness.
Elastography methods and SWE examination
Three shear wave elastography (SWE) methods were assessed in the study and are listed below
in chronological order of assessment. The scanner settings were standardized for all systems.
All measurements were performed by a single operator (A.M.). In order to evaluate interob-
server variation, a subset of subjects (n = 24) were examined by two independent observers (A.
M. and A.B.M.). Observer A (A.M.) and B (A.B.M.) had >3 and 1 years’ experience in ultra-
sound liver scanning and elastography, respectively. The subjects were fasting (minimum 4
hours) and examined in the supine position with their right arm abducted. All SWE measure-
ments were obtained in the right liver lobe through an intercostal space in relaxed mid-breath
hold with minimal transducer pressure being applied; for Samsung RS80A and GE S8 the mea-
surements were acquired in the right lobe about 2 cm beneath the Glisson capsule, perpendic-
ular to the capsule, avoiding large liver vessels, bile ducts and rib shadow in B-mode. Each
observer performed first 10, and then 5 separate measurements in the same area with each of
the ultrasound based elastography methods. A valid LS assessment was considered as the
median value and range of 10 and 5 measurements, acquired in a homogenous area (Samsung
RS80A) or in a homogenous elastogram (GE S8 2D-SWE) with an interquartile range (IQR)/
median<30% and a success rate (SR)60%.
Samsung RS80A SWE. The Prestige ultrasound system (Samsung Medison Co. Ltd.,
Seoul, Korea) was applied using a CA1-7A convex array probe with a frequency of 1–7 MHz.
The software version was 3.00.03.0824. The method measured the average liver elasticity
within a region of interest (ROI). Within the brightness mode (B-mode) window, using default
scanner settings, the ROI could be placed freely, with a fixed height of 10 mm. The width was
automatically adjusted depending on the measurement depth (Fig 2). LSM was expressed in
kilopascals (kPa) and meters per second (m/s).
GE Logiq S8 2D-SWE. 2D-SWE from the S8 Ultrasound scanner (GE Healthcare, Mil-
waukee, Wisconsin, USA), Version R4.1.2, was applied using the C1-6 convex array probe
with a frequency of 1–6 MHz. Within the elastogram a circular ROI was placed, standardized
to 10 mm in our study and under default scanner settings. The elastic modulus of the liver was
automatically acquired by the system. The colour 2D-SWE images were captured and 2–3 elas-
ticity frames per breath-hold (3–5 seconds) were recorded. One ROI was placed within each
homogenously coloured elastogram (Fig 3). LSM was expressed in m/s and kPa.
Transient elastography (TE). Integrated in the GE Logiq S8 ultrasound scanner, TE
(Fibroscan1, EchoSens, Paris, France), was applied using the M-probe with a frequency of 3.5
MHz and used according to the manufacturer’s instructions. A reliable and valid measurement
acquisition was defined as SR60% and IQR/median <30% [7].
Statistical analysis
The statistical analysis was performed using SPSS, Version 24.0, IBM Statistics (Armon, New
York, NY, USA). We used descriptive statistics for demographic, clinical and laboratory char-
acteristics. Sample size power estimation was performed using a 2-sided comparison of two-
means model. Estimating a difference in means of 4.0–4.5 kPa with a standard deviation of 0.5
kPa between the methods, 80% power and type I error of 5% yielded a sample size of 16; we
compared groups consisting of 20 individuals or more. Variables were tested for normal
Liver elasticity in healthy individuals by two novel shear-wave elastography systems
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distribution by calculation and graphics using the Shapiro Wilk test and Q-Q Plot. Differences
between numerical variables with a normal distribution were assessed with parametric tests (t-
test), and those with a non-normal distribution, with nonparametric tests (Mann-Whitney).
P-values of< 0.05 were considered significant. Data are presented as mean (SD) when the
data were normally distributed. We calculated the coefficient of variation (CV) of the intraob-
server variability. Inter-class correlation coefficients (ICC) were calculated to present the
Fig 3. 2D-SWE by GE S8 performed on a healthy liver. The figure illustrates the method of 2D-SWE by GE
performed on a healthy subject. The coloured box (centre) represents the elastogram, and the circle represents the ROI
where the elastic modulus (LSM, liver stiffness measurement) of the liver is acquired. The blue colour indicates soft
liver tissue, as semi-quantitatively presented by the colour scale to the left.
https://doi.org/10.1371/journal.pone.0203486.g003
Fig 2. Samsung RS80A SWE performed on a healthy liver. The figure illustrates Samsung RS80A SWE method
performed on a healthy subject. The yellow box (centre) represents the shear-wave measurement area and is expressed
below the obtained elasticity measurement of 3.4 kPa.
https://doi.org/10.1371/journal.pone.0203486.g002
Liver elasticity in healthy individuals by two novel shear-wave elastography systems
PLOS ONE | https://doi.org/10.1371/journal.pone.0203486 September 14, 2018 6 / 18
interobserver reliability. Inter-observer agreement was classified as poor (0.00–0.20), fair
(0.21–0.40), moderate (0.41–0.60), good (0.61–0.80) and excellent (0.81–1.00) [8]. Correlations
were tested by Pearson correlation coefficient. Limits of agreement were assessed according to
Bland and Altman to discover differences between individual measurements and to detect pos-
sible biases for each method [9, 10]. IQR/Median (%) was calculated for both observers indi-
vidually as well as together, and for all systems [3, 11].
Results
A total of 100 healthy subjects were included. LSM was obtained by three different elastogra-
phy methods (Samsung RS80A, GE S8 2D-SWE and TE). The feasibility of the methods was
excellent and successful measurements were obtained in all 100 subjects by all three methods.
The characteristics of the healthy subjects are shown in Table 1.
Measurement variability for the different elastography methods
The overall mean value of the median liver stiffness (LSM-mean) in 100 healthy subjects ran-
ged from 2–6.8 kPa (Table 2).
LSM-mean by GE S8 2D-SWE was significantly higher compared to LSM-mean by TE
(4.5 ± 0.8 kPa vs. 4.2 ± 1.1, respectively, p<0.001) and Samsung RS80A (4.1 ±0.8 kPa,
p>0.001), whereas no significant difference was seen between Samsung RS80A and TE
(p = 0.11) (Fig 4).
The coefficient of variation (CV) ranged from 0.03–0.28 for all systems (0.03–0.28 for Sam-
sung RS80A SWE, 0.05–0.28 for GE S8 2D-SWE and 0.04–0.20 for TE). TE had a significantly
higher CV than GE S8 2D-SWE (p<0.001) and Samsung RS80A (p = 0.005). Furthermore,
between GE S8 2D-SWE and Samsung RS80A we found a small, but significant difference in
CV (p = 0.03). Interobserver analysis was performed on 24 randomly selected subjects. No sig-
nificant differences in LSM-mean between two independent observers (A.M. and A.B.M) was
demonstrated for Samsung RS80A SWE (4.4 ± 0.8kPa vs. 4.4 ± 0.8 kPa, respectively, p = 0.42),
however, we did find a significant difference between observers for GE S8 2D-SWE (4.5 ± 0.6
kPa vs. 5.1 ± 0.7 kPa, respectively, p = 0.009) (Fig 5).
Interoperator reliability was good for both Samsung RS80A SWE and GE S8 2D-SWE.
Pearson’s correlation coefficient between observers was significant for both methods (r = 0.74,
p<0.001 vs. r = 0.65, p<0.001, respectively) (Fig 6).
The intraclass correlation coefficient (ICC) was good for both Samsung RS80A and GE S8
2D-SWE (ICC = 0.85 vs. ICC = 0.78, respectively). There was no indication of observer bias
for either GE S8 2D-SWE or Samsung RS80A SWE as illustrated by limits of agreement
Table 2. Liver stiffness values (kPa) for the different methods.
Method 2D-SWE GE S8 Samsung RS80A SWE Fibroscan (TE)
Mean LS, kPa 4.5 4.1 4.2
Range 2.9–6.3 2.5–6.8 2.0–6.4
SD 0.8 0.8 1.1
95% CI 4.37–4.67 3.91–4.23 4.0–4.5
CV 0.17 0.21 0.27
CV [range] 0.05–0.28 0.03–0.28 0.04–0.20
Liver stiffness (LS) values (kPa) for 2D-SWE GE, Samsung RS80A and TE. Data are presented as mean with 95%
Confidence Interval (CI) and standard deviation (SD), coefficient of variation (CV) and the range of CV for the
respective methods.
https://doi.org/10.1371/journal.pone.0203486.t002
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analysis; however, GE S8 2D-SWE showed a trend of a slightly larger deviation of the mean
than Samsung RS80A SWE (Figs 7 and 8).
Difference in liver elasticity by gender, age and BMI
LSM-mean was significantly higher in males compared to females for TE (4.5 ± 1.0 kPa vs.
3.9 ± 1.1 kPa, respectively, p = 0.006) and GE S8 2D-SWE (4.7 ± 0.7 kPa vs. 4.3 ± 0.7 kPa,
respectively, p = 0.006). A similar trend for Samsung RS80A SWE did not reach significance
(4.2 ± 0.7 kPa vs. 3.9 ± 0.9 kPa, respectively, p = 0.063) (Fig 9, Table 3). In a post hoc analysis
of subjects consuming 5 alcohol units or less per week (n = 69) we found significant differences
in LSM-mean between males (n = 33) and females (n = 36) for all systems; for GE S8 (4.8 ± 0.7
kPa vs. 4.2 ± 0.8 kPa, p = 0.003), TE (4.7 ± 1.0 kPa vs. 3.8 ± 1.1 kPa, p = 0.001) and Samsung
(4.2 ± 0.7 kPa vs. 3.8 ± 0.7 kPa, p = 0.006).
None of the systems demonstrated statistical significant difference in LSM across age
groups (Table 4).
LSM-mean showed no significant difference between subjects with BMI 25–30 kg/m2 and
BMI 18.0–25.0 kg/m2 for any individual system (GE S8 2D-SWE (4.5 ± 0.8 kPa vs. 4.4 ± 0.8
kPa, respectively, p = 0.49), TE (4.3 ± 1.1 kPa vs. 4.1 ± 1.1 kPa, respectively, p = 0.36), Samsung
RS80A SWE (4.1 ± 0.9 kPa vs. 3.9 ± 0.6 kPa, respectively, p = 0.28) or all systems combined
(4.1 ± 0.9 kPa vs. 4.3 ± 0.9 kPa, p = 0.128) (Fig 10).
Fig 4. Liver stiffness (kPa) in a healthy cohort for the different methods. This boxplot figure displays the median
and the interquartile range for LSM for each system. Whiskers represent the 90% percentile of the measured liver
stiffness. The height of the box represents the variability in LSM between the healthy study subjects for each of the
following three systems: blue, GE S8 2D-SWE; green, Transient Elastography (TE, Fibroscan) and orange, Samsung
RS80A SWE. P-values indicate if there is a significant difference between the novel systems (Samsung RS80A or GE S8)
and TE.
https://doi.org/10.1371/journal.pone.0203486.g004
Liver elasticity in healthy individuals by two novel shear-wave elastography systems
PLOS ONE | https://doi.org/10.1371/journal.pone.0203486 September 14, 2018 8 / 18
Difference in variability and reproducibility of LSM when using 5
measurements instead of 10
There was no significant difference in LSM-mean using 5 or 10 measurements for the ultra-
sound based SWE methods (GE S8 2D-SWE 4.4 ± 0.66 kPa vs. 4.5 ± 0.76 kPa, respectively,
p = 0.05; and Samsung RS80A SWE: 4.1 ± 0.86 kPa vs. 4.1 ± 0.81 kPa, respectively, p = 0.08)
(Fig 11).
Discussion
To the best of our knowledge, this is the first study to investigate normal LSM values by two
new elastography techniques (Samsung RS80A SWE and GE S8 2D-SWE) compared head-to-
head and with TE as reference, in a healthy cohort. The comprehensive exclusion of liver dis-
ease as well as the direct comparison to TE as a reference standard represent strengths of our
study. Data regarding normal values in liver stiffness for each of the new elastography tech-
niques are needed to establish standardized reference bases [12], which are pivotal for clinical
implementation of novel elastography systems as reliable methods for diagnostics, staging and
assessment of disease progression in chronic liver diseases.
We found a mean LSM of 4.3 kPa ± 0.8 across the two methods, confirming that on average
LSM for 2D-SWE GE S8 (4.5 ± 0.8 kPa) and Samsung RS80A (4.1 ±0.8 kPa) were in the same
range as other elastography systems [13–15]. In this head-to-head comparison between elasto-
graphy systems, 2D-SWE GE S8 demonstrated slightly higher values than both Samsung
RS80A and TE, while measurements made with Samsung RS80A were not significantly differ-
ent from the reference method. There was also a small, but significant difference in the
Fig 5. Liver stiffness (kPa) of healthy adult livers, interobservation. The boxplot shows interobservation between
observer A (dark blue) and B (light blue). The horizontal axis represents the systems Samsung RS80A SWE and GE S8
2D-SWE and the p-value is given. For boxplot interpretation, we refer to Fig 4.
https://doi.org/10.1371/journal.pone.0203486.g005
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coefficient of variation between the two novel methods. Previous studies have shown similar
results for 2D-SWE from Aixplorer [16, 17]. Our results confirm that LSM levels are signifi-
cantly different depending on the method applied. We found differences both between SWE
methods and TE as the reference method, and between the two different SWE systems. In clin-
ical practice LSM greater than 6.8–7.6 kPa indicates a higher probability of significant fibrosis
(F2) on liver biopsy; however, the EASL clinical practice guidelines state that cut-off values
vary considerably and ranging 5.2–9.6 kPa for different systems. For predicting cirrhosis (F4),
the optimal cut-off ranges from 11 to 15 kPa [18]. In that context, a net difference of 0.3 kPa is
probably too small to represent a clinically significant difference, however, it underscores the
need to compare methods also in fibrotic livers, where the differences may be more expressed,
as we know that variability increases with higher liver stiffness [19].
Both methods showed good interobserver reliability and intraclass correlation. Similarly,
previous studies have shown excellent interobserver agreement ranging from r = 0.80–0.97 for
pSWE methods [20, 21]. However, we observed a significant difference in LS measurements
between the two observers for 2D-SWE GE S8 but not for Samsung RS80A. One possible
explanation for this discrepancy may be that 2D-SWE allows the examiner to place the mea-
surement ROI within the elastogram and avoid incongruent signals, while Samsung SWE per-
forms several automated SWE speed measurements within the elasticity measurement area
without visualisation of the stiffness. The 2D-SWE method is slightly more user dependent
and may acquire a longer learning curve. Previous studies on 2D-SWE measurements of liver
Fig 6. Correlation between observer A and B. The horizontal and vertical axes represent measurements by observer
B and A, respectively. The unit measured is kilopascals (kPa). The line in the graph represents the line of unity. The
Pearson correlation coefficient (r) and significance (p) for each system is given in the lower right corner. For colour
representation, we refer to Fig 4.
https://doi.org/10.1371/journal.pone.0203486.g006
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elasticity have demonstrated a learning curve for this method, but with similar reproducibility
[16, 22]. Evaluating the intra- and interobserver agreement for 2D-SWE from GE and SWE
from Samsung, we demonstrated a good interobserver and better intraobserver agreement for
both systems compared to the results reported for Aixplorer 2D-SWE (Figs 7 and 8).
We found a significantly higher LSM in adult male subjects for TE and GE S8 2D-SWE,
whereas a similar trend for Samsung RS80A SWE did not reach significance. This is an impor-
tant finding, indicating that it may be necessary to define separate cut-off values for normal
liver and possibly also for levels of liver fibrosis for male and female patients. Previous studies
have shown inconsistent results regarding the effect of gender on LSM [23, 24]. Using pSWE,
Ling et al. demonstrated that males had 8% higher LSM than females; however, the study had
more than twice as many female participants compared to male participants [14]. In contrast,
using ARFI, one study found no significant difference between genders in 137 subjects [25] in
line with our results for Samsung RS80A. Two studies conducting reliable LSM with TE in
1190 subjects over 45 years, and in 746 healthy subjects, found that male gender was associated
with higher liver stiffness [26, 27] and our results for TE confirmed this. Using Aixplorer
2D-SWE from Supersonic Imagine, it has been suggested that males may have higher LSM
than females [13]. A study of LSM in healthy children, using the same system, did not demon-
strate significant difference between genders [28]. The lack of significant gender difference for
LSM in healthy liver tissue for Samsung SWE in the present study may be due to different
Fig 7. Limits of agreement for Samsung RS80A SWE. The figure presents the limits of agreement for Samsung
RS80A. The horizontal axis represents the common mean value of all measurements in both observers for, while the
vertical axis represents the difference between individual measurements and this common mean (kPa), displaying the
variability of measurements. The black line within each system represents the common mean value, the dotted lines
represent the 95% confidence intervals. A mean value close to 0 on the vertical axis means that the two observers apply
the measurement scale without bias.
https://doi.org/10.1371/journal.pone.0203486.g007
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technology and signal processing compared to the two other scanners. Despite that we found a
significant difference between genders for all systems in our post hoc analysis (n = 69), the
study may be underpowered considering the observed SD of 0.8 kPa for the Samsung SWE
compared to our power estimation anticipating 0.5 kPa as SD. Furthermore, different hor-
mone levels have been proposed as an explanation of LSM differences between genders, and
should be investigated further in in vivo studies [29].
In our study, LSMs were not significantly affected by age or BMI. Multiple studies have
addressed age as a variable of influencing liver stiffness in normal subjects, and the results have
been inconsistent, reporting no difference across age groups [14], higher LSM in older [26] or
younger [27] age. We did not demonstrate significant differences in LSM between the five age
groups for any of the methods. Possibly, analyses of the effect of age on LSM is confounded by
other factors such as steatosis and heart failure that are more prevalent in older populations.
One study investigating GE E9 Logic 2D-SWE in healthy subjects reported an LSM-mean of
5.1 kPa ± 1.3, with higher LSM values compared to TE, similar to our findings [17]. In contrast
to our results, they reported that age over 40 years was associated with higher LSM, but did not
find significant difference in LSM between genders (21 males and 58 females). In the present
study, we included only healthy volunteers, carefully interviewed all subjects regarding alcohol
consumption, and performed full biochemical analyses and B-mode ultrasound examination of
all in contrast to some other studies [12], and in our view, less strict inclusion criteria and miss-
ing data regarding liver enzymes in the other study may contribute to these differences. Higher
LSM values have been reported in healthy subjects with low BMI (<18.5 kg/m2) as well as in
obese subjects compared with normal-weight subjects [30]. We did not demonstrate a differ-
ence in LSM between subjects with BMI 18.0–25.0 kg/m2 compared to BMI 25–30 kg/m2;
Fig 8. Limits of agreement for 2D-SWE GE S8. Limits of agreement for 2D-SWE GE S8, for legend we refer to Fig 7.
https://doi.org/10.1371/journal.pone.0203486.g008
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however, obese patients with BMI>30 were not included in this study. Normal values for LS in
underweight and obese subjects, as well as technical feasibility of Samsung RS80A SWE and GE
S8 2D-SWE, should be further investigated and established.
There is an ongoing discussion of the minimum number of measurements needed when
acquiring LSM with SWE. The EFSUMB guidelines recommend at least 10 measurements for
pSWE and TE, and a minimum of 3 measurements when using 2D-SWE, to obtain consistent
results [31, 32]. One study reported excellent intraobserver reproducibility based on 6
Fig 9. Liver stiffness (kPa) of healthy adult livers, by gender. The boxplot shows the liver stiffness by gender. The
horizontal axis represents the gender; males and females. The colour interpretation for each system and the level of
significance is given in the upper right corner. For legend interpretation, we refer to Fig 4.
https://doi.org/10.1371/journal.pone.0203486.g009
Table 3. Liver stiffness values (kPa) of healthy adult livers, by gender.
Gender Female (n = 50) Male (n = 50) p-value
GE S8 2D-SWE
Mean ± SD (kPa) 4.3 ± 0.7 4.7 ± 0.7 p = 0.006
95% CI 4.1–4.5 4.5–4.9
Samsung RS80A SWE
Mean ± SD (kPa) 3.9 ± 0.9 4.2 ± 0.7 p = 0.063
95% CI 3.7–4.2 4.0–4.4
Fibroscan (TE)
Mean ± SD (kPa) 3.9 ± 1.1 4.5 ± 1.0 p = 0.006
95% CI 3.6–4.2 4.2–4.8
Liver stiffness values (kPa) for 2D-SWE GE, Samsung RS80A and TE, by gender. Data are presented as mean ± standard deviation with 95% Confidence interval (CI).
https://doi.org/10.1371/journal.pone.0203486.t003
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Table 4. Liver stiffness values (kPa) of healthy adult livers, by age group.
Age group 20–30 (n = 20) 31–40 (n = 20) 41–50 (n = 20) 51–60 (n = 20) 61–70 (n = 20) p-value
GE S8 2D-SWE
Mean ± SD (kPa) 4.5 ± 0.9 4.7 ± 0.8 4.5 ± 0.7 4.4 ± 0.7 4.5 ± 0.7 p = 0.843
95% CI 4.1–4.9 4.3–5.1 4.1–4.8 4.1–4.8 4.2–4.9
Samsung RS80A SWE
Mean ± SD (kPa) 4.3 ± 0.9 4.2 ± 0.8 4.0 ± 0.8 4.1 ± 0.6 3.9 ± 1.0 p = 0.630
95% CI 3.9–4.7 3.8–4.5 3.6–4.4 3.8–4.3 3.4–4.4
Fibroscan (TE)
Mean ± SD (kPa) 4.4 ± 1.1 4.3 ± 1.3 4.2 ± 1.0 4.2 ± 1.1 4.1 ± 1.1 p = 0.630
95% CI 3.9–4.9 3.7–5 3.7–4.7 3.7–4.7 3.6–4.7
Liver stiffness values (kPa) for 2D-SWE GE, Samsung RS80A and TE, by age group. Data are presented as mean ± standard deviation with 95% Confidence interval (CI).
https://doi.org/10.1371/journal.pone.0203486.t004
Fig 10. Liver stiffness (kPa) of healthy adult livers, by weight group. The boxplot shows the liver stiffness by weight group. The horizontal axis represents the BMI
group. The colour interpretation for each system and the level of significance is given in the upper right corner. For boxplot interpretation, we refer to Fig 4.
https://doi.org/10.1371/journal.pone.0203486.g010
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measurements, concluding that the optimal minimum number of measurements with
2D-SWE was 6 [15]. For pSWE (ARFI), one study concluded that 10 measurements instead of
5 should be performed to obtain a reliable estimation [33]. To the best of our knowledge there
are no studies that have directly investigated the difference in mean LS between 5 and 10 sepa-
rate measurements for several ultrasound SWE methods. Our results did not show significant
difference in median LS for 5 versus 10 measurements. This suggests that a reliable median
LSM can be obtained with fewer measurements than ten for both 2D-SWE GE S8 and Sam-
sung RS80A in healthy livers. This is important as it indicates that adequate measurements can
be made by fewer repetitions and in less time, however our results in healthy livers may not
apply in patients with higher degree of liver fibrosis where measurement variability may be
higher.
The main limitation of the study is the lack of liver biopsies as a reference method, which is
not ethically feasible in a healthy group. Our study design included 100 healthy participants,
excluding unknown liver disease by imaging, blood tests and anamnesis.
Conclusion
All methods were successfully applied in our cohort of 100 healthy subjects. The mean of
median LSM for the two new elastography methods (GE S8 and Samsung RS80A) showed a
slight difference. Our study shows a significantly higher liver stiffness in males compared to
Fig 11. Difference in liver stiffness (kPa) for 5 and 10 measurements. The boxplots show difference in liver stiffness
for 5 and 10 measurements. The horizontal axis represents the systems, and the vertical axis the liver stiffness
measured. The colour interpretation for 5 and 10 measurements (green and blue, respectively) is given in the upper
right corner. For boxplot interpretation, we refer to Fig 4.
https://doi.org/10.1371/journal.pone.0203486.g011
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females, however we found no significant difference in LS between BMI groups 18–30 kg/m2
or between the age groups 20–70 years. Furthermore, our findings indicate that five acquisi-
tions are sufficient to obtain a reliable LSM using Samsung RS80A or GE S8 2D-SWE in
healthy subjects.
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Abstract—The aim of the study described here was to characterize three different liver elastography methods in pri-
mary sclerosing cholangitis (PSC) patients, for the first time exploring 2-D shear wave elastography (2-D-SWE) in PSC
patients and its putative advantages over point shear wave elastography (pSWE). Sixty-six adult PSC patients (51 males,
77%) underwent liver elastography: Transient elastography (TE), pSWE and 2-D-SWEwere applied head-to-head after
B-mode ultrasonography and blood tests. Liver stiffness measurements (LSMs) by pSWE yielded lower values than
those by TE; 2-D-SWE had less steep slope but was overall not significantly different from TE. Correlation between
LSMs by pSWE and TE was excellent (intraclass correlation coefficient = 0.92); correlation for 2-D-SWE with either
pSWE or TE was moderate but improved with exclusion of overweight individuals. LSMs correlated with the Enhanced
Liver Fibrosis test (ELF) across all scanner systems. Our study indicates that LSM by different systems is feasible in
PSC patients and that 2-D-SWE tends to underestimate stiffness compared with TE. (E-mail addresses:
abmjelle@gmail.com, adnj@helse-bergen.no) © 2020 The Author(s). Published by Elsevier Inc. on behalf of World
Federation for Ultrasound inMedicine & Biology. This is an open access article under the CC BY license.
(http://creativecommons.org/licenses/by/4.0/).
Key Words: Elastography, Liver fibrosis, Point shear wave elastography, Primary sclerosing cholangitis, Shear
wave elastography, Transient elastography, Ultrasound.
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a progressive fibro-
inflammatory disease affecting primarily the bile ducts,
causing strictures and dilations and progressing over time
through increasing stages of liver fibrosis and eventually
cirrhosis. The natural history of PSC is notoriously unpre-
dictable, with population-based studies reporting substan-
tial variation in disease progression (Broome et al. 1996;
Boonstra et al. 2013). Histologic disease stage is associated
with prognosis in PSC but requires invasive biopsies and is
flawed by sampling error and inter-observer variation.
Liver elastography has gained a significant role as a
method for non-invasive evaluation of liver fibrosis in
chronic liver diseases, enabling quantification of liver stiff-
ness as a proxy for fibrosis with a high diagnostic accuracy
compared with liver biopsy, which is considered the refer-
ence standard (Sandrin et al. 2003; Corpechot et al. 2006;
Friedrich-Rust et al. 2008). Transient elastography (TE)
has exhibited excellent ability to stratify between milder
and severe stages of fibrosis in PSC compared with liver
biopsy, clinical scoring systems and serologic markers and
liver stiffness by TE was associated with clinical outcome
in two independent studies (Corpechot et al. 2014; Ehlken
et al. 2016a, 2016b). However, intermittent cholestasis
caused by (dominant) strictures is common in PSC and has
been reported to affect liver stiffness measurement (LSM)
levels, thus constituting an important confounder (Millonig
et al. 2008).
Liver elastography encompasses several techni-
cally different methods all based on the measurement
of shear wave velocity, such as TE, point shear wave
elastography (pSWE) and 2-D shear wave elastography
(2-D-SWE). pSWE and 2-D-SWE allow simultaneous
B-mode visualization of the liver, which may be
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particularly useful in PSC to exclude cholestasis as a
confounder. Potentially, 2-D-SWE might have advan-
tages because of visualization of an elastogram before
LSM in PSC, owing to the patchy distribution of fibrosis.
Previous studies in healthy controls of all ages (Mulabe-
cirovic et al. 2018a, 2018b; Mjelle et al. 2019) and in
patients with various liver diseases (Sporea et al. 2014,
2018; Piscaglia et al. 2017; Ferraioli et al. 2019; Iijima et
al. 2019; Lefebvre et al. 2019) have revealed differences
between methods with respect to both LSM levels and
feasibility.
In PSC, data on liver elastography are scarce, par-
ticularly for 2-D-SWE and pSWE and head-to-head
comparisons of methods. Thus, in this study, we aimed
to perform a parallel assessment of three different scan-




The study was performed at Haukeland University
Hospital, Bergen, Norway, in 2017 and 2018. All
patients were part of a well-characterized cohort of non-
transplanted PSC patients. PSC was diagnosed according
to acknowledged criteria. Data collection was performed
prospectively as part of annual study visits consisting of
patient history, clinical examination, blood tests and
ultrasound investigation including liver elastography.
Informed written consent was obtained from all partici-
pants.
B-Mode ultrasound examination
All patients were examined by B-mode ultrasound
scanning of the liver and spleen before liver stiffness
measurements. All examinations were performed by a
single operator (M.V.) using a Philips iU22 (Philips
Healthcare, Andover, MA, USA) scanner with software
Version 6.3.2.2, and a C5-1 convex probe. Scores were
registered for visual signs of liver fibrosis, including
parenchyma heterogeneity, liver capsule regularity, liver
angle, ascites, bile duct variability, sludge or gallbladder
stones. Splenomegaly was defined as a spleen length
12 cm.
Liver stiffness measurements
LSM was measured using a right intercostal
approach in fasting (3 h) patients placed in a supine
position, with the right hand resting under the head. All
measurements were acquired in relaxed mid-ventilation
breath hold with minimal probe pressure. pSWE using
the Philips iU22 (ElastPQ, iU22, Philips Healthcare) was
performed by a single operator (M.V.) using a convex
C5-1 probe, followed head-to-head by examinations by
another single operator (A.B.M.) using 2-D-SWE.GE
(GE S8, GE Healthcare, Milwaukee, WI) with a C1-6
probe, and TE using Fibroscan incorporated into the GE
S8 (GE Healthcare) using an M-probe, or XL-probe if
the machine indicated that the M-probe was not suitable.
2-D-SWE.GE and TE results were given in kilopascals
(kPa), and pSWE results in meters per second (m/s). The
latter values were converted into kilopascals for compar-
ison, using the equation kPa = 3 (m/s)2. Operators were
very experienced (M.V., many years of experience) or
moderately experienced (A.B.M., >300 elastography
measurements with 2-D-SWE.GE and pSWE); both
were certified Fibroscan users. For both pSWE and 2-D-
SWE.GE, a region of interest (for pSWE, a fixed region
of 0.5 £ 1.5 cm, and for 2-D-SWE.GE, a fixed circle
with a diameter of 1 cm) was placed in a homogenous
area 26 cm under the liver capsule, avoiding vessels
and visible bile ducts. Quality criteria were applied
according to the specific manufacturer’s recommenda-
tions: For all systems, a valid measurement required a
success rate 60%, and for 2-D-SWE.GE and TE valid
measurements required an interquartile range divided by
the median (IQR/M) 30%.
Enhanced liver fibrosis test
Serum samples were analyzed with the commer-
cially available enhanced liver fibrosis (ELF) test (Sie-
mens Medical Solutions Diagnostics Inc., Tarrytown,
NY, USA), with essays performed with the Siemens
ELF Test kits and an ADVIA Centaur XP analyzer (Sie-
mens Medical Solutions Diagnostics Inc.).
Statistical analyses
For all analyses, SPSS Version 25 (IBM, Armonk,
NY, USA) was used. All variables were tested for nor-
mality, and data were presented as the mean (standard
deviation [SD]) or median (range) as appropriate. We
applied Student’s t-test or MannWhitney U-test as
appropriate. Correlations were tested with Pearson’s cor-
relation or Spearman’s rank correlation coefficient as
appropriate. Degree of correlation was defined as poor
(<0.40), moderate (0.400.69), good (0.700.89) or
excellent (0.9). p Values < 0.05 were considered to
indicate statistical significance.
Ethical aspects
The protocol was in accordance with the Declara-
tion of Helsinki and approved by the Regional Commit-
tee on Medical and Health Research Ethics of Western
Norway (2012/2214/REK VEST).
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RESULTS
We prospectively recruited and included 66 non-
transplanted PSC patients (51 males, 77.3%) with a
mean (SD) age of 49 y (16.3 y). Median (range) time
since diagnosis was 8 y (037 y). Fifty-eight (78.8%)
patients had inflammatory bowel disease (IBD) and 3
(4.5%) had overlapping features of autoimmune hepati-
tis. Generally, 64.1% of these patients had B-mode find-
ings of liver pathology and/or bile duct pathology, while
25 (39.7%) patients had B-mode findings indicating liver
fibrosis. Liver pathology was defined as coarse paren-
chyma, absence of a smooth liver capsule or blunt liver
angle, while bile duct pathology was mainly segmental
dilations or multifocal strictures or bile duct wall thick-
ening. In 23 patients (35.9%), neither liver pathology nor
bile duct variability was observed. Splenomegaly was
observed in 33 (52.4%) patients. Only a few patients
(n = 3) had significant hyperbilirubinemia (bilirubin >50
mmol/L). Baseline characteristics are summarized in
Table 1.
LSMs by three scanner systems
Feasibility was good to excellent for all systems,
with valid results for TE in 89.4%, for pSWE in 93.9%
and for 2-D-SWE.GE in 71.2%. Median (range) LSM
was 7.1 kPa (3.561.4 kPa) for TE, 4.9 kPa (2.664.9
kPa) for pSWE and 6.4 kPa (4.240.1 kPa) for 2-D-
SWE.GE. Valid results for all three systems were avail-
able for 42 patients (63.6%), with LSM values of 6.4
(3.532.7), 4.7 (2.725.8) and 6.4 (4.534.9) for TE,
pSWE and 2-D-SWE.GE, respectively. Median LSM
was significantly lower by pSWE than by TE (p <
0.001), whereas there were no significant overall differ-
ences between 2-D-SWE.GE and either pSWE or TE.
Intersystem differences were however not linear: 2-D-
SWE.GE was significantly higher than TE for low-aver-
age LSM values, and significantly lower for middle-
range and high-average LSM values (i.e., LSM by 2-D-
SWE.GE exhibited a less steep slope compared with TE;
Fig. 1). Similarly, 2-D-SWE.GE yielded significantly
higher values than pSWE for low to middle-range LSM
values.
LSM values exhibited a good correlation between
systems (r = 0.70, 0.72, 0.65 for pSWE vs. TE, TE vs. 2-
D-SWE.GE and pSWE vs. 2-D-SWE.GE, respectively;
p < 0.001). Correlation improved when patients with
body mass indexes (BMIs) 30 were excluded (r =
0.81, 0.78 and 0.76 for pSWE vs. TE, TE vs. 2-D-SWE.
GE and pSWE vs. 2-D-SWE.GE, respectively). The
intraclass correlation coefficient (ICC) was excellent for
pSWE versus TE (ICC = 0.91, p < 0.001), while moder-
ate for pSWE versus 2-D-SWE.GE and for TE versus 2-
D-SWE.GE (ICC = 0.49, p = 0.013 and 0.43, p = 0.035,
respectively). This discrepancy was largely caused by
BMI. When analyzed for normal-weight individuals
only (n = 31), the ICC values improved to 0.93, 0.92 and
0.81, respectively. By excluding only individuals with a
BMI 30, ICC values were 0.91, 0.6 and 0.43, respec-
tively. In trying to establish a threshold BMI, similar
high ICC values were kept with a cutoff of BMI <28 kg/
m2 for pSWE versus TE (n = 45, ICC = 0.90, p < 0.001)
and 27 kg/m2 for 2-D-SWE.GE versus TE (n = 33; ICC
= 0.81, p < 0.001).
Factors associated with LSM differences between
scanner systems
Difference in LSM (DLSM) between pSWE and TE
was associated with BMI (r = 0.53, p < 0.001) (Fig. 2)
in linear regression, with higher DLSM in the obese.
When patients were classified as either obese (BMI 30)
Table 1. Baseline characteristics in patients with PSC under-
going elastography
Number of patients 66
Males 51 (77.3%)
Age, y, mean (SD) 49.0 (16.3)
Age at diagnosis, y, mean (SD) 37.7 (14.9)
Body mass index, kg/m2, mean (SD) 25.7 (4.4)
















Feature of autoimmune hepatitis 3 (4.5%)
Decompensated liver disease* 3 (4.5%)
Mayo risk score, median (range) 0.37 (1.89 to 2.94)
APRI score, median (range) 0.47 (0.123.36)








Coarse liver parenchymay 11 (16.7%)
Blunt liver angle* (missing = 1) 11 (16.7%)
Any liver pathology (missing = 3) 25 (39.7%)
Bile duct variabilityy 31 (47.0%)
Any liver or bile duct pathology 41 (62.1%)
Spleen length, cm, mean (SD) 12.1 (2.2)
Splenomegaly (12 cm) (missing = 3) 33 (52.4%)
Laboratory values, median (range)
Alanine transaminase 47.5 (4657)
Aspartate transaminase 46 (14299)
g-Glutamyl transferase 205 (152389)




APRI = aspartate transaminase-to-platelet ratio index SD = standard
deviation; IBD = inflammatory bowel disease; PSC = primary scleros-
ing cholangitis.
* Decompensating event before baseline (ascites, variceal bleeding,
encephalopathy or liver synthesis failure).
y Missing = 2.
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or not obese, the DLSM between pSWE and TE was sig-
nificantly higher in the obese (p = 0.002). Use of the XL
probe for TE in 8 PSC patients was not associated with
increased DLSM between pSWE and TE. DLSM was
not associated with any laboratory value, fibrosis marker
or B-mode finding, nor to LSM levels.
For DLSM for pSWE versus 2-D-SWE.GE or 2-D-
SWE.GE versus TE, there was no difference between
the obese and non-obese (p > 0.3). The DLSM between
pSWE and 2-D-SWE.GE was shown in linear regression
to be affected mainly by the pSWE LSM value (p <
0.001), but otherwise no single factor. DLSM for 2-D-
SWE.GE and TE was significantly associated with LSM
values, mainly by TE (p < 0.001), with serum ALP
(p = 0.009) and GT (p = 0.02) and BMI (p = 0.047).
Comparison of 2-D-SWE.GE with either TE or
pSWE revealed that there were some outliers with highly
deviant 2-D-SWE.GE LSM values, particularly in the
higher LSM range (Fig. 1). This was further illustrated
with BlandAltman plots (Fig. 3). We did not reveal
any common characteristic explaining this deviance, and
it is thus possible that these were operator dependent.
LSMs and suggested prognostic markers (ELF test,
Mayo risk score and spleen length)
LSMs correlated significantly with liver enzymes
and serum-based fibrosis scores (Table 2). In general,
TE and pSWE exhibited higher correlations with all lab-
oratory values compared with 2-D-SWE.GE (Table 2).
LSMs by pSWE, TE and 2-D-SWE.GE all correlated
significantly (r 0.57, 0.59 and 0.40, p  0.009) with the
Fig. 1. Liver stiffness measurements (LSMs) for 2-D shear wave elastography (2-D-SWE.GE) plotted against those for
transient elastography (TE). LSMs by 2-D-SWE.GE were higher than LSMs by TE in patients with a relatively low aver-
age LSM value, while TE values were higher than 2-D-SWE.GE values in patients with a higher average LSM value. A
good correlation was observed (r = 0.716), but two outliers exhibited a major discrepancy. Exclusion of the two outliers
increased r to 0.785. Patients representing these two outliers had quite average body mass indexes (27.5 and 28.1,
respectively) and normal laboratory values. One had B-mode signs of steatosis, and the other had a pathologic liver cap-
sule, but otherwise normal B-mode findings. Both had point shear wave elastography (pSWE) LSM measurements mim-
icking TE values, although one of them were deemed invalid because of a success rate just under 60%.
Fig. 2. Scatterplot of difference in liver stiffness values between point shear wave elastography and transient elastogra-
phy in percent (y-axis) and body mass index (BMI, x-axis), r = 0.528, p < 0.001. The intersystem difference increases
with increasing BMI. Looking at the systems separately, there was no increasing LSM with increasing BMI.
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Fig. 3. BlandAltman plots comparing scanner systems, with average liver stiffness measurements (LSMs) on the x-
axis and intersystem differences on the y-axis, for (a) point shear wave elastography (pSWE) and transient elastography
(TE); (b) TE and 2-D shear wave elastography (2-D-SWE.GE); and (c) pSWE and 2-D-SWE.GE.
Table 2. Correlation between liver stiffness measurements and laboratory values including fibrosis markers*
Laboratory value r (p value)
TE (Fibroscan) pSWE (Philips) 2-D-SWE.GE (GE)
Aspartate transaminase 0.71 (<0.001) 0.60 (<0.001) 0.50 (<0.001)
Alkaline phosphatase 0.69 (<0.001) 0.58 (<0.001) 0.50 (<0.001)
Enhanced liver fibrosis test 0.59 (<0.001) 0.57 (<0.001) 0.40 (0.009)
Mayo risk score 0.57 (<0.001) 0.67 (<0.001) 0.45 (0.001)
Fibrosis 4 (Fib4) score 0.48 (<0.001) 0.59 (<0.001) 0.47 (0.001)
g-Glutamyl transferase 0.59 (<0.001) 0.41 (0.001) 0.39 (0.006)
Bilirubin 0.49 (<0.001) 0.47 (<0.001) 0.35 (0.015)
Alanine transaminase 0.53 (<0.001) 0.36 (0.003) 0.36 (0.01)
Albumin 0.23 (0.081) 0.46 (<0.001) 0.18 (0.23)
IgG4 0.008 (0.955) 0.17 (0.194) 0.173 (0.257)
TE = transient elastography; pSWE = point shear wave elastography; 2-D-SWE.GE = 2-D shear wave elastography.
* Sorted after average r value between all three scanner systems.
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enhanced liver fibrosis (ELF) test, a well-validated
serum biomarker panel based on three direct markers of
fibrosis that has been found to be strongly associated
with clinical outcome in PSC (Vesterhus et al. 2015; de
Vries et al. 2017). The suggested cutoff value for ELF of
11.2 discriminated well between high and low LSMs
(Fig. 7), exhibiting an abrupt rise in LSM values beyond
the cutoff value (Fig. 4a, 4b). LSMs by all methods were
correlated with the Mayo risk score (Table 2). There
seemed to be a cutoff value of 0.5, after which a rapid
increase in LSM values was seen (Fig. 4c, 4d), and
LSMs were elevated in high-risk compared with low-
risk Mayo risk score groups (Fig. 5).
There was no LSM difference between patients
with and without splenomegaly (spleen length 12 cm).
However, at a cutoff of 13 cm, as proposed by a study on
a large healthy patient panel (Chow et al. 2016), patients
with splenomegaly had significantly higher LSM values
by pSWE (4.7 vs. 6.6 kPa, p = 0.019) and TE (6.2 vs. 8.9
kPa, p = 0.034), but not by 2-D-SWE.GE.
Fig. 4. Correlation between between liver stiffness and scores of fibrosis (enhanced liver fibrosis [ELF] score) or prognosis
(Mayo risk score). For ELF scores, a previously published cutoff value of 11.2 is noted (vertical line), while for transient
elastography (TE), a published cutoff value for cirrhosis of 14.4 is noted (horizontal line). (a) ELF score versus point shear
wave elastography (pSWE). (b) ELF score versus TE. (c) Mayo risk score versus pSWE. (d) Mayo risk score versus TE.
Fig. 5X X. Boxplot revealing a vast difference in liver stiffness measurements between patients with a high Mayo risk score
and a low Mayo risk score (median values: 20.9 kPa vs. 4.5 kPa, p < 0.001).
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LSMs and associations with clinical and B-mode
characteristics in PSC patients
LSMs did not differ between men and women, nor
between obese and non-obese patients, for any scanner
system. LSMs were significantly higher for all systems
in patients with either coarse liver parenchyma or an
irregular liver capsule (Table 3, Fig. 6) (TE and pSWE:
p < 0.001, 2-D-SWE.GE: p = 0.028).
Fig. 6. Liver stiffness measurement (LSMs) for all methods, grouped by liver parenchyma on B-mode ultrasound (nor-
mal or coarse liver tissue). LSM values were significantly higher by all scanner systems in patients with coarse liver tis-
sue, although substantially less significant by 2-D-SWE.GE (p = 0.028 vs. p < 0.001 and p < 0.001). TE = transient
elastography; pSWE = point shear wave elastography; 2-D-SWE.GE = 2-D shear wave elastography.
Table 3. Comparison of liver stiffness measurements in patients with visible pathology or normal findings on B-mode ultrasound
scanning*
TE (kPa) pSWE(kPa) 2-D-SWE.GE (kPa)
Normal vs. pathologic p Value Normal vs. pathologic p Value Normal vs. pathologic p Value
Liver parenchyma 6.0 vs. 19.4 <0.001 4.4 vs. 19.2 <0.001 6.3 vs. 8.5 0.028
Liver capsule 5.9 vs. 10.1 0.008 4.0 vs. 7.0 <0.001 6.2 vs. 7.7 0.009
Liver angle 6.1 vs. 16.6 0.005 4.6 vs. 12.1 0.019 6.4 vs. 7.2 0.485
Any liver pathology 5.9 vs. 9.2 0.005 4.0 vs. 6.3 0.001 6.2 vs. 7.5 0.055
Bile duct variability 6.0 vs. 7.1 0.5 4.4 vs. 5.5 0.086 6.3 vs. 6.6 0.434
Splenomegaly 6.5 vs. 8.0 0.252 4.7 vs. 5.4 0.442 6.2 vs. 7.2 0.115
TE = transient elastography; pSWE = point shear wave elastography; 2-D-SWE.GE = 2-D shear wave elastography.
* All values are medians.
Fig. 7. Boxplot of liver stiffness measurement (LSM) by point shear wave elastography (pSWE) using a cutoff enhanced
liver fibrosis (ELF) score of 11.2, discriminating high-risk (11.2) from low-risk patients. LSM values were significantly
higher for patients with a high ELF score.
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Discriminative ability of pSWE and 2-D-SWE.GE to
identify significant fibrosis and advanced disease
By applying published cutoff values for fibrosis
staging in PSC using TE (Corpechot et al. 2014), we
identified 50.8% as F0, 10.2% as F1, 1.7% as F2, 23.7%
as F3 and 13.6% as F4. The ability of pSWE as well as
2-D-SWE.GE to discriminate between mild and
advanced (F3F4) disease as defined by TE was good
(area under the receiver operating characteristic curve
[AUROC] = 0.85 for both pSWE and 2-D-SWE.GE),
with optimal cutoff values as decided by Youden’s index
of 4.9 kPa (sensitivity 90.9%, specificity 72.5%) and 7.8
kPa (sensitivity 76.9%, specificity 88.2%) for pSWE and
2-D-SWE.GE, respectively (Fig. 8).
DISCUSSION
To the best of our knowledge, this is the first study to
explore the use of 2-D-SWE.GE in PSC with different ultra-
sound elastography scanner systems in a head-to-head fash-
ion in an exclusive PSC cohort. Previous studies have
described the use of either TE (Corpechot et al. 2014;
Ehlken et al. 2016a, 2016b; Krawczyk et al. 2017) or pSWE
(Mjelle et al. 2016; Goertz et al. 2019). Intersystem differen-
ces are known (Mjelle et al. 2016; Dietrich et al. 2017;
Mulabecirovic et al. 2018a, 2018b) and may result from the
different system technologies, but it is unknown how these
are affected by the patchy fibrosis distribution in complex
cholestatic diseases such as PSC, which is histologically dif-
ferent from viral hepatitis and metabolic liver diseases.
We found good to excellent feasibility for all three
elastography systems in PSC patients. Previous studies in
patients with liver diseases are discrepant; some describe a
similar lower feasibility for 2-D-SWE.GE versus TE
(Cassinotto et al. 2014; Staugaard et al. 2016), while others
report the opposite (Bota et al. 2015; Cassinotto et al.
2015). LSM values in PSC patients were significantly lower
by pSWE than by TE, while measurements with 2-D-SWE.
GE were not different from those by either TE or pSWE.
This is in line with previous results, describing similar inter-
system differences in healthy cohorts (Mulabecirovic et al.
2018a, 2018b; Mjelle et al. 2019) and in various liver dis-
eases (Rizzo et al. 2011; Sporea et al. 2014; Belei et al.
2016; Thiele et al. 2016), as well as phantoms (Mulabecir-
ovic et al. 2016).
We obtained overall lower LSM values by pSWE
than by TE in PSC patients, with a steeper slope for TE
compared with either pSWE or 2-D-SWE.GE (e.g., 2-D-
SWE.GE yielded higher LSM values compared with TE
for low mean LSM values, but lower values in the higher
LSM range; Fig. 1), confirming findings suggested by
previous reports (Cassinotto et al. 2014; Thiele et al.
2016; Mulabecirovic et al. 2018a, 2018b; Mjelle et al.
2019). Such differences between elastography methods
regarding the slope of the LSM curve are important to
acknowledge in clinical follow-up of patients.
We found good correlations for LSM values between
scanner systems (r between 0.65 and 0.72). The ICC for
pSWE versus TE was excellent (0.91). The ICC for 2-D-
SWE.GE versus pSWE or TE was only moderate (0.49 and
0.43, respectively), but improved markedly when excluding
overweight individuals with a BMI >2728 kg/m2, agree-
ing with reports of increased unreliable LSMmeasurements
in patients with a BMI>27.7 kg/m2 (Bota et al. 2014).
Exploring the intersystem difference for LSM values
(DLSM), we found that these correlated with a few select
parameters, which differed between each intersystem com-
parison. DLSM between pSWE and TE was associated
only with BMI (p< 0.001), while DLSM for pSWE and 2-
D-SWE.GE was influenced by the pSWE LSM value (p <
Fig. 8. Receiver operating characteristic curve of liver stiffness measurements by point shear wave elastography
(pSWE) and 2-D shear wave elastography (2-D-SWE.GE) for the diagnosis of advanced fibrosis (F3F4), using pub-
lished cutoff values for transient elastography in a primary sclerosing cholangitis cohort.
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0.001). DLSM between 2-D-SWE.GE and TE was signifi-
cantly associated with individual LSM values (in particular
TE) (p < 0.001), with serum alkaline phosphatase and
g-glutamyl transferase and ELF values and with BMI. Ear-
lier publications report conflicting results, with some
describing increased failure rate or changing LSM values
with increasing BMI (Guzman-Aroca et al. 2011;
Popescu et al. 2013; Cassinotto et al. 2014; Liao et al.
2015), while some report that BMI exert no effect on LSM
values (Takahashi et al. 2010; Rizzo et al. 2011; Son et al.
2012; Huang et al. 2014; Mulabecirovic et al. 2018a,
2018b). Some of these discrepancies may well be the result
of different study designs, as most studies include no or few
obese (BMI 30 kg/m2) patients, with some studies even
setting the BMI cutoff well into the normal range before
testing for differences, the lowest at 22 kg/m2 (Liao et al.
2015). Taken together, our results suggest that LSM values
in overweight patients with PSC may be subject to
increased uncertainty. Further studies are warranted to tease
out the effects of high BMI on LSM with the various elas-
tography scanner systems.
Limits of agreement analysis revealed a substantial
dispersion in LSM values between all machines, mainly
restricted to average LSM values >10 kPa, as illustrated in
BlandAltman plots (Fig. 3). Our results indicated that 2-
D-SWE.GE gave a more pronounced dispersion in intersys-
tem differences. Patients with the highest DLSM between
TE and pSWE often had invalid results for 2-D-SWE.GE.
This could suggest that the ICC values with 2-D-SWE.GE
measurements were falsely elevated compared with those
with pSWE and TE, as 2-D-SWE.GE had mainly valid
measurements for patients in which LSM was easily mea-
sured and where the different scanner systems agreed.
TE has been reported to correlate well with liver
biopsy in the evaluation of liver fibrosis in PSC patients
(Corpechot et al. 2014). We therefore tested the perfor-
mance of pSWE and 2-D-SWE.GE using TE as a gold
standard, with published cutoff values for different fibro-
sis stages. pSWE and 2-D-SWE.GE both performed well
in the identification of advanced fibrosis (F3F4) with
similar AUROC values of 0.85, with corresponding opti-
mal cutoffs of 4.9 and 7.8 kPa as decided by Youden’s
index.
We found that ELF correlates rather well with
LSMs by pSWE and TE and, more importantly, that
there is a clear linear relationship between the parame-
ters, with an abrupt rise in LSM after the suggested cut-
off for ELF of 11.2. A similar relationship was not
observed for 2-D-SWE.GE, although there was a signifi-
cant correlation.
There was no difference in LSM between those
with and without splenomegaly defined as spleen
length 12 cm, while LSM was elevated in PSC
patients with spleen length 13 cm for pSWE as well
as TE. Previous studies have reported that spleen
length 12 cm is associated with poorer prognosis in
PSC patients (Ehlken et al. 2016a, 2016b). However,
spleen size depends on body length and weight, as
well as sex, and it has been reported that one in four
healthy males has a spleen length 12 cm (Chow et al.
2016). Our findings may indicate that the cutoff values
for spleen length as a prognostic factor might benefit
from body size adjustment or vary between countries,
and perhaps change in spleen size over time may be a
better parameter with respect to disease progression
(Jung et al. 2019).
Limitations of the study
The lack of liver biopsies is the main limitation of
this study. Although liver biopsies would have strength-
ened our results, this invasive procedure is not clinically
indicated in PSC, is associated with adverse events and
hence is not acceptable from an ethical perspective. Fur-
thermore, LSMs were not necessarily made at the exact
same spot in the liver with all three scanner systems in
any given patient; in particular, pSWE measurements
were performed by a different operator than TE and 2-D-
SWE.GE measurements. Stricter system recommenda-
tions for TE and 2-D-SWE.GE, requiring IQR/M% 30
for valid results, compared with the Philips iU22 (lack-
ing such recommendations), may have affected results,
in particular the feasibility. Considering the patchy dis-
tribution of PSC, it is possible that LSM measurements
throughout the entire liver would have affected our
results. However, given the results indicating closer
ICCs for TE and pSWE (performed by two observers)
than for TE and 2-D-SWE.GE (performed by a single
observer), we do not believe this biased our results.
CONCLUSIONS
We have for the first time described the use of 2-D-
SWE.GE in an exclusive PSC patient cohort, with a
head-to-head comparison using three different elastogra-
phy methods. We found good feasibility and moderate to
excellent correlations for 2-D-SWE.GE, pSWE and TE,
respectively. LSM levels differed between scanner sys-
tems. The ICC was excellent for pSWE versus TE. For
2-D-SWE.GE compared with TE or pSWE, the ICC was
moderate, but improved significantly when overweight
patients were excluded. LSM was correlated with the
ELF test. Our results further suggest that a spleen length
cutoff of 13 cm may be more appropriate as a prognostic
marker in PSC than the recommended 12 cm.
Further research is warranted to clarify the effects
of BMI on LSM for the various elastography scanner
systems and the factors causing diverging LSM values
between scanner systems in PSC patients.
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